Combination therapies of chimeric antigen receptors and pd-1 inhibitors
Combining CAR-expressing cells with PD-1 inhibitors addresses the limitations of CAR therapies by enhancing persistence and proliferation of CAR cells, leading to improved cancer treatment outcomes through the combination therapy.
Patent Information
- Application Number
- JP2024129900
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-06-02
- Filing Date
- 2024-08-06
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current cancer treatments, such as chimeric antigen receptor (CAR)-engineered T cell therapies, face challenges in achieving clinical efficacy due to variations in T cell quality, anergy, suppression, or depletion, leading to suboptimal persistence and proliferation of CAR-transformed T cells, and the use of PD-1 inhibitors alone may not enhance therapeutic outcomes sufficiently.
A combination therapy involving CAR-expressing cells, which specifically bind to antigens like CD19, and PD-1 inhibitors, administered sequentially or concurrently, to enhance tumor progression inhibition, expand CAR-expressing cell populations, prolong therapeutic response, and improve persistence and function of immune effector cells.
The combination therapy improves therapeutic outcomes by enhancing CAR therapy efficacy through increased persistence and proliferation of CAR-expressing cells, reducing T cell depletion, and increasing cytokine levels, resulting in improved clinical responses compared to single-agent treatments.
Smart Images

Figure 2024167225000243 
Figure 2024167225000244 
Figure 2024167225000245
Abstract
Description
[Technical Field]
[0001] This application claims priority to U.S. Provisional Patent Application No. 62 / 368100, filed July 28, 2016, U.S. Provisional Patent Application No. 62 / 455,547, filed February 6, 2017, U.S. Provisional Patent Application No. 62 / 482846, filed April 7, 2017, and U.S. Provisional Patent Application No. 62 / 514542, filed June 2, 2017, the contents of all of which are incorporated herein by reference in their entireties.
[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format, which is incorporated herein by reference in its entirety. The ASCII copy created on July 27, 2017 is named N2067-7109WO_SL.txt and is 907,582 bytes in size.
[0003] The present invention relates generally to the use of cells, e.g., immune effector cells, engineered to express a chimeric antigen receptor (CAR) that targets an antigen, e.g., CD19, in combination with a PD-1 inhibitor to treat disease. [Background technology]
[0004] Many patients with B-cell malignancies are incurable with standard therapies. In addition, conventional treatment options often have severe side effects. While attempts have been made at cancer immunotherapy, several obstacles make this an extremely difficult goal to achieve clinical efficacy. Hundreds of so-called tumor antigens have been identified, but they are generally self-derived and therefore poorly immunogenic. Furthermore, tumors use several mechanisms to render themselves unsuitable for initiating and propagating immune attack.
[0005] Recent advances in chimeric antigen receptor (CAR)-modified autologous T cell (CART) therapy, which relies on redirecting T cells to appropriate cell surface molecules on cancer cells, such as B cell malignancies, have shown promising results in harnessing the power of the immune system to treat B cell malignancies and other cancers (see, e.g., Non-Patent Document 1). Clinical results with murine-derived CART19 (i.e., "CTL019") have shown promise for complete remission in patients with CLL and pediatric ALL (see, e.g., Non-Patent Document 2, Non-Patent Document 3, Non-Patent Document 4). In addition to the ability of the chimeric antigen receptor on genetically modified T cells to recognize and destroy target cells, successful therapeutic T cell therapy requires that they have the ability to proliferate and persist long-term to monitor leukemia relapse. Variations in T cell quality due to anergy, suppression, or exhaustion can affect the performance of CAR-transformed T cells, which practitioners currently have limited control over. To be effective, CAR-transformed patient T cells must persist and maintain the ability to proliferate in response to cognate antigens. It has been shown that ALL patient T cells can do this with CART19 containing a mouse scFv (see, for example, Non-Patent Document 5). [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] Sadelain et al., Cancer Discovery 3:388-398(2013) [Non-patent document 2] Kalos et al., Sci Transl Med 3:95ra73(2011) [Non-patent document 3] Porter et al.,NEJM 365:725-733(2011) [Non-patent document 4] Grupp et al.,NEJM 368:1509-1518(2013) [Non-patent document 5] Grupp et al.,NEJM 368:1509-1518(2013) Summary of the Invention [Means for solving the problem]
[0007] The present disclosure features, at least in part, methods and compositions for treating a disease (e.g., cancer) in a subject, e.g., a disease associated with an antigen, e.g., a disease associated with expression of CD19, e.g., cancer, by using a combination therapy including cells, e.g., immune effector cells (also referred to herein as "CD19 CAR-expressing cells"), that express a chimeric antigen receptor (CAR) that specifically binds to an antigen, e.g., an antigen described herein, e.g., CD19 (also referred to herein as "CAR therapy"), and an inhibitor of programmed death 1 (also referred to herein as a "PD-1 inhibitor"). In some embodiments, the CAR that specifically binds to an antigen, e.g., CD19, comprises an antigen-binding domain, e.g., a CD19-binding domain, e.g., as described herein, a transmembrane domain, and an intracellular signaling domain. In some embodiments, the PD-1 inhibitor is an antibody molecule, a polypeptide, a small molecule, or a polynucleotide, e.g., an inhibitory nucleic acid. In one embodiment, the PD-1 inhibitor is an antibody molecule, e.g., an antibody molecule described herein. Without wishing to be bound by theory, it is believed that treating a subject having a disease (e.g., cancer), e.g., a disease associated with CD19 expression, e.g., a cancer described herein, with a combination therapy comprising a CAR-expressing cell (e.g., a CD19 CAR-expressing cell) and a PD-1 inhibitor results in improved inhibition or reduction of tumor progression in the subject, as compared to, for example, treating a subject with the disease with either a CAR-expressing cell (e.g., a CD19 CAR-expressing cell) or a PD-1 inhibitor alone.For example, inhibition of PD-1 / PD-L1 interaction in combination with CAR therapy can result in one or more of: (i) activation (or reactivation) of CAR-expressing cells (e.g., CD19 CAR-expressing cells); (ii) expansion of the population of CAR-expressing cells; (iii) prolonged therapeutic response to CAR therapy; (iv) increased durability of CAR therapy; (v) reduction in exhausted effector T cell function; (vi) reversal or attenuation of T cell exhaustion; (vii) increased cytokine (e.g., IL-6, or IL-2) levels; or (viii) decreased expression of checkpoint inhibitors (e.g., one or more of PD-1, TIM-3, or LAG-3) on immune effector cells (e.g., CD4+ and / or CD8+ cells, e.g., CAR-expressing immune effector cells), and thus may result in improved therapeutic outcomes in subjects treated with the combination therapy compared to, for example, subjects receiving CAR therapy alone or a PD-1 inhibitor alone.
[0008]
[0010] Accordingly, in one aspect, the disclosure features a method of treating a subject having a disease (e.g., cancer), e.g., a disease associated with an antigen, e.g., a disease associated with expression of CD19, e.g., a cancer as described herein. The method includes administering to the subject cells, e.g., a population of cells, comprising, e.g., expressing, a CAR that specifically binds to an antigen, e.g., CD19 (also referred to herein as CAR therapy), and a PD-1 inhibitor. In one embodiment, the CAR-expressing cells and the PD-1 inhibitor are administered sequentially. In one embodiment, the PD-1 inhibitor is administered before administration of the CAR-expressing cells (e.g., CD19 CAR-expressing cells). In one embodiment, the PD-1 inhibitor is administered after administration of the CAR-expressing cells (e.g., CD19 CAR-expressing cells). In one embodiment, the PD-1 inhibitor and the CAR-expressing cells (e.g., CD19 CAR-expressing cells) are administered simultaneously or concurrently.
[0009] In embodiments, the CAR-expressing cells, e.g., CD19 CAR-expressing cells described herein, and the PD-1 inhibitor are administered sequentially, e.g., in any order. In one embodiment, the combination is administered during a treatment interval. In one embodiment, the treatment interval comprises a single dose of the PD-1 inhibitor and a single dose of the CAR-expressing cells (e.g., in any order). In another embodiment, the treatment interval comprises multiple doses (e.g., a first and a second dose) of the PD-1 inhibitor and a dose of the CAR-expressing cells (e.g., in any order).
[0010] In a related aspect, the disclosure provides a method of treating a subject having cancer, the method comprising: (i) CAR therapy comprising a population of immune effector cells comprising, e.g., expressing, a CAR, wherein the CAR comprises an antigen (e.g., CD19) binding domain, a transmembrane domain, and an intracellular signaling domain; and (ii) PD-1 inhibitor to a subject.
[0011] In some embodiments, the dose of the PD-1 inhibitor, e.g., an anti-PD-1 antibody molecule, is about 200 mg to about 450 mg, e.g., about 300 mg to about 400 mg, administered, for example, every 2 weeks, 3 weeks, 4 weeks, or 5 weeks.
[0012] In another aspect, the present disclosure provides a method of treating a subject having cancer, the method comprising: (i) CAR therapy comprising a population of immune effector cells comprising, e.g., expressing, a CAR, wherein the CAR comprises an antigen (e.g., CD19) binding domain, a transmembrane domain, and an intracellular signaling domain; and (ii) PD-1 inhibitor to a subject.
[0013] In some embodiments, administration of the PD-1 inhibitor is initiated within 20 days after administration of the CAR therapy. For example, administration of the PD-1 inhibitor is initiated within 16 days, 15 days, 14 days, 13 days, 12 days, 11 days, 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days, or 2 days after administration of the CAR therapy.
[0014] In another aspect, the present disclosure provides a method of treating a subject having cancer, the method comprising: (i) CAR therapy comprising a population of immune effector cells comprising, e.g., expressing, a CAR, wherein the CAR comprises an antigen (e.g., CD19) binding domain, a transmembrane domain, and an intracellular signaling domain; and (ii) PD-1 inhibitor to a subject.
[0015] In some embodiments, administration of the PD-1 inhibitor is initiated when the subject has: (a) partial response or no detectable response to CAR therapy; (b) recurrent cancer after CAR therapy; (c) cancer refractory to CAR therapy; (d) advanced cancer after CAR therapy, or (e) B cell recovery after CAR therapy, e.g., less than 3 months The method is initiated after a patient has or is identified as having one or more of the following:
[0016] In yet another aspect, the present disclosure provides a method of treating a subject having cancer, the method comprising: (i) a chimeric antigen receptor (CAR) therapy comprising a population of immune effector cells comprising, e.g., expressing, a CAR, wherein the CAR comprises an antigen (e.g., CD19) binding domain, a transmembrane domain, and an intracellular signaling domain; and (ii) PD-1 inhibitor to a subject.
[0017] In some embodiments, administration of the PD-1 inhibitor is initiated after administration of the CAR therapy, and the subject receives one of the following: (a) partial response or no detectable response to CAR therapy; (b) recurrent cancer after CAR therapy; (c) cancer refractory to CAR therapy; (d) advanced cancer, or (e) B cell recovery after CAR therapy, e.g., less than 3 months does not have or has not been identified as having one or more of the following:
[0018] In another aspect, the present disclosure provides CAR therapy for use in combination with a PD-1 inhibitor in any of the methods disclosed herein. In other embodiments, disclosed herein is the use of CAR therapy in combination with a PD-1 inhibitor in the preparation of a medicament for the treatment of a disorder, e.g., a proliferative disorder, e.g., cancer.
[0019] Further features or embodiments of any method, use, composition or combination disclosed herein include one or more of the following:
[0020] In some embodiments, one or more subsequent doses of a PD-1 inhibitor may be administered, for example, 1, 2, 3, 4, or 5 or more doses. In one embodiment, up to 6 doses of a PD-1 inhibitor are administered.
[0021] In some embodiments, the method or use further comprises assessing the presence or absence of CRS in the subject. In one embodiment, the subject does not have or is identified as not having CRS, e.g., severe CRS (e.g., CRS grade 3 or grade 4), after CAR therapy.
[0022] In other embodiments, administration of the PD-1 inhibitor is initiated after the subject is identified as not having CRS, e.g., severe CRS (e.g., CRS grade 3 or grade 4), following CAR therapy.
[0023] In other embodiments, administration of the PD-1 inhibitor is initiated after treatment of CRS following CAR therapy, e.g., after CRS has resolved. In one embodiment, CRS has resolved to Grade 1. In certain embodiments, CRS has resolved to undetectable levels.
[0024] Where a treatment interval comprises a single dose of a PD-1 inhibitor and a single dose of CAR-expressing cells, in certain embodiments, the dose of the PD-1 inhibitor and the dose of the CAR-expressing cells are administered simultaneously or concurrently. For example, the dose of the PD-1 inhibitor and the dose of the CAR-expressing cells are administered within 20 days, 18 days, 16 days, 15 days, 12 days, 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days, 2 days, 1 day, 24 hours, 12 hours, 6 hours, 4 hours, 2 hours, or less of each other. In embodiments, the treatment interval begins with administration of the first administered dose and is completed with administration of the last administered dose.
[0025] When a treatment interval comprises a single dose of a PD-1 inhibitor and a single dose of CAR-expressing cells, in certain embodiments, the dose of the PD-1 inhibitor and the dose of the CAR-expressing cells are administered sequentially. In embodiments, the dose of the CAR-expressing cells is administered before the dose of the PD-1 inhibitor, and the treatment interval begins with the administration of a dose of the CAR-expressing cells and is completed with the administration of a dose of the PD-1 inhibitor. In other embodiments, the dose of the PD-1 inhibitor is administered before the dose of the CAR-expressing cells, and the treatment interval begins with the administration of a dose of the PD-1 inhibitor and is completed with the administration of a dose of the CAR-expressing cells. In one embodiment, the treatment interval further comprises one or more, e.g., one, two, three, four, or five or more, subsequent doses of a PD-1 inhibitor. In such embodiments, the treatment interval comprises two, three, four, five, six, or more doses of a PD-1 inhibitor and one dose of CAR-expressing cells. In one embodiment, the dose of CAR-expressing cells is administered at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, or at least 2 weeks before or after the dose of the PD-1 inhibitor is administered. In embodiments in which more than one dose of a PD-1 inhibitor is administered, the dose of CAR-expressing cells is administered at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, or at least 2 weeks before or after the first dose of the PD-1 inhibitor is administered, or after the start of the treatment interval. In one embodiment, the dose of the PD-1 inhibitor is administered about 25 to 40 days (e.g., about 25 to 30, 30 to 35, or 35 to 40 days, e.g., about 35 days) or about 2 to 7 weeks (e.g., 2, 3, 4, 5, 6, or 7 weeks) after the dose of the CAR-expressing cells is administered.In embodiments, when two or more doses of the PD-1 inhibitor are administered, the second dose of the PD-1 inhibitor is administered about 15 to 30 days (e.g., about 15 to 20, 20 to 25, or 25 to 30 days, e.g., about 20 days) or about 2 to 5 weeks (e.g., 2, 3, 4, or 5 weeks) after the first dose of the PD-1 inhibitor is administered.
[0026] Where a treatment interval comprises multiple doses (e.g., a first and a second, and optionally one or more subsequent doses) of a PD-1 inhibitor and a dose of CAR-expressing cells, in certain embodiments, the dose of CAR-expressing cells and the first dose of the PD-1 inhibitor are administered simultaneously or concurrently, e.g., within two days of each other (e.g., within 2 days, 1 day, 24 hours, 12 hours, 6 hours, 4 hours, 2 hours, or less). In embodiments, the second dose of the PD-1 inhibitor is administered after the later of (i) the dose of the CAR-expressing cells or (ii) the first dose of the PD-1 inhibitor. In embodiments, the second dose of the PD-1 inhibitor is administered at least two days (e.g., at least 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or more) after (i) or (ii). In embodiments, a subsequent dose of the PD-1 inhibitor (e.g., a third, fourth, or fifth dose, etc.) is administered after the second dose of the PD-1 inhibitor. In embodiments, the subsequent dose of the PD-1 inhibitor is administered at least two days (e.g., at least two, three, four, five, six, seven days, one week, two weeks, three weeks, four weeks, five weeks, or more) after the second dose of the PD-1 inhibitor. In such embodiments, a treatment interval begins with administration of the first administered dose of the PD-1 inhibitor and is completed with administration of the second dose (or subsequent dose).
[0027] In other embodiments in which the treatment interval comprises multiple doses (e.g., first and second, and optionally subsequent doses) of a PD-1 inhibitor and a dose of CAR-expressing cells, the dose of CAR-expressing cells and the first dose of the PD-1 inhibitor are administered sequentially. In embodiments, the dose of CAR-expressing cells is administered after administration of the first dose of the PD-1 inhibitor but before administration of the second dose of the PD-1 inhibitor. In embodiments, a subsequent dose of the PD-1 inhibitor (e.g., a third, fourth, or fifth dose, etc.) is administered after the second dose of the PD-1 inhibitor. In such embodiments, the treatment interval begins with administration of the first dose of the PD-1 inhibitor and is completed with administration of the second dose (or subsequent doses) of the PD-1 inhibitor. In one embodiment, the second dose of the PD-1 inhibitor is administered at least two days (e.g., at least 2, 3, 4, 5, 6, 7 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or more) after administration of the first dose of the PD-1 inhibitor. In one embodiment, when the PD-1 inhibitor is an inhibitory RNA, e.g., siRNA, the second dose is administered every two days to every two weeks. In one embodiment, when the PD-1 inhibitor is an antibody molecule, the second dose is administered every two to three weeks. In one embodiment, a subsequent dose of the PD-1 inhibitor (e.g., the third, fourth, or fifth dose) is administered at least two days (e.g., at least 2, 3, 4, 5, 6, 7 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or more) after the second dose of the PD-1 inhibitor. In one embodiment, the dose of CAR-expressing cells is administered at least two days (e.g., at least 2, 3, 4, 5, 6, 7 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks or more) after administration of the first dose of the PD-1 inhibitor. In one embodiment, the second dose of the PD-1 inhibitor is administered at least two days (e.g., at least 2, 3, 4, 5, 6, 7 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks or more) after administration of the dose of CAR-expressing cells. In an embodiment, the PD-1 inhibitor (e.g., an anti-PD-1 antibody molecule) is administered every 2 to 3 weeks (e.g., every 2 weeks or every 3 weeks) during the treatment interval.
[0028] In other embodiments, the dose of CAR-expressing cells is administered prior to administration of the first dose of the PD-1 inhibitor. In such embodiments, a treatment interval begins with administration of the CAR-expressing cells and is completed with administration of the first dose (or subsequent dose) of the PD-1 inhibitor. In embodiments, the first dose of the PD-1 inhibitor is administered at least 2 days (e.g., at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 2 weeks, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 3 weeks, at least 4 weeks, at least 5 weeks or more) after administration of the CAR-expressing cells. In some embodiments, administration of the first dose of the PD-1 inhibitor occurs about 5 to about 10 days, e.g., about 8 days, after administration of the CAR-expressing cells. In other embodiments, administration of the first dose of the PD-1 inhibitor occurs about 10 to about 20 days, e.g., about 15 or 16 days, after administration of the CAR-expressing cells. In embodiments, the second dose of the PD-1 inhibitor is administered at least 2 days (e.g., at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, 2 weeks, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, 3 weeks, 4 weeks, 5 weeks, or more) after administration of the first dose of the PD-1 inhibitor. In embodiments, the second dose of the PD-1 inhibitor is administered about 2 to 4 weeks, e.g., 3 weeks, after the first dose of the PD-1 inhibitor. In embodiments, the subsequent dose of the PD-1 inhibitor (e.g., the third, fourth, or fifth dose) is administered at least two days (e.g., at least two, three, four, five, six, seven days, one week, two weeks, three weeks, four weeks, five weeks, or more weeks) after the second dose of the PD-1 inhibitor.In embodiments, the subsequent dose of the PD-1 inhibitor (e.g., the third, fourth, or fifth dose) is administered about 2 to 4 weeks, e.g., 3 weeks, after the previous dose of the PD-1 inhibitor. In embodiments, the first dose of the PD1 inhibitor is administered at least 2 days (e.g., at least 2, 3, 4, 5, 6, 7 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks or more) after administration of the CAR-expressing cells.
[0029] In some embodiments, the treatment interval comprises one, two, or three doses (e.g., first, second, and third doses) of a PD-1 inhibitor and a dose of CAR-expressing cells. In one embodiment, the dose of CAR-expressing cells and the first dose of the PD-1 inhibitor are administered sequentially. For example, a subject, e.g., a patient, receives one, two, or three doses of the PD-1 inhibitor after administration of the CAR-expressing cells, e.g., starting about 1 week to 4 months, e.g., about 14 days to 2 months, after administration of the dose of CAR-expressing cells.
[0030] In one embodiment, any of the treatment intervals described herein can be repeated one or more additional times, for example, 1, 2, 3, 4, or 5 times. In one embodiment, the treatment interval is repeated only once, resulting in a treatment regimen including two treatment intervals. In some embodiments, the repeated treatment interval is administered at least one day after the completion of the first or previous treatment interval, e.g., at least one day, at least two days, at least three days, at least four days, at least five days, at least six days, at least seven days, at least two weeks, at least one month, at least three months, at least six months, at least one year, or more. In some embodiments, the repeated treatment interval is administered at least three days after the completion of the first or previous treatment interval.
[0031] In one embodiment, any of the treatment intervals described herein can be followed by one or more subsequent treatment intervals, e.g., 1, 2, 3, 4, or 5 subsequent treatment intervals. The one or more subsequent treatment intervals are different from the first or previous treatment interval. For example, a first treatment interval consisting of a single dose of a PD-1 inhibitor and a single dose of CAR-expressing cells is followed by a second treatment interval consisting of multiple doses (e.g., 2, 3, 4, or more) of a PD-1 inhibitor and a single dose of CAR-expressing cells. In one embodiment, the one or more subsequent treatment intervals are administered at least 1 day, e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, or 2 weeks after the completion of the first or previous treatment interval.
[0032] In any of the methods described herein, one or more subsequent doses, e.g., 1, 2, 3, 4, or 5 or more doses, of the PD-1 inhibitor are administered after completion of one or more treatment intervals. In embodiments in which treatment intervals are repeated or more than one treatment interval is administered, one or more subsequent doses, e.g., 1, 2, 3, 4, or 5 or more doses of the PD-1 inhibitor are administered after completion of one treatment interval and before the start of another treatment interval. In one embodiment, doses of the PD-1 inhibitor are administered every 5 days, 7 days, 2 weeks, 3 weeks, or 4 weeks after completion of one or more or each treatment interval.
[0033] In any of the methods described herein, one or more subsequent doses, e.g., 1, 2, 3, 4, or 5 or more, of CAR-expressing cells are administered after completion of one or more treatment intervals. In embodiments in which treatment intervals are repeated or more than one treatment interval is administered, one or more subsequent doses, e.g., 1, 2, 3, 4, or 5 or more, of CAR-expressing cells are administered after completion of one treatment interval and before the start of another treatment interval. In one embodiment, a dose of CAR-expressing cells is administered every 2 days, 3 days, 4 days, 5 days, 7 days, 2 weeks, 3 weeks, or 4 weeks after completion of one or more or each treatment interval.
[0034] In one embodiment, the treatment interval comprises a single dose of CAR-expressing cells administered prior to the first dose of the PD-1 inhibitor. In this embodiment, the first dose of the PD-1 inhibitor is administered about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 25, about 30, or about 35 days after administration of the CAR-expressing cells. In an embodiment, a second dose of the PD-1 inhibitor is administered after administration of the first dose of the PD-1 inhibitor. In an embodiment, the second dose of the PD-1 inhibitor is administered about 20 days after administration of the first dose of the PD-1 inhibitor, e.g., about 2-4 weeks, e.g., 3 weeks, after the first dose of the PD-1 inhibitor. In embodiments, after the second dose of the PD-1 inhibitor, e.g., after the previous dose of the PD-1 inhibitor, the subsequent dose of the PD-1 inhibitor is administered every 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 5 days, 7 days, 10 days, 14 days, 20 days, 25 days, 30 days, or 35 days, e.g., about every 2 to 4 weeks, e.g., about every 3 weeks.
[0035] In certain embodiments, the methods include administering lymphodepleting chemotherapy to the subject, e.g., prior to administration of the CAR-expressing cells. In embodiments, the lymphodepleting chemotherapy is administered in a range of, e.g., 1-10 doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses), e.g., about 200-400 mg / m 2 , for example, about 300 mg / m 2In embodiments, the method comprises administering a treatment interval comprising a dose of CAR-expressing cells and multiple doses of a PD-1 inhibitor. In embodiments, the treatment interval comprises a single dose of CAR-expressing cells (e.g., CD19 CAR-expressing cells) administered prior to the first dose of the PD-1 inhibitor, e.g., at least 2 weeks (e.g., 2, 3, 4, 5, 6 or more weeks) prior to the first dose of the PD-1 inhibitor (e.g., about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16 or more days prior to the first dose of the PD-1 inhibitor). In embodiments, the dose of CAR-expressing cells is administered about 3 to 4 weeks prior to the first dose of the PD-1 inhibitor. In an embodiment, the PD-1 inhibitor is administered every 2-4 weeks (e.g., every 2-3 weeks or every 3-4 weeks, e.g., every 3 weeks) during the treatment interval. In an embodiment, the PD-1 inhibitor is administered at a dose of about 1-3 mg / kg, e.g., about 2 mg / kg. In an embodiment, the CAR-expressing cells are administered at a dose of about 1-10 x 10 6 cells / kg, e.g., about 5 x 10 6 cells / kg, e.g., about 5.3 x 10 6 In embodiments, CAR-expressing cells are administered at a dose of about 1-10 x 10 cells / kg per infusion. 8 Cells, e.g., about 5 x 10 per infusion 8 The cells are administered in doses.
[0036] In any of the methods described herein, the subject is administered a single dose of CAR-expressing cells and a single dose of a PD-1 inhibitor. In one embodiment, the single dose of CAR-expressing cells is administered at least 2 days, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, 15, 16, 17, 18, 20, 25, 30, 35, 40 days, or 2 weeks, 3 weeks, 4 weeks, or more, before the administration of the single dose of the PD-1 inhibitor. In an embodiment, the single dose of CAR-expressing cells is administered about 35 days before the administration of the PD-1 inhibitor.
[0037] In one embodiment, after the initial dose of CAR-expressing cells, one or more subsequent doses of CAR-expressing cells, for example, 1, 2, 3, 4, or 5 doses, are administered to the subject. In one embodiment, the one or more subsequent doses of CAR-expressing cells are administered at least 2 days, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, 20, 25, 30, 35, 40 days, or 2 weeks, 3 weeks, 4 weeks, or more, after the previous dose of CAR-expressing cells. In one embodiment, the one or more subsequent doses of CAR-expressing cells are administered at least 1 month, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 months, or more, after the previous dose of CAR-expressing cells. In one embodiment, the one or more subsequent doses of CAR-expressing cells are administered at least 5 days after the previous dose of CAR-expressing cells. In one embodiment, a subject receives three doses of CAR-expressing cells per week or one dose every two days.
[0038] In one embodiment, a single dose of the PD-1 inhibitor is administered followed by one or more subsequent doses of the PD-1 inhibitor, e.g., 1, 2, 3, 4, or 5 doses. In one embodiment, the one or more subsequent doses of the PD-1 inhibitor are administered at least 5 days, 7 days, 10 days, 14 days, 20 days, 25 days, 30 days, 2 weeks, 3 weeks, 4 weeks, or 5 weeks, e.g., 3 weeks, after the previous dose of the PD-1 inhibitor.
[0039] In one embodiment, the one or more subsequent doses of the PD-1 inhibitor are administered at least 1, 2, 3, 4, 5, 6, or 7 days after the dose of the CAR-expressing cells, e.g., the initial dose of the CAR-expressing cells.
[0040] In one embodiment, one or more doses, for example 1, 2, 3, 4, or 5 doses, of a PD-1 inhibitor are administered prior to the first dose of CAR-expressing cells.
[0041] In one embodiment, one or more doses, e.g., 1, 2, 3, 4, 5, or 6 doses, of the PD-1 inhibitor are administered after the first dose of CAR-expressing cells, e.g., 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, or 8 weeks after the first dose of CAR-expressing cells. In one embodiment, one or more doses, e.g., 1, 2, 3, 4, or 5 doses, of the PD-1 inhibitor are administered after the first dose of CAR-expressing cells, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 months after the first dose of CAR-expressing cells.
[0042] In one embodiment, the one or more doses, e.g., 1, 2, 3, 4, 5, or 6 doses, of the PD-1 inhibitor administered after the first dose of CAR-expressing cells are administered every 2-3 weeks, e.g., every 2, 3, 4, or 5 weeks, for at least 1 month, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months or more. In one embodiment, the one or more doses of the PD-1 inhibitor are administered, e.g., about 2-4 weeks, e.g., 3 weeks, after the previous dose of the PD-1 inhibitor, e.g., for up to 6 doses.
[0043] In one embodiment, the administration of one or more doses of CAR-expressing cells and one or more doses of a PD-1 inhibitor is repeated, for example, 1, 2, 3, 4, or 5 additional times.
[0044] In any of the methods described herein, in embodiments, the subject further receives chemotherapy, such as a chemotherapy described herein. In embodiments, the chemotherapy is administered prior to administration of the CAR-expressing cells. In embodiments, the chemotherapy is administered about 1 to 10 days (e.g., about 1 to 4, 1 to 5, 4 to 8, 4 to 10, or 5 to 10 days) prior to administration of the CAR-expressing cells.
[0045] Dosages and treatment regimens for the therapeutic agents disclosed herein can be determined by one of skill in the art.
[0046] In any dosing regimen or treatment interval described herein, in some embodiments, the dose of CAR-expressing cells (e.g., CD19 CAR-expressing cells) is about 10 4 ~about 10 9 cells / kg, e.g., about 10 4 ~about 10 5 cells / kg, approximately 10 5 ~about 10 6 cells / kg, approximately 10 6 ~about 10 7 cells / kg, approximately 10 7 ~about 10 8 cells / kg or approximately 10 8 ~about 10 9 cells / kg, or 1 x 10 7 , 1.5×10 7 , 2 × 10 7 , 2.5×10 7 , 3×10 7 , 3.5×10 7 , 4×10 7 , 5×10 7 , 1×10 8 , 1.5×10 8 , 2 × 10 8 , 2.5×10 8 , 3×10 8 , 3.5×10 8 , 4×10 8 , 5×10 8 , 1×10 9 , 2 × 10 9 Or 5 x 10 9 In some embodiments, the dose of CAR-expressing cells (e.g., CD19 CAR-expressing cells) comprises at least about 1-5 x 10 7 ~1~5×10 8 In some embodiments, the subject receives approximately 1-5 x 10 CAR-expressing cells. 7 In other embodiments, the subject is administered about 1-5 x 10 CAR-expressing cells (e.g., CD19 CAR-expressing cells). 8 The patient is administered a CAR-expressing cell (e.g., a CD19 CAR-expressing cell).
[0047] In embodiments, CAR-expressing cells (e.g., CD19 CAR-expressing cells) are administered to a subject according to a dosing regimen that includes a total dose of cells administered to the subject via dose fractionation, e.g., one, two, three, or more separate administrations of partial doses. In embodiments, a first fraction of the total dose is administered on the first day of treatment, a second fraction of the total dose is administered on a subsequent day of treatment (e.g., day 2, 3, 4, 5, 6, or 7 or later), and, optionally, a third fraction (e.g., the remaining fraction) of the total dose is administered on a further subsequent day of treatment (e.g., day 3, 4, 5, 6, 7, 8, 9, 10 or later). For example, 10% of the total dose of cells is delivered on day 1 of treatment, 30% of the total dose of cells is delivered on day 2, and the remaining 60% of the total dose of cells is delivered on day 3. For example, the total cell dose is between 1 and 5 x 10 7 or 1 to 5 x 10 8 The cells include CAR-expressing cells (e.g., CD19 CAR-expressing cells).
[0048] In any of the dosing regimens described herein, the dose of the PD-1 inhibitor, e.g., an anti-PD-1 antibody molecule described herein (e.g., pembrolizumab, nivolumab, PDR001, or an anti-PD-1 antibody molecule provided in Table 6), comprises about 1 to 30 mg / kg, e.g., about 1 to 20 mg / kg, about 2 to 15 mg / kg, about 5 to 25 mg / kg, about 10 to 20 mg / kg, about 1 to 5 mg / kg, about 2 mg / kg, about 3 mg / kg, or about 10 mg / kg. In one embodiment, the dose comprises about 10 to 20 mg / kg. In one embodiment, the dose comprises about 1 to 5 mg / kg. In one embodiment, the dose is less than 5 mg / kg, less than 4 mg / kg, less than 3 mg / kg, less than 2 mg / kg, or less than 1 mg / kg. In one embodiment, the dose is about 2 mg / kg.
[0049] In embodiments, in any of the dosing regimens described herein, the dose of the PD-1 inhibitor is administered every 1 to 4 weeks, for example every week, every 2 weeks, every 3 weeks, or every 4 weeks.
[0050] In certain embodiments, the anti-PD-1 antibody molecule (e.g., pembrolizumab, nivolumab, PDR001, or an anti-PD-1 antibody molecule provided in Table 6) is administered by injection (e.g., subcutaneously or intravenously) at a dose of about 1-30 mg / kg, e.g., about 1-20 mg / kg, about 2-15 mg / kg, about 5-25 mg / kg, about 10-20 mg / kg, about 1-5 mg / kg, about 3 mg / kg, or about 2 mg / kg. Dosing schedules can vary, for example, from once weekly to once every two, three, or four weeks. In one embodiment, the anti-PD-1 antibody molecule is administered every other week at a dose of about 10-20 mg / kg. In one embodiment, the dose is about 1-5 mg / kg every two, three, or four weeks. In one embodiment, the dose is less than 5 mg / kg, less than 4 mg / kg, less than 3 mg / kg, less than 2 mg / kg, or less than 1 mg / kg every 2 weeks, 3 weeks, or 4 weeks, hi one embodiment, the dose is about 2 mg / kg every 2 weeks, 3 weeks, or 4 weeks.
[0051] In some embodiments, the dose of the PD-1 inhibitor, e.g., an anti-PD-1 antibody molecule (e.g., pembrolizumab, nivolumab, PDR001, or an anti-PD-1 antibody molecule provided in Table 6), is a fixed dose. In some embodiments, the anti-PD-1 antibody molecule is administered by injection (e.g., subcutaneously or intravenously) at a dose (e.g., a flat dose) of about 200 mg to 500 mg, e.g., about 250 mg to 450 mg, about 300 mg to 400 mg, about 250 mg to 350 mg, about 350 mg to 450 mg, or about 200 mg, about 300 mg, or about 400 mg. The dosing schedule (e.g., a fixed dose administration schedule) can vary, for example, from once weekly to once every 2, 3, 4, 5, or 6 weeks. In one embodiment, the anti-PD-1 antibody molecule is administered once every 3 weeks or once every 4 weeks at a dose starting from about 200 mg. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose of about 300 mg to 400 mg once every three weeks or once every four weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose from about 300 mg, for example, by iv infusion, once every three weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose from about 200 mg, for example, by iv infusion, once every three weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose from about 400 mg, for example, by iv infusion, once every four weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose from about 300 mg, for example, by iv infusion, once every four weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose from about 400 mg, for example, by iv infusion, once every three weeks.
[0052] In one embodiment, the PD-1 inhibitor is pembrolizumab administered at 200 mg every three weeks for up to six doses. In some embodiments, the PD-1 inhibitor is pembrolizumab administered at 300 mg every three weeks for up to six doses.
[0053] In one embodiment, the PD-1 inhibitor is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, PDR001, AMP 514, AMP-224, and any anti-PD-1 antibody molecule provided in Table 6.
[0054] In some embodiments, the present disclosure provides methods of treating a subject having a disease associated with expression of CD19, e.g., a hematological cancer (e.g., DLBCL (e.g., primary DLBCL) or B-cell acute lymphoblastic leukemia (B-ALL)). The method includes administering to the subject an effective number of cells expressing a CAR molecule that binds CD19, e.g., a CD19 CAR as described herein ("CD19 CAR therapy"), in combination with a PD1 inhibitor, e.g., an anti-PD1 antibody as described herein. In some embodiments, the CD19 CAR therapy is administered before, simultaneously with, or after the PD-1 inhibitor. In one embodiment, the CD19 CAR therapy is administered before the PD-1 inhibitor. For example, one or more doses of a PD-1 inhibitor can be administered after CD19 CAR therapy (e.g., starting 5 days to 4 months, e.g., 10 days to 3 months, e.g., 14 days to 2 months after CD19 CAR therapy). In some embodiments, the combination of CD19 CAR therapy and PD-1 inhibitor therapy is repeated.
[0055] In one embodiment of a therapy comprising a CD19 CAR-expressing cell and a PD1 inhibitor, the CD19 CAR therapy comprises one or more treatments with cells expressing a CD19 CAR as described herein. In embodiments, the CD19 CAR molecule comprises an antigen-binding domain that specifically binds to CD19, e.g., as described herein. In embodiments, the CD19 CAR and PD-1 inhibitor therapy are administered in dosages described herein.
[0056] In some embodiments, the CD19 CAR (or the nucleic acid encoding it) comprises a sequence shown in either Table 2 or Table 3.
[0057] In embodiments of therapies comprising CD19 CAR-expressing cells and a PD1 inhibitor, the CD19 CAR therapy includes one or more treatments with cells expressing a murine CAR molecule described herein, e.g., a murine CD19 CAR molecule having CDRs in Table 3 or as shown in Tables 4 and 5. In embodiments, the CD19 CAR is, e.g., CTL019, as described herein.
[0058] In another embodiment of a therapy comprising CD19 CAR-expressing cells and a PD1 inhibitor, the CD19 CAR therapy includes one or more treatments with cells expressing a humanized CD19 CAR, e.g., a humanized CD19 CAR according to Table 2 or having CDRs as set forth in Tables 4 and 5, e.g., a CAR2 according to Table 2, e.g., CTL119.
[0059] In some embodiments, the CAR molecule comprises one, two, and / or three CDRs from the heavy chain variable region and / or one, two, and / or three CDRs from the light chain variable region of a murine or humanized CD19 CAR of Table 4 and Table 5.
[0060] In another embodiment of a therapy comprising CD19 CAR-expressing cells and a PD1 inhibitor, the PD-1 inhibitor is an antibody against PD-1. In some embodiments, the PD-1 inhibitor is selected from pembrolizumab, nivolumab, PDR001 (e.g., an antibody molecule in Table 6), MEDI-0680 (AMP-514), AMP-224, REGN-2810, or BGB-A317.
[0061] In one embodiment of the therapy comprising CD19 CAR-expressing cells and a PD1 inhibitor, the PD-1 inhibitor is pembrolizumab. (i) a heavy chain variable (VH) region comprising a VHCDR1 amino acid sequence of SEQ ID NO: 503, a VHCDR2 amino acid sequence of SEQ ID NO: 504, and a VHCDR3 amino acid sequence of SEQ ID NO: 505; and (ii) a light chain variable (VL) region comprising the VLCDR1 amino acid sequence of SEQ ID NO: 500, the VLCDR2 amino acid sequence of SEQ ID NO: 501, and the VLCDR3 amino acid sequence of SEQ ID NO: 502; or High amino acid sequence identity of at least 85%, 90%, 95% or more Includes:
[0062] In another embodiment of the therapy comprising CD19 CAR-expressing cells and a PD1 inhibitor, the PD-1 inhibitor, e.g., an anti-PD-1 antibody molecule, is any of BAP049-hum01, BAP049-hum02, BAP049-hum03, BAP049-hum04, BAP049-hum05, BAP049-hum06, BAP049-hum07, BAP049-hum08, BAP049-hum09, BAP049-hum10, BAP049-hum11, BAP049-hum12, BAP049-hum13, BAP049-hum14, BAP049-hum15, BAP049-hum16, BAP049-clone-A, BAP049-clone-B, BAP049-clone-C, BAP049-clone-D, or BAP049-clone-E. or as described in Table 1 of U.S. Patent Application Publication No. 2015 / 0210769, or Table 6 herein, or encoded by the nucleotide sequence of Table 1, or encoded by the nucleotide sequence of Table 6 herein; or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical) to any of the foregoing sequences, or closely related CDRs, e.g., CDRs that are identical or have at least one amino acid change but no more than two, three, or four changes (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions).
[0063] In yet another embodiment of the therapy comprising CD19 CAR-expressing cells and a PD1 inhibitor, the PD-1 inhibitor, e.g., an anti-PD-1 antibody molecule, is an antibody described herein, e.g., BAP049-hum01, BAP049-hum02, BAP049-hum03, BAP049-hum04, BAP049-hum05, BAP049-hum06, BAP049-hum07, BAP049-hum08, BAP049-hum09, BAP049-hum10, BAP049-hum11, BAP049-hum12, BAP049-hum13, BAP049-hum14, BAP049-hum15, BAP049-hum16, BAP049-hum17, BAP049-hum18, BAP049-hum19, BAP049-hum20, BAP049-hum21, BAP049-hum22, BAP049-hum23, BAP049-hum24, BAP049-hum25, BAP049-hum26, BAP049-hum27, BAP049-hum28, BAP049-hum29, BAP049-hum30, BAP049-hum31, BAP049-hum32, BAP049-hum33, BAP049-hum34, BAP049-hum35, BAP049-hum36, BAP049-hum37, BAP049-hum38, BAP049-hum39, BAP049-hum40, BAP049-hum41, BAP049-hum42, BAP049-hum43, BAP049-hum44, BAP049-hum45, BAP049 or at least one, two, three, or four variable regions from an antibody selected from any of BAP049-clone-A, BAP049-clone-B, BAP049-clone-C, BAP049-clone-D, or BAP049-clone-E, or as described in Table 1 of U.S. Patent Application Publication No. 2015 / 0210769, or Table 6 herein, or encoded by the nucleotide sequence of Table 1, or encoded by the nucleotide sequence of Table 6 herein, or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical) to any of the foregoing sequences.
[0064] In an embodiment, the PD-1 inhibitor, e.g., the anti-PD-1 antibody molecule, is PDR-001, which comprises the variable light chain and variable heavy chain amino acid sequences of BAP049-clone-E as set forth in Table 6.
[0065] In one embodiment of a therapy comprising CD19 CAR-expressing cells and a PD1 inhibitor, the PD-1 inhibitor, e.g., pembrolizumab, is administered after CD19 CAR therapy (e.g., starting 5 days to 4 months, e.g., 10 days to 3 months, e.g., 14 days to 2 months after CTL019 or CTL119 therapy, or combination therapy with CTL019 and CTL119). In an embodiment, the administration of the therapy is to a subject with B-ALL, e.g., relapsed or refractory B-ALL.
[0066] In yet another embodiment of the therapy comprising CD19 CAR-expressing cells and a PD1 inhibitor, the hematological cancer is B-ALL or DLBCL, e.g., relapsed or refractory B-ALL or DLBCL. In one embodiment, the subject has a hematological malignancy, e.g., B-ALL or DLBCL, that may not respond to CAR T therapy or may relapse due to, e.g., a lack of CAR T cell persistence. In one embodiment of CD19 CAR therapy-PD1 inhibitor therapy, the subject exhibits improved treatment outcome, e.g., the subject achieves one or more of a partial remission, a complete remission, or long-term CAR T cell persistence in response to CD19 CAR therapy-PD1 inhibitor therapy, e.g., one or more cycles of CD19 CAR therapy-PD1 inhibitor therapy.
[0067] In one embodiment of a therapy comprising CD19 CAR-expressing cells and a PD1 inhibitor, prior to administration of the PD-1 inhibitor, the subject has relapsed or refractory B-ALL or DLBCL to prior treatment with CD19 CAR therapy, e.g., prior treatment with one or both of CTL019 and CTL119. In some embodiments, the subject exhibits reduced or deficient CAR T-cell persistence. In some embodiments, the subject is being treated or has been treated with CTL019 followed by CTL119.
[0068] In some embodiments, the subject exhibits a CD19+ relapse. In some embodiments, the subject has relapsed or refractory CD19+ B-ALL. In some embodiments, the subject has relapsed or refractory CD19+ DLBCL. In one embodiment, the subject has relapsed or refractory B-ALL with lymph node involvement, e.g., lymphomatous disease.
[0069] In some embodiments, a subject with relapsed or refractory B-ALL with lymph node involvement, e.g., a lymphomatous disease, to prior treatment with CD19 CAR therapy, shows a decrease in PET-rich lesions, e.g., a decrease in the number or intensity of lesions, in response to CD19 CAR therapy-PD1 inhibitor therapy, e.g., in response to one or more cycles of CD19 CAR therapy-PD1 inhibitor therapy.
[0070] In some embodiments, a subject, e.g., a subject who exhibits CD19+ relapse after CD19CAR therapy, is administered an additional CD19 CAR therapy in combination with a PD-1 inhibitor, e.g., pembrolizumab. In embodiments, the additional administration of the combination therapy results in an improved treatment outcome, e.g., the subject achieves one or more of a partial remission, a complete remission, or long-term CAR T cell persistence. In certain embodiments, the administration of the combination therapy results in long-term persistence of CAR T cells, e.g., CD19 CAR-expressing cells. In certain embodiments, the administration of the combination therapy results in a longer time to B-cell recovery, e.g., a longer time to B-cell aplasia, e.g., compared to a subject treated with CD19 CAR therapy alone. In some embodiments, a subject treated with a combination disclosed herein has one or more of: (i) a reduced risk of relapse; (ii) a delayed timing of relapse; or (iii) a reduced severity of relapse, e.g., compared to a subject treated with CD19 CAR therapy alone. In certain embodiments, the administration of the combination therapy results in an objective clinical response.
[0071] In some embodiments, a subject, e.g., a subject who exhibits relapse after CD19 CAR therapy, is eligible to receive a repeat administration of CD19 CAR therapy, e.g., a second, third, or fourth dose. In some embodiments, a subject is eligible to receive a repeat administration of CD19 CAR therapy together with a PD-1 inhibitor, e.g., a second, third, or fourth dose. In some embodiments, a subject who exhibits poor persistence of CD19 CAR therapy after an initial administration of CD19 CAR therapy is eligible to receive a repeat administration of CD19 CAR therapy together with a PD-1 inhibitor, e.g., a second, third, or fourth dose.
[0072] Optionally, the subject has or is identified as having cancer cells, e.g., DLBCL cells, that are at least 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% CD3+ / PD1+.
[0073] In another aspect, the disclosure features a composition (e.g., one or more dosage formulations, combinations, or one or more pharmaceutical compositions) comprising cells expressing a CAR described herein (e.g., a CD19 CAR) and a PD-1 inhibitor described herein. In one embodiment, the CAR (e.g., a CD19 CAR) comprises an antigen binding domain (e.g., a CD19 antigen binding domain) as described herein, a transmembrane domain, and an intracellular signaling domain. In one embodiment, the CD19 CAR comprises a CD19 antigen binding domain listed in Table 2 or Table 3. In one embodiment, the PD-1 inhibitor comprises an antibody molecule, a small molecule, a polypeptide, such as a fusion protein, or an inhibitory nucleic acid, such as an siRNA or shRNA. In one embodiment, the PD-1 inhibitor comprises an antibody molecule, such as pembrolizumab, nivolumab, PDR001, or an antibody molecule listed in Table 6. The CAR-expressing cells and the PD-1 inhibitor can be in the same or different formulations or pharmaceutical compositions.
[0074] In another aspect, the disclosure features a composition (e.g., one or more dosage formulations, combinations, or one or more pharmaceutical compositions) comprising a cell expressing a CAR described herein (e.g., a CD19 CAR) and a PD-1 inhibitor described herein, for use in a method of treating a disease (e.g., cancer), e.g., a disease associated with CD19 expression, e.g., a cancer described herein. In one embodiment, the CAR (e.g., a CD19 CAR) comprises an antigen binding domain (e.g., a CD19 antigen binding domain) as described herein, a transmembrane domain, and an intracellular signaling domain. In one embodiment, the CD19 CAR comprises a CD19 antigen binding domain listed in Table 2 or Table 3. In one embodiment, the PD-1 inhibitor comprises an antibody molecule, a small molecule, a polypeptide, e.g., a fusion protein, or an inhibitory nucleic acid, e.g., an siRNA or shRNA. In one embodiment, the PD-1 inhibitor comprises an antibody molecule, e.g., pembrolizumab, nivolumab, PDR001, or an antibody molecule listed in Table 6. The CAR-expressing cells and the PD-1 inhibitor can be in the same or different formulations or pharmaceutical compositions.
[0075] PD-1 inhibitors Provided herein are PD-1 inhibitors for use in any of the methods or compositions described herein. In any of the methods or compositions described herein, the PD-1 inhibitor includes an antibody molecule, a small molecule, a polypeptide, such as a fusion protein, or an inhibitory nucleic acid, such as an siRNA or shRNA.
[0076] In one embodiment, the PD-1 inhibitor is characterized by one or more of the following: inhibiting or reducing PD-1 expression, e.g., the transcription or translation of PD-1; inhibiting or reducing PD-1 activity, e.g., inhibiting or reducing binding of PD-1 to its ligand, e.g., PD-L1; or binding to PD-1 or its ligand, e.g., PD-L1.
[0077] In one embodiment, the PD-1 inhibitor is an antibody molecule.
[0078] In one embodiment, the PD-1 inhibitor comprises an anti-PD-1 antibody molecule comprising heavy chain complementarity determining region 1 (HC CDR1), heavy chain complementarity determining region 2 (HC CDR2), and heavy chain complementarity determining region 3 (HC CDR3) of any PD-1 antibody molecule amino acid sequence listed in Table 6, and / or light chain complementarity determining region 1 (LC CDR1), light chain complementarity determining region 2 (LC CDR2), and light chain complementarity determining region 3 (LC CDR3) of any PD-1 antibody molecule amino acid sequence listed in Table 6. In one embodiment, the anti-PD1 antibody molecule comprises an HC CDR1 amino acid sequence selected from SEQ ID NO: 137 or 140, an HC CDR2 amino acid sequence of SEQ ID NO: 138 or 141, and an HC CDR3 amino acid sequence of SEQ ID NO: 139, and / or an LC CDR1 amino acid sequence of SEQ ID NO: 146 or 149, an LC CDR2 amino acid sequence of SEQ ID NO: 147 or 150, and an LC CDR3 amino acid sequence of SEQ ID NO: 148, 151, 166, or 167. In one embodiment, the anti-PD-1 antibody comprises an HC CDR1 amino acid sequence selected from SEQ ID NO: 137 or 140, an HC CDR2 amino acid sequence of SEQ ID NO: 138 or 141, and an HC CDR3 amino acid sequence of SEQ ID NO: 139, and / or an LC CDR1 amino acid sequence of SEQ ID NO: 146 or 149, an LC CDR2 amino acid sequence of SEQ ID NO: 147 or 150, and an LC CDR3 amino acid sequence of SEQ ID NO: 166 or 167.
[0079] In one embodiment, the anti-PD-1 antibody molecule comprises a heavy chain variable region comprising any of the heavy chain variable region amino acid sequences listed in Table 6, e.g., SEQ ID NO: 142, 144, 154, 158, 154, 158, 172, 184, 216, or 220. In one embodiment, the anti-PD-1 antibody molecule comprises a heavy chain variable region comprising an amino acid sequence that has at least one, two, or three alterations, but no more than 30, 20, or 10 alterations, relative to any of the heavy chain variable region amino acid sequences provided in Table 6, e.g., SEQ ID NO: 142, 144, 154, 158, 154, 158, 172, 184, 216, or 220. In one embodiment, the anti-PD-1 antibody molecule comprises a heavy chain variable region comprising an amino acid sequence at least 95% identical (e.g., 95-99% identical) to any of the heavy chain variable region amino acid sequences provided in Table 6, e.g., SEQ ID NO: 142, 144, 154, 158, 154, 158, 172, 184, 216, or 220.
[0080] In one embodiment, the anti-PD-1 antibody molecule comprises a heavy chain comprising an amino acid sequence of any heavy chain listed in Table 6, e.g., SEQ ID NO: 156, 160, 174, 186, 218, 222, 225, or 236. In one embodiment, the anti-PD-1 antibody molecule comprises a heavy chain comprising an amino acid sequence that has at least one, two, or three alterations but no more than 30, 20, or 10 alterations relative to any heavy chain listed in Table 6, e.g., SEQ ID NO: 156, 160, 174, 186, 218, 222, 225, or 236. In one embodiment, the anti-PD-1 antibody molecule comprises a heavy chain comprising an amino acid sequence that is 95-99% identical to any heavy chain amino acid sequence listed in Table 6, e.g., SEQ ID NO: 156, 160, 174, 186, 218, 222, 225, or 236.
[0081] In one embodiment, the anti-PD-1 antibody molecule comprises a light chain variable region comprising any of the light chain variable region amino acid sequences listed in Table 6, e.g., SEQ ID NO: 152, 162, 168, 176, 180, 188, 192, 196, 200, 204, 208, or 212. In one embodiment, the anti-PD-1 antibody molecule comprises a light chain variable region comprising an amino acid sequence that has at least one, two, or three alterations, but no more than 30, 20, or 10 alterations, relative to any of the light chain variable region amino acid sequences provided in Table 6, e.g., SEQ ID NO: 152, 162, 168, 176, 180, 188, 192, 196, 200, 204, 208, or 212. In one embodiment, the anti-PD-1 antibody molecule comprises a light chain variable region comprising an amino acid sequence at least 95% identical (e.g., 95-99% identical) to any of the light chain variable region amino acid sequences provided in Table 6, e.g., SEQ ID NO: 152, 162, 168, 176, 180, 188, 192, 196, 200, 204, 208, or 212.
[0082] In one embodiment, the anti-PD-1 antibody molecule comprises a light chain comprising the amino acid sequence of any light chain listed in Table 6, e.g., SEQ ID NO: 164, 170, 178, 182, 190, 194, 198, 202, 206, 210, or 214. In one embodiment, the anti-PD-1 antibody molecule comprises a light chain comprising an amino acid sequence that has at least one, two, or three, but not more than 30, 20, or 10, modifications relative to any light chain listed in Table 6, e.g., SEQ ID NO: 164, 170, 178, 182, 190, 194, 198, 202, 206, 210, or 214. In one embodiment, the anti-PD-1 antibody molecule comprises a light chain comprising an amino acid sequence at least 95% identical (e.g., having 95-99% identity) to any light chain listed in Table 6, e.g., SEQ ID NO: 164, 170, 178, 182, 190, 194, 198, 202, 206, 210, or 214.
[0083] In one embodiment, the anti-PD-1 antibody molecule is i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 144 and a light chain comprising the amino acid sequence of SEQ ID NO: 152; ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 156 or 160 and a light chain comprising the amino acid sequence of SEQ ID NO: 164; iii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 156 or 160 and a light chain comprising the amino acid sequence of SEQ ID NO: 170 iv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 178; v) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 182; vi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 186 and a light chain comprising the amino acid sequence of SEQ ID NO: 182; vii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 186 and a light chain comprising the amino acid sequence of SEQ ID NO: 190; viii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 190; ix) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 194; x) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 198; xi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 186 and a light chain comprising the amino acid sequence of SEQ ID NO: 202; xii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 202; xiii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 186 and a light chain comprising the amino acid sequence of SEQ ID NO: 206; xiv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 206; xv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 210; xvi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 214; xvii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 218 and a light chain comprising the amino acid sequence of SEQ ID NO: 206; xviii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 218 and a light chain comprising the amino acid sequence of SEQ ID NO: 202; xix) a heavy chain comprising the amino acid sequence of SEQ ID NO: 222 and a light chain comprising the amino acid sequence of SEQ ID NO: 202; xx) a heavy chain comprising the amino acid sequence of SEQ ID NO: 225 and a light chain comprising the amino acid sequence of SEQ ID NO: 178; xxi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 225 and a light chain comprising the amino acid sequence of SEQ ID NO: 190; xxii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 225 and a light chain comprising the amino acid sequence of SEQ ID NO: 202; xxiii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 236 and a light chain comprising the amino acid sequence of SEQ ID NO: 206, or xxiv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 225 and a light chain comprising the amino acid sequence of SEQ ID NO: 206 Includes:
[0084] In one embodiment, the anti-PD-1 antibody molecule is i) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 204; ii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 142 or 144 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 152; iii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 154 or 158 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 162; iv) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 154 or 158 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 168; v) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 176; vi) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 180; vii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 184 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 180; viii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 184 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 188; ix) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 188; x) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 192; xi) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 196; xii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 184 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 200; xiii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 200; xiv) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 184 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 204; xv) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 204; xvi) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 208; xvii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 212; xviii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 216 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 204; xix) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 216 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 200; xx) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 220 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 200; xxi) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 176; xxii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 188; xxiii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 200, or xxiv) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 184 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 204 Includes:
[0085] In one embodiment, the anti-PD-1 antibody molecule comprises at least one or two heavy chain variable domains (optionally including constant regions), at least one or two light chain variable domains (optionally including constant regions), or both, comprising the amino acid sequence of BAP049-clone-A, BAP049-clone-B, BAP049-clone-C, BAP049-clone-D, or BAP049-clone-E, or as set forth in Table 1 of U.S. Patent Application Publication No. 2015 / 0210769, or Table 6 herein, or as encoded by the nucleotide sequence of Table 6, or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical) to any of the foregoing sequences. The anti-PD-1 antibody molecule optionally comprises a leader sequence from the heavy chain, the light chain, or both, as set forth in Table 4 of U.S. Patent Application Publication No. 2015 / 0210769, or a sequence substantially identical thereto.
[0086] In yet another embodiment, the anti-PD-1 antibody molecule is an antibody described herein, e.g., BAP049-hum01, BAP049-hum02, BAP049-hum03, BAP049-hum04, BAP049-hum05, BAP049-hum06, BAP049-hum07, BAP049-hum08, BAP049-hum09, BAP049-hum10, BAP049-hum11, BAP049-hum12, BAP049-hum13, BAP049-hum14, BAP049-hum15, BAP049-hum16, BAP049-hum17, BAP049-hum18, BAP049-hum19, BAP049-hum20, BAP049-hum21, BAP049-hum22, BAP049-hum23, BAP049-hum24, BAP049-hum25, BAP049-hum26, BAP049-hum27, BAP049-hum28, BAP049-hum29, BAP049-hum30, BAP049-hum31, BAP049-hum32, BAP049-hum33, BAP049-hum34, BAP049-hum35, BAP049-hum36, BAP049-hum37, BAP049-hum38, BAP049-hum39, BAP049-hum40, BAP049-hum41, BAP049-hum42, BAP049-hum43, BAP049-hum44, BAP049-hum45, BAP049-hum46, BAP049-hum47, BAP049-hum48, BAP049-hum and / or BAP049-clone-A, BAP049-clone-B, BAP049-clone-C, BAP049-clone-D, or BAP049-clone-E, or as set forth in Table 6, or encoded by the nucleotide sequence of Table 6, or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical) to any of the foregoing sequences.
[0087] In yet another embodiment, the anti-PD-1 antibody molecule comprises at least one, two, or three CDRs (or collectively, all of the CDRs) from a heavy chain variable region comprising the amino acid sequence shown in Table 1 of U.S. Patent Application Publication No. 2015 / 0210769, or Table 6 herein, or encoded by the nucleotide sequence shown in Table 6. In one embodiment, one or more of the CDRs (or collectively, all of the CDRs) have one, two, three, four, five, six, or more alterations, e.g., amino acid substitutions or deletions, compared to the amino acid sequence shown in Table 6, or encoded by the nucleotide sequence shown in Table 6.
[0088] In yet another embodiment, the anti-PD-1 antibody molecule comprises at least one, two, or three CDRs (or collectively, all of the CDRs) from a light chain variable region comprising the amino acid sequence shown in Table 1 of U.S. Patent Application Publication No. 2015 / 0210769, or Table 6 herein, or encoded by the nucleotide sequence shown in Table 6. In one embodiment, one or more of the CDRs (or collectively, all of the CDRs) have one, two, three, four, five, six, or more alterations, e.g., amino acid substitutions or deletions, compared to the amino acid sequence shown in Table 6, or encoded by the nucleotide sequence shown in Table 6. In a specific embodiment, the anti-PD-1 antibody molecule comprises a substitution in a light chain CDR, e.g., one or more substitutions in CDR1, CDR2, and / or CDR3 of the light chain. In one embodiment, the anti-PD-1 antibody molecule comprises a substitution in the light chain CDR3 at position 102 of the light chain variable region, e.g., a cysteine to tyrosine or cysteine to serine substitution at position 102 of a light chain variable region according to Table 6 (e.g., SEQ ID NO: 152 or 162 for murine or chimeric, unmodified, or any of SEQ ID NOs: 168, 176, 180, 188, 192, 196, 200, 204, 208, or 212 for modified sequences).
[0089] In another embodiment, the anti-PD-1 antibody molecule comprises at least one, two, three, four, five, or six CDRs (or collectively, all of the CDRs) from heavy and light chain variable regions comprising the amino acid sequences shown in Table 1 of U.S. Patent Application Publication No. 2015 / 0210769, or Table 6 herein, or encoded by the nucleotide sequences shown in Table 6. In one embodiment, one or more of the CDRs (or collectively, all of the CDRs) have one, two, three, four, five, six, or more alterations, e.g., amino acid substitutions or deletions, compared to the amino acid sequence shown in Table 6, or encoded by the nucleotide sequence shown in Table 6.
[0090] In one embodiment, the anti-PD-1 antibody molecule is (a) a heavy chain variable region (VH) comprising the VHCDR1 amino acid sequence of SEQ ID NO: 140, the VHCDR2 amino acid sequence of SEQ ID NO: 141, and the VHCDR3 amino acid sequence of SEQ ID NO: 139, and a light chain variable region (VL) comprising the VLCDR1 amino acid sequence of SEQ ID NO: 149, the VLCDR2 amino acid sequence of SEQ ID NO: 150, and the VLCDR3 amino acid sequence of SEQ ID NO: 167 (disclosed in Table 1 of U.S. Patent Application Publication No. 2015 / 0210769 or Table 6 herein, respectively); (b) a VH comprising a VHCDR1 amino acid sequence selected from SEQ ID NO: 137, a VHCDR2 amino acid sequence of SEQ ID NO: 138, and a VHCDR3 amino acid sequence of SEQ ID NO: 139, and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 146, a VLCDR2 amino acid sequence of SEQ ID NO: 147, and a VLCDR3 amino acid sequence of SEQ ID NO: 166 (disclosed in Table 1 of U.S. Patent Application Publication No. 2015 / 0210769 or Table 6 herein, respectively); (c) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 286, a VHCDR2 amino acid sequence of SEQ ID NO: 141, and a VHCDR3 amino acid sequence of SEQ ID NO: 139, and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 149, a VLCDR2 amino acid sequence of SEQ ID NO: 150, and a VLCDR3 amino acid sequence of SEQ ID NO: 167 (disclosed in Table 1 of U.S. Patent Application Publication No. 2015 / 0210769 or Table 6 herein, respectively); or (d) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 286, a VHCDR2 amino acid sequence of SEQ ID NO: 138, and a VHCDR3 amino acid sequence of SEQ ID NO: 139, and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 146, a VLCDR2 amino acid sequence of SEQ ID NO: 147, and a VLCDR3 amino acid sequence of SEQ ID NO: 166 (disclosed in Table 1 of U.S. Patent Application Publication No. 2015 / 0210769 or Table 6 herein, respectively). Includes:
[0091] In the combinations described herein below, in another embodiment, the anti-PD-1 antibody molecule comprises (i) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence selected from SEQ ID NO: 137, SEQ ID NO: 140, or SEQ ID NO: 286, a VHCDR2 amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 141, and a VHCDR3 amino acid sequence of SEQ ID NO: 139, and (ii) a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 146 or SEQ ID NO: 149, a VLCDR2 amino acid sequence of SEQ ID NO: 147 or SEQ ID NO: 150, and a VLCDR3 amino acid sequence of SEQ ID NO: 166 or SEQ ID NO: 167 (as disclosed in Table 1 of U.S. Patent Application Publication No. 2015 / 0210769 or Table 6 herein, respectively).
[0092] In embodiments, the PD-1 inhibitor, e.g., the anti-PD-1 antibody molecule, is PDR-001, which comprises the variable light chain and variable heavy chain amino acid sequences of BAP049-clone-E as set forth in Table 6. In one embodiment, the anti-PD-1 antibody molecule comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 204.
[0093] In some embodiments, the PD-1 inhibitor is selected from nivolumab, pembrolizumab, pidilizumab, AMP 514, AMP-224, or an anti-PD1 antibody described in U.S. Pat. No. 8,609,089, U.S. Patent Application Publication No. 2010028330, and / or U.S. Patent Application Publication No. 20120114649, each of which is incorporated by reference herein in its entirety.
[0094] In one embodiment, the PD-1 inhibitor is pembrolizumab. (i) a heavy chain variable (VH) region comprising a VHCDR1 amino acid sequence of SEQ ID NO: 503, a VHCDR2 amino acid sequence of SEQ ID NO: 504, and a VHCDR3 amino acid sequence of SEQ ID NO: 505; and (ii) a light chain variable (VL) region comprising the VLCDR1 amino acid sequence of SEQ ID NO: 500, the VLCDR2 amino acid sequence of SEQ ID NO: 501, and the VLCDR3 amino acid sequence of SEQ ID NO: 502; or High amino acid sequence identity of at least 85%, 90%, 95% or more Includes:
[0095] CAR-expressing cells Provided herein are cells, e.g., immune effector cells, expressing a chimeric antigen receptor (CAR) that targets, e.g., specifically binds, an antigen (e.g., CD19), for use in any of the methods or compositions described herein. A CAR that specifically binds to antigen X is also referred to herein as an "X CAR." For example, a CAR that specifically binds to CD19 is also referred to herein as a "CD19 CAR." A CAR (e.g., a CD19 CAR) expressed by a CAR-expressing cell (e.g., a CD19 CAR-expressing cell) described herein comprises an antigen-binding domain (e.g., a CD19-binding domain), a transmembrane domain, and an intracellular signaling domain. In one embodiment, the intracellular signaling domain comprises a costimulatory domain and / or a primary signaling domain.
[0096] In embodiments, the CAR molecule comprises an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain (e.g., an intracellular signaling domain comprising a costimulatory domain and / or a primary signaling domain).
[0097] In one embodiment, the CAR molecule comprises an antigen binding domain capable of binding to an antigen described herein, e.g., a tumor antigen, e.g., selected from one or more of the following: CD19, CD123, CD22, CD30, CD171, CS-1 (also referred to as CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24), C-type lectin-like molecule-1 (CLL-1 or CLECL1), CD33, epidermal growth factor receptor variant III (EGFRvIII), ganglioside G2 (GD2), ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer), TNF receptor family member B-cell maturation (BCMA), Tn antigen ((Tn Ag) or (GalNAcα-Ser / Thr)), prostate-specific membrane antigen (PSMA), receptor tyrosine kinase-like orphan receptor 1 (ROR1), Fms-like tyrosine kinase 3 (FLT3), tumor-associated glycoprotein 72 (TAG72), CD38, CD44v6, carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EPCAM), B7H3 (CD276), KIT (CD117), interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD213A2), mesothelin, interleukin-11 receptor alpha (IL-11Ra), prostate stem cell antigen (PSCA), protease serine 21 (testisin or PRSS21), vascular endothelial growth factor receptor 2 (VEGFR2), Lewis (Y) antibody Hara, CD24, platelet-derived growth factor receptor beta (PDGFR-β), stage-specific embryonic antigen-4 (SSEA-4), CD20, folate receptor alpha, receptor tyrosine-protein kinase ERBB2 (Her2 / neu), mucin 1, cell surface-associated (MUC1), epidermal growth factor receptor (EGFR), neural cell adhesion molecule (NCAM), prostase, prostatic acid phosphatase (PAP), elongation factor 2 mutated (ELF2M), ephrin B2, fibroblast activation protein alpha (FAP), insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CAIX), proteasome (prosome, macropain) subunit, beta, 9 (LMP2), glycoprotein 100 (gp100),The oncogene fusion protein (bcr-abl) consisting of the breakpoint cluster region (BCR) and Abelson murine leukemia viral oncogene homolog 1 (Abl), tyrosinase, ephrin type A receptor 2 (EphA2), fucosyl GM1, sialyl Lewis adhesion molecule (sLe), ganglioside GM3 (aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer), transglutaminase 5 (TGS5), and high molecular weight melanoma-associated protein (HMWPE) were also detected. Human mesenchymal tumor antigen (HMWMAA), o-acetyl-GD2 ganglioside (OAcGD2), folate receptor β, tumor endothelial marker 1 (TEM1 / CD248), tumor endothelial marker 7-related (TEM7R), claudin 6 (CLDN6), thyroid-stimulating hormone receptor (TSHR), G protein-coupled receptor class C group 5, member D (GPRC5D), X chromosome open reading frame 61 (CXORF61), CD97, CD179a, anaplastic lymphoma Alveolar kinase (ALK), polysialic acid, placenta-specific 1 (PLAC1), hexasaccharide moiety of globo-H glycoceramide (GloboH), mammary differentiation antigen (NY-BR-1), uroplakin 2 (UPK2), hepatitis A virus cellular receptor 1 (HAVCR1), adrenoceptor β3 (ADRB3), pannexin 3 (PANX3), G protein-coupled receptor 20 (GPR20), lymphocyte antigen 6 complex, gene locus K9 (LY6K), olfactory receptor 51E2 (OR51 E2), TCRγ alternative reading frame protein (TARP), Wilms tumor protein (WT1), cancer / testis antigen 1 (NY-ESO-1), cancer / testis antigen 2 (LAGE-1a), melanoma-associated antigen 1 (MAGE-A1), ETS translocation variant gene 6, located on chromosome 12p (ETV6-AML), sperm protein 17 (SPA17), X antigen family, member 1A (XAGE1), angiopoietin-binding cell surface receptor 2 (Tie 2), melanoma cancer testis antigen-1 (MAD-CT-1), melanoma cancer testis antigen-2 (MAD-CT-2), Fos-related antigen 1, tumor protein p53 (p53), p53 mutant, prostein, surviving, telomerase, prostate cancer tumor antigen-1 (PCTA-1 or galectin 8), melanoma antigen 1 recognized by T cells (Melan-A or MART1), rat sarcoma (Ras) mutant,Human telomerase reverse transcriptase (hTERT), sarcoma translocation breakpoints, melanoma inhibitor of apoptosis (ML-IAP), ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene), N-acetylglucosaminyltransferase V (NA17), paired box protein Pax-3 (PAX3), androgen receptor, cyclin B1, v-myc avian myelocytomatosis viral oncogene neuroblastoma-derived homolog (MYCN), Ras homolog family member C (RhoC), tyrosinase-related protein 2 (TRP-2), cytochrome P450 1B1 (CYP1B1), CCCTC-binding factor (zinc finger protein)-like (BORIS or Brother of the Regulator of Imprinted Sites) Sites), squamous cell carcinoma antigen 3 recognized by T cells (SART3), paired box protein Pax-5 (PAX5), proacrosin-binding protein sp32 (OY-TES1), lymphocyte-specific protein tyrosine kinase (LCK), A-kinase anchor protein 4 (AKAP-4), synovial sarcoma, X-breakpoint 2 (SSX2), receptor for advanced glycation end products (RAGE-1), renal ubiquitous 1 (RU1), renal ubiquitous 2 (RU2), legumain, human papillomavirus E6 (HPV E6), human papillomavirus E7 (HPV E7), intestinal carboxylesterase, heat shock protein 70-2 mutant (mutated) hsp70-2), CD79a, CD79b, CD72, leukocyte-associated immunoglobulin-like receptor 1 (LAIR1), Fc fragment of IgA receptor (FCAR or CD89), leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2), CD300 molecule-like family member f (CD300LF), C-type lectin domain family 12 member A (CLEC12A), bone marrow stromal cell antigen 2 (BST2), EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2), lymphocyte antigen 75 (LY75), glypican-3 (GPC3), Fc receptor-like 5 (FCRL5), and immunoglobulin lambda-like polypeptide 1 (IGLL1).
[0098] In one embodiment, the antigen binding domain of the CAR binds to a B cell antigen, such as CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, and / or CD79a.
[0099] In embodiments, the antigen binding domain of the CAR binds to CD123.
[0100] In embodiments, the antigen binding domain of the CAR binds to CD19.
[0101] In other embodiments, the antigen binding domain of the CAR binds to BCMA.
[0102] In embodiments, the antigen binding domain of the CAR binds to CLL.
[0103] CD19 antigen-binding domain In one embodiment, the CD19 binding domain comprises heavy chain complementarity determining region 1 (HC CDR1), heavy chain complementarity determining region 2 (HC CDR2), and heavy chain complementarity determining region 3 (HC CDR3) of any CD19 heavy chain binding domain amino acid sequence listed in Table 2 or Table 3, and light chain complementarity determining region 1 (LC CDR1), light chain complementarity determining region 2 (LC CDR2), and light chain complementarity determining region 3 (LC CDR3) of any CD19 light chain binding domain amino acid sequence listed in Table 2 or Table 3. In one embodiment, the CD19 binding domain comprises HC CDR1, HC CDR2, and HC CDR3 according to the HC CDR amino acid sequences of Table 4, and LC CDR1, LC CDR2, and LC CDR3 according to the LC CDR amino acid sequences of Table 5.
[0104] In one embodiment, the CD19 binding domain comprises (e.g., consists of) an amino acid sequence selected from the group consisting of SEQ ID NO: 109, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 110, SEQ ID NO: 112, or SEQ ID NO: 115. In one embodiment, the CD19 binding domain comprises (e.g., consists of) an amino acid sequence with at least one, two, or three modifications but no more than 30, 20, or 10 modifications (e.g., substitutions, e.g., conservative substitutions) relative to any of SEQ ID NO: 109, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 110, SEQ ID NO: 112, or SEQ ID NO: 115. In one embodiment, the CD19 binding domain comprises (e.g., consists of) an amino acid sequence having 95 to 99% identity to any of the amino acid sequences set forth in SEQ ID NO: 109, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 110, SEQ ID NO: 112, or SEQ ID NO: 115.
[0105] Further domains of the CAR molecule In one embodiment, the CAR, e.g., a CD19 CAR, comprises a transmembrane domain comprising a transmembrane domain of a protein selected from the group consisting of the α, β, or ζ chain of the T cell receptor, CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154, e.g., a protein described herein. In one embodiment, the transmembrane domain comprises the sequence of SEQ ID NO: 6. In one embodiment, the transmembrane domain comprises an amino acid sequence containing at least one, two, or three but not more than 20, 10, or five modifications of the amino acid sequence of SEQ ID NO: 6, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO: 6. In one embodiment, the nucleic acid sequence encoding the transmembrane domain comprises the nucleotide sequence of SEQ ID NO: 17, or a sequence at least 95% identical (e.g., with 95-99% identity) thereto.
[0106] In one embodiment, the antigen-binding domain (e.g., CD19-binding domain) is connected to the transmembrane domain by a hinge region, e.g., a hinge region described herein. In one embodiment, the encoded hinge region comprises SEQ ID NO: 2, or a sequence at least 95% identical thereto (e.g., having 95-99% identity). In one embodiment, the nucleic acid sequence encoding the hinge region comprises the nucleotide sequence of SEQ ID NO: 13, or a sequence at least 95% identical thereto (e.g., having 95-99% identity).
[0107] In one embodiment, the isolated nucleic acid molecule further comprises a sequence encoding a costimulatory domain, e.g., a costimulatory domain described herein. In an embodiment, the intracellular signaling domain comprises a costimulatory domain. In an embodiment, the intracellular signaling domain comprises a primary signaling domain. In an embodiment, the intracellular signaling domain comprises a costimulatory domain and a primary signaling domain.
[0108] In one embodiment, the costimulatory domain is selected from the group consisting of, for example, an MHC class I molecule, a TNF receptor protein, an immunoglobulin-like protein, a cytokine receptor, an integrin, a signaling lymphocyte activation molecule (SLAM protein), an activating NK cell receptor, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a / CD18), 4-1BB (CD137), ), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NK p46, CD19, CD4, CD8α, CD8β, IL2Rβ, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d , ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, T NFR2, TRANCE / RANKL, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), CEACAM1, CRTAM, Ly9(CD229), CD160(BY55) ), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, and a ligand that specifically binds to CD83, e.g., a protein described herein.
[0109] In one embodiment, the costimulatory domain of 4-1BB comprises the amino acid sequence of SEQ ID NO: 7. In one embodiment, the encoded costimulatory domain comprises an amino acid sequence having at least one, two, or three, but not more than 20, 10, or five, modifications of the amino acid sequence of SEQ ID NO: 7, or a sequence at least 95% identical (e.g., 95-99% identity) to the amino acid sequence of SEQ ID NO: 7. In one embodiment, the nucleic acid sequence encoding the costimulatory domain comprises the nucleotide sequence of SEQ ID NO: 18, or a sequence at least 95% identical (e.g., 95-99% identity) thereto. In another embodiment, the costimulatory domain of CD28 comprises the amino acid sequence of SEQ ID NO: 36. In one embodiment, the costimulatory domain comprises an amino acid sequence having at least one, two, or three, but not more than 20, 10, or five modifications of the amino acid sequence of SEQ ID NO: 36, or a sequence that is 95-99% identical to the amino acid sequence of SEQ ID NO: 36. In one embodiment, the nucleic acid sequence encoding the costimulatory domain of CD28 comprises the nucleotide sequence of SEQ ID NO: 37, or a sequence at least 95% identical thereto (e.g., 95-99% identity). In another embodiment, the costimulatory domain of CD27 comprises the amino acid sequence of SEQ ID NO: 8. In one embodiment, the costimulatory domain comprises an amino acid sequence having at least one, two, or three but not more than 20, 10, or 5 modifications of the amino acid sequence of SEQ ID NO: 8, or a sequence at least 95% identical thereto (e.g., 95-99% identity). In one embodiment, the nucleic acid sequence encoding the costimulatory domain of CD27 comprises the nucleotide sequence of SEQ ID NO: 19, or a sequence at least 95% identical thereto (e.g., 95-99% identity). In another embodiment, the costimulatory domain of ICOS comprises the amino acid sequence of SEQ ID NO: 38. In one embodiment, the costimulatory domain of ICOS comprises an amino acid sequence having at least one, two, or three, but not more than 20, 10, or 5, modifications of the amino acid sequence of SEQ ID NO: 38, or a sequence having 95-99% identity to the amino acid sequence of SEQ ID NO: 38.In one embodiment, the nucleic acid sequence encoding the costimulatory domain of ICOS comprises the nucleotide sequence of SEQ ID NO: 44 or a sequence at least 95% identical thereto (e.g., 95-99% identical thereto). In an embodiment, the costimulatory domain comprises an ICOS costimulatory domain mutant (e.g., a Y to F mutant) comprising the amino acid sequence of SEQ ID NO: 43.
[0110] In some embodiments, the primary signaling domain comprises a functional signaling domain of CD3ζ. In embodiments, the functional signaling domain of CD3ζ comprises the amino acid sequence of SEQ ID NO:9 (mutant CD3ζ) or SEQ ID NO:10 (wild-type human CD3ζ), or a sequence at least 95% identical thereto (e.g., 95-99% identical thereto).
[0111] In one embodiment, the intracellular signaling domain comprises a functional signaling domain of 4-1BB and / or a functional signaling domain of CD3ζ. In one embodiment, the intracellular signaling domain of 4-1BB comprises the sequence of SEQ ID NO:7 and / or the CD3ζ amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises an amino acid sequence having at least one, two, or three modifications, but not more than 20, 10, or five modifications, of the amino acid sequence of SEQ ID NO:7 and / or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, or a sequence at least 95% identical (e.g., 95-99% identity) to the amino acid sequence of SEQ ID NO:7 and / or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises the sequence of SEQ ID NO:7 and the sequence of SEQ ID NO:9 or SEQ ID NO:10, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame as a single polypeptide chain. In one embodiment, the nucleic acid sequence encoding the intracellular signaling domain comprises the nucleotide sequence of SEQ ID NO: 18, or a sequence at least 95% identical thereto (e.g., 95-99% identical thereto), and / or the CD3ζ nucleotide sequence of SEQ ID NO: 20 or SEQ ID NO: 21, or a sequence at least 95% identical thereto (e.g., 95-99% identical thereto).
[0112] In one embodiment, the intracellular signaling domain comprises a functional signaling domain of CD27 and / or a functional signaling domain of CD3ζ. In one embodiment, the encoded intracellular signaling domain of CD27 comprises the amino acid sequence of SEQ ID NO:8 and / or the CD3ζ amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises an amino acid sequence having at least one, two, or three modifications but not more than 20, 10, or five modifications of the amino acid sequence of SEQ ID NO:8 and / or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, or a sequence at least 95% identical (e.g., 95-99% identity) to the amino acid sequence of SEQ ID NO:8 and / or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises the sequence of SEQ ID NO:8 and the sequence of SEQ ID NO:9 or SEQ ID NO:10, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame as a single polypeptide chain. In one embodiment, the nucleic acid sequence encoding the intracellular signaling domain of CD27 comprises the nucleotide sequence of SEQ ID NO: 19, or a sequence at least 95% identical thereto (e.g., 95-99% identical thereto), and / or the CD3ζ nucleotide sequence of SEQ ID NO: 20 or SEQ ID NO: 21, or a sequence at least 95% identical thereto (e.g., 95-99% identical thereto).
[0113] In one embodiment, the intracellular signaling domain comprises a functional signaling domain of CD28 and / or a functional signaling domain of CD3ζ. In one embodiment, the intracellular signaling domain of CD28 comprises the amino acid sequence of SEQ ID NO:36 and / or the CD3ζ amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises an amino acid sequence having at least one, two, or three, but not more than 20, 10, or five, modifications of the amino acid sequence of SEQ ID NO:36 and / or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, or a sequence at least 95% identical (e.g., 95-99% identity) to the amino acid sequence of SEQ ID NO:36 and / or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises the sequence of SEQ ID NO:36 and the sequence of SEQ ID NO:9 or SEQ ID NO:10, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame as a single polypeptide chain. In one embodiment, the nucleic acid sequence encoding the intracellular signaling domain of CD28 comprises the nucleotide sequence of SEQ ID NO: 37, or a sequence at least 95% identical thereto (e.g., having 95-99% identity), and / or the CD3ζ nucleotide sequence of SEQ ID NO: 20 or SEQ ID NO: 21, or a sequence at least 95% identical thereto (e.g., having 95-99% identity).
[0114] In one embodiment, the intracellular signaling domain comprises a functional signaling domain of ICOS and / or a functional signaling domain of CD3ζ. In one embodiment, the intracellular signaling domain of ICOS comprises the amino acid sequence of SEQ ID NO:38 and / or the CD3ζ amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises an amino acid sequence having at least one, two, or three modifications, but not more than 20, 10, or five modifications, of the amino acid sequence of SEQ ID NO:38 and / or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, or a sequence at least 95% identical (e.g., 95-99% identity) to the amino acid sequence of SEQ ID NO:38 and / or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises the sequence of SEQ ID NO:38 and the sequence of SEQ ID NO:9 or SEQ ID NO:10, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame as a single polypeptide chain. In one embodiment, the nucleic acid sequence encoding the intracellular signaling domain of ICOS comprises the nucleotide sequence of SEQ ID NO: 44 or a sequence at least 95% identical thereto (e.g., having 95-99% identity), and / or the CD3ζ nucleotide sequence of SEQ ID NO: 20 or SEQ ID NO: 21 or a sequence at least 95% identical thereto (e.g., having 95-99% identity).
[0115] In one embodiment, the CAR, e.g., a CD19 CAR, further comprises a leader sequence comprising the amino acid sequence of SEQ ID NO:1.
[0116] Exemplary CAR Molecules In one embodiment, the CD19 CAR comprises the amino acid sequence of any of SEQ ID NO: 108, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 111, SEQ ID NO: 114, or SEQ ID NO: 116. In one embodiment, the CD19 CAR comprises an amino acid sequence with at least one, two, or three modifications but no more than 30, 20, or 10 modifications relative to any of SEQ ID NO: 108, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 111, SEQ ID NO: 114, or SEQ ID NO: 116. In one embodiment, the CD19 CAR comprises an amino acid sequence at least 95% identical (e.g., having 95-99% identity) to any of SEQ ID NO:108, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:111, SEQ ID NO:114, or SEQ ID NO:116.
[0117] In one embodiment, the CAR molecule comprises a CD123 CAR described herein, such as a CD123 CAR described in U.S. Patent Application Publication No. 2014 / 0322212A1 or U.S. Patent Application Publication No. 2016 / 0068601A1 (both of which are incorporated by reference herein). In an embodiment, the CD123 CAR comprises the amino acid or has the nucleotide sequence set forth in U.S. Patent Application Publication No. 2014 / 0322212A1 or U.S. Patent Application Publication No. 2016 / 0068601A1 (both of which are incorporated by reference herein).
[0118] In embodiments, the CAR molecule comprises a CD19 CAR molecule described herein, such as a CD19 CAR molecule described in U.S. Patent Application Publication No. 2015-0283178-A1, e.g., CTL019. In embodiments, the CD19 CAR comprises the amino acid or has the nucleotide sequence set forth in U.S. Patent Application Publication No. 2015-0283178-A1, which is incorporated herein by reference.
[0119] In one embodiment, the CAR molecule comprises a BCMA CAR molecule described herein, such as the BCMA CAR described in U.S. Patent Application Publication No. 2016-0046724-A1. In an embodiment, the BCMA CAR comprises the amino acid or has the nucleotide sequence set forth in U.S. Patent Application Publication No. 2016-0046724-A1, which is incorporated herein by reference.
[0120] In one embodiment, the CAR molecule comprises a CLL1 CAR described herein, such as the CLL1 CAR described in U.S. Patent Application Publication No. 2016 / 0051651A1, which is incorporated herein by reference. In an embodiment, the CLL1 CAR comprises the amino acid or has the nucleotide sequence set forth in U.S. Patent Application Publication No. 2016 / 0051651A1, which is incorporated herein by reference.
[0121] In one embodiment, the CAR molecule comprises a CD33 CAR described herein, such as the CD33 CAR described in U.S. Patent Application Publication No. 2016 / 0096892A1, which is incorporated herein by reference. In an embodiment, the CD33 CAR comprises the amino acid or has the nucleotide sequence set forth in U.S. Patent Application Publication No. 2016 / 0096892A1, which is incorporated herein by reference.
[0122] In some embodiments, the CAR molecule comprises an EGFRvIII CAR molecule described herein, such as the EGFRvIII CAR described in U.S. Patent Application Publication No. 2014 / 0322275A1, which is incorporated herein by reference. In embodiments, the EGFRvIII CAR comprises the amino acid or has the nucleotide sequence set forth in U.S. Patent Application Publication No. 2014 / 0322275A1, which is incorporated herein by reference.
[0123] In some embodiments, the CAR molecule comprises a mesothelin CAR described herein, such as the mesothelin CAR described in WO 2015 / 090230 (incorporated herein by reference). In embodiments, the mesothelin CAR comprises the amino acid or has the nucleotide sequence set forth in WO 2015 / 090230 (incorporated herein by reference).
[0124] In embodiments of any of the methods and compositions described herein, the cell comprising a CAR comprises a nucleic acid encoding the CAR.
[0125] In one embodiment, the nucleic acid encoding CAR is a lentiviral vector.In one embodiment, the nucleic acid encoding CAR is introduced into cells by lentiviral transduction.In one embodiment, the nucleic acid encoding CAR is RNA, for example, in vitro transcribed RNA.In one embodiment, the nucleic acid encoding CAR is introduced into cells by electroporation.
[0126] In embodiments of any of the methods and compositions described herein, the cell is a T cell or an NK cell. In one embodiment, the T cell is an autologous T cell or an allogeneic T cell.
[0127] In one embodiment, the method further comprises administering an additional therapeutic agent for the treatment of a disease described herein, e.g., an anti-cancer therapeutic agent. In an embodiment, the method further comprises administering a lymphodepleting agent, e.g., as described herein, before, concomitantly with, or after administration comprising, e.g., a CAR-expressing cell (e.g., a CD19 CAR-expressing cell) and / or a PD-1 inhibitor described herein. In an embodiment, the lymphodepleting agent comprises one or more chemotherapeutic agents, combinations of chemotherapeutic agents, radiation therapy, or combination chemotherapy-radiotherapy, including, but not limited to, melphalan, cyclophosphamide, fludarabine, bendamustine, and cyclophosphamide-radiotherapy.
[0128] In embodiments of any of the methods and compositions described herein, the disease (e.g., cancer), e.g., a disease associated with CD19 expression, is cancer. In one embodiment, the cancer is a hematological cancer. In embodiments, the hematological cancer is selected from the group consisting of B-cell acute lymphoblastic leukemia (BALL), T-cell acute lymphoblastic leukemia (TALL), small lymphocytic lymphoma (SLL), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large intestinal lymphoma, and diffuse large intestinal lymphoma. The hematological cancer is selected from one or more of: chronic large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplastic and myelodysplastic syndromes, non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, or Waldenstrom's macroglobulinemia. In one embodiment, the hematological cancer is a leukemia, such as acute leukemia or chronic leukemia. In another embodiment, the hematological cancer is a lymphoma, such as non-Hodgkin's lymphoma or Hodgkin's lymphoma. In embodiments, the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma, mycosis fungoides, anaplastic large cell lymphoma, or precursor T-lymphoblastic lymphoma.
[0129] In one embodiment, the cancer expresses CD19, e.g., expresses CD19. In another embodiment, the cancer is relapsed or refractory B-ALL. In one embodiment, the cancer is relapsed or refractory B-ALL with lymph node involvement, e.g., lymphomatous disease. In another embodiment, the cancer is DLBCL, e.g., relapsed or refractory DLBCL.
[0130] In some embodiments, CAR therapy, e.g., CD19 CAR therapy, is administered to a subject with Hodgkin lymphoma (HL), e.g., relapsed or refractory HL, in combination with a PD-1 inhibitor, e.g., a PD-1 inhibitor as described herein. In an embodiment, CAR therapy is administered to a subject with relapsed and / or refractory HL after the PD-1 inhibitor. In another embodiment, a PD-1 inhibitor is administered to a subject with relapsed and / or refractory HL after CAR therapy, e.g., as described herein. In another embodiment, administration of the PD-1 inhibitor is initiated, e.g., within 20 days after administration of CAR therapy, e.g., as described herein. In some embodiments, the CD19 CAR-expressing cells are cells into which RNA encoding CD19CAR has been introduced, e.g., by electroporation. In an embodiment, the subject comprises CD19-negative and CD19-positive cancer cells. In an embodiment, the subject is treated with 6 doses of CAR-expressing cells, e.g., over a 2-week period. In an embodiment, the dose is, e.g., 1 x 10 per dose for a subject weighing <80 kg. 5 ~5×10 6 Pieces or 8 x 10 5 ~1.5×10 6 CD19 CAR-expressing cells, or 1 x 10 per dose, for example, for a subject ≥ 80 kg 8 pieces (±50%) or 1×10 8 (±20%) CD19 CAR-expressing cells. In embodiments, the dose comprises about 1 x 10 per dose. 5 ~1.5×10 6 In an embodiment, the subject does not experience CRS or does not experience severe CRS. In an embodiment, the subject experiences a complete response, a partial response, or stable disease.
[0131] subject In one embodiment, the subject, e.g., the subject from whom the immune cells are obtained and / or the subject to be treated, is a human, e.g., a cancer patient. In a specific embodiment, the subject is 18 years of age or younger (e.g., 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 year old or younger (e.g., 12 months, 6 months, 3 months or younger)). In one embodiment, the subject is a pediatric cancer patient.
[0132] In other embodiments, the subject is an adult, e.g., the subject is over 18 years of age (e.g., over 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80 years of age or older). In one embodiment, the subject is an adult cancer patient.
[0133] In certain embodiments, the subject has a disease associated with expression of a tumor-associated or cancer-associated antigen, e.g., a disease as described herein. In one embodiment, the subject has cancer, e.g., a cancer as described herein.
[0134] In one embodiment, the subject has a cancer selected from a hematological cancer, a solid tumor, or a metastatic lesion thereof. Exemplary cancers include, but are not limited to, B-cell acute lymphoblastic leukemia (B-ALL), T-cell acute lymphoblastic leukemia (T-ALL), acute lymphoblastic leukemia (ALL), chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), B-cell promyelocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma. These include hairy cell leukemia, small cell or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, and Waldenstrom's macroglobulinemia. In one embodiment, the cancer is ALL. In another embodiment, the cancer is CLL. In one embodiment, the cancer is DLBCL, for example, relapsed or refractory DLBCL.
[0135] In embodiments, the subject has leukemia, e.g., ALL (e.g., B-ALL). In embodiments, the subject has leukemia, e.g., ALL, and is a pediatric patient, e.g., 18 years of age or younger (e.g., 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 year old or younger (e.g., 12 months, 6 months, 3 months or younger)).
[0136] In embodiments, the subject has lymphoma, e.g., DLBCL. In embodiments, the subject has lymphoma, e.g., DLBCL (e.g., relapsed or refractory DLBCL), and is an adult patient, e.g., over 18 years of age (e.g., over or under 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80 years of age).
[0137] In embodiments, the subject has (e.g., is diagnosed with) a disease (e.g., cancer) described herein, e.g., a disease associated with CD19 expression, e.g., a cancer associated with CD19 expression described herein. In embodiments, the subject has a relapsed and / or refractory cancer, e.g., a relapsed or refractory lymphoma, e.g., a CD19+ lymphoma. In embodiments, the subject has DLBCL, e.g., CD19+ DLBCL. In embodiments, the subject has DLBCL transformed from follicular lymphoma. In embodiments, the subject has DLBCL and aggressive lymphoma. In embodiments, the subject has primary mediastinal DLBCL. In embodiments, the subject has previously been treated for lymphoma, e.g., DLBCL, and has refractory lymphoma, e.g., refractory DLBCL.
[0138] In embodiments, the subject has (e.g., is diagnosed with) a cancer with a high tumor burden, e.g., before the first dose is administered. In one embodiment, the cancer is ALL or CLL. In embodiments, the subject has a bone marrow blast level of at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%, e.g., at least 5%. In embodiments, the subject has stage I, II, III, or IV cancer. In embodiments, the subject has a tumor burden of at least 1, 2, 5, 10, 20, 50, 100, 200, 500, or 1000 g, e.g., a single tumor or multiple tumors.
[0139] In embodiments, the subject has received chemotherapy, e.g., a chemotherapy described herein (e.g., lymphodepleting chemotherapy, e.g., carboplatin and / or gemcitabine), prior to administration comprising a CAR-expressing cell and / or a PD-1 inhibitor described herein. In embodiments, the subject has received immunotherapy, e.g., an allogeneic bone marrow transplant, prior to administration comprising a CAR-expressing cell and / or a PD-1 inhibitor described herein.
[0140] In any of the embodiments of the methods and compositions described herein, the subject is a mammal, e.g., a human. In one embodiment, the subject expresses PD-1. In one embodiment, cancer cells or cells in proximity to cancer cells, e.g., cancer-associated cells, in the subject express PD-1 or PL-L1. In some embodiments, the cancer-associated cells are anti-tumor immune cells, e.g., tumor-infiltrating lymphocytes (TILs).
[0141] In one embodiment, the cells expressing a CAR, such as the CD19 CAR-expressing cells described herein, express PD-1.
[0142] Unless otherwise defined, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. Additionally, the materials, methods, and examples are illustrative only and not intended to be limiting. Headings, subheadings, or numbered or lettered elements, e.g., (a), (b), (i), etc., are provided merely for ease of reading. The use of headings or numbered or lettered elements herein does not require the steps or elements to be performed in alphabetical order or that the steps or elements are necessarily separate from one another. Other features, objects, and advantages of the present invention will be apparent from the description and drawings, and from the claims. [Brief explanation of the drawings]
[0143] [Figure 1-1] Image of PD-L1 (CD274) expression on diffuse large B-cell lymphoma cells from a patient. The biopsy was taken before CART19 cell infusion. Immunohistochemical staining with anti-PD-L1 antibody from Cell Signaling (clone E1J2J, catalog number 15165BF). The main image is at 40x magnification, and the inset image in the upper right corner is at 100x magnification. [Figure 1-2] 1 is a panel of CT scans demonstrating clinical response to pembrolizumab after 3 weeks. The image on the left is the day of pembrolizumab infusion (day 26), and the image on the right is 3 weeks after pembrolizumab infusion (day 45). [Figure 2-1]Graphs showing correlation studies examining changes in T cell subsets in response to CART19 and pembrolizumab infusion. (Figure 2A) Percentage of CART19+CD3+ cells in peripheral blood. Percentage of CD3+ cells CART19+ before CART19 infusion (Pre), 3 days after CART19 infusion (Day 3), 7 days after CART19 (Day 7), 10 days after CART19 (Day 10), 14 days after CART19 (Day 14), 26 days after CART19 infusion and 1 hour after pembrolizumab infusion (Day 26), 27 days after CART19 infusion and 1 day after pembrolizumab (Day 27), 28 days after CART19 infusion and 2 days after pembrolizumab (Day 28), and 45 days after CART19 and 14 days after pembrolizumab (Day 45). (Figure 2B) Fold change from baseline in IL-6 serum levels. [Figure 2-2] (Fig. 2C) Percentages of PD1+CD4+ cells and PD1+CART19+CD4+ cells in peripheral blood. (Fig. 2D) Percentages of PD1+CD8+ cells and PD1+CART19+CD8+ cells in peripheral blood. [Figure 2-3] (FIG. 2E) Percentages of PD1+Eomes+CD4+ cells and PD1+Eomes+CART19+CD4+ cells in peripheral blood. (FIG. 2F) Percentages of PD1+Eomes+CD8+ cells and PD1+Eomes+CART19+CD8+ cells in peripheral blood. [Figure 2-4] (FIG. 2G) Percentages of Granzyme B+CD4+ cells and Granzyme B+CART19+CD4+ cells in peripheral blood. (FIG. 2H) Percentages of Granzyme B+CD8+ cells and Granzyme B+CART19+CD8+ cells in peripheral blood. [Figure 2-5] (FIG. 2I) Percentages of PD1+CD4+ cells and PD1+Eomes+CD4+ cells in peripheral blood. (FIG. 2J) Percentages of PD1+CD4+CART19+ cells and PD1+Eomes+CD4+CART19+ cells in peripheral blood. [Figure 2-6](Fig. 2K) Percentages of PD1+CD8+ cells and PD1+Eomes+C8+ cells in peripheral blood. (Fig. 2L) Percentages of PD1+CD8+CART19+ cells and PD1+Eomes+CD8+CART19+ cells in peripheral blood. [Figure 3] Shown is the expression of PD-L1, PD1, LAG3, and TIM3 (from left to right in each set of four bars) in lymph node (LN) and bone marrow (BM) samples from five CR patients, one unclassified patient, and six PD patients. [Figure 4-1] Flow cytometry analysis of PD1 and CAR19 expression on T cells. Figures 4A and 4B are representative flow cytometry profiles demonstrating the distribution of PD-1 and CAR19 expression on CD4+ T cells from subjects who were complete responders (CR) or non-responders (NR) to CART therapy. [Figure 4-2] Figure 4C is a graph showing the percentage of PD1 cells in the CD4+ T cell population from subjects with different responses to CART therapy, and Figure 4D is a graph showing the percentage of PD1 cells in the CD8+ T cell population from subjects with different responses to CART therapy. [Figure 5] The distribution of PD1 expression in CD4- and CAR19-expressing cells (FIG. 5A) or CD8- and CAR19-expressing cells (FIG. 5B) from subject groups with different responses to CART therapy is shown. [Figure 6] 1 shows flow cytometry analysis of PD1, CAR 19, LAG3, and TIM3 expression on T cells from subjects who are complete responders (CR) or non-responders (NR) to CAR therapy. [Figure 7] The distribution of PD1 and LAG3 expression (FIG. 7A) or PD1 and TIM3 expression (FIG. 7B) from groups of subjects with different responses to CART therapy is shown. [Figure 8] 1 shows multiplexed FIHC AQUA analysis demonstrating significant differences between CD3+ / PD-1+ cell populations in primary and secondary human DLBCL patient samples. [Figure 9]AQUA analysis showing various levels of CD19 (lower panel) and PD-L1 (upper panel) in primary and secondary sites of DLBCL samples. A total of 40 human DLBCL patient samples, representing 25 primary sites and 15 secondary sites, were subjected to multiplex FIHC, followed by AQUA analysis to identify the expression levels of CD19 and PD-L1 proteins. [Figure 10] 1 shows the percentage of CART19 cells in patients from Case 3 after infusion of CART19 cells alone or with a dose of pembrolizumab. [Figure 11] 1 shows a graph of the probability of B-cell recovery versus months after huCART19 infusion for patients receiving huCART19 alone or huCART19 and pembrolizumab. [Figure 12] Shown are the percentages of CART19 in patients from Case 6 who were infused with CART19 alone (circles) and after treatment with pembrolizumab (squares). [Figure 13] Shown are the percentages of CART19 in patients from Case 6 with CART19 pre- and post-treatment with pembrolizumab, combined with pre- and post-treatment PET scan data with pembrolizumab. [Figure 14] 1 is a graph depicting CART19 RNA expression levels in the peripheral blood of four patients who received RNA CART19 therapy. Quantitative RT-PCR was performed on cells collected before and after each infusion (days 0, 2, 4, 9, 11, and 14). DETAILED DESCRIPTION OF THE INVENTION
[0144] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
[0145] The terms "a" and "an" refer to one or to more than one (i.e., to at least one) of the grammatical referent of the article. By way of example, "an element" means one element or more than one element.
[0146] The term "about," when referring to a measurable value, such as an amount, a temporal duration, or the like, means that variations of ±20%, or in some cases ±10%, or in some cases ±5%, or in some cases ±1%, or in some cases ±0.1% from the specified value are encompassed, as such variations are appropriate for the practice of the methods of the present disclosure.
[0147] As used herein, "administered in combination" means that two (or more) different therapies are delivered to a subject during the course of the subject's illness, e.g., two or more therapies are delivered after the subject is diagnosed with a disorder and before the disorder has been cured or eliminated or before treatment is discontinued for other reasons. In some embodiments, delivery of one treatment is still occurring when delivery of a second treatment begins, thus resulting in overlap in administration. This is sometimes referred to herein as "simultaneous" or "concurrent delivery." In other embodiments, delivery of one treatment ends before delivery of the other treatment begins. In either case, in some embodiments, the treatments are more effective as a result of the combined administration. For example, the second treatment is more effective than would be seen if the second treatment were administered without the first treatment, e.g., an equivalent effect is seen with less of the second treatment, or the second treatment reduces symptoms to a greater extent, or a similar situation is seen with the first treatment. In some embodiments, the delivery is such that the reduction in symptoms or other parameters associated with the disorder is greater than would be observed if one treatment were administered without the other. The effects of the two treatments can be partially additive, fully additive, or greater than additive, and the delivery is such that the effect of the first treatment delivered is still detectable upon delivery of the second treatment.
[0148] The term "chimeric antigen receptor" or alternatively "CAR" refers to a recombinant polypeptide construct comprising at least an extracellular antigen-binding domain, a transmembrane domain, and a cytoplasmic signaling domain (also referred to herein as an "intracellular signaling domain") that comprises a functional signaling domain derived from a stimulatory molecule, as defined below. In some embodiments, the domains of a CAR polypeptide construct are on the same polypeptide chain, e.g., comprising a chimeric fusion protein. In some embodiments, the domains of a CAR polypeptide construct are not contiguous with one another, e.g., are on different polypeptide chains, e.g., as provided in an RCAR as described herein.
[0149] In one embodiment, the stimulatory molecule is the zeta chain associated with the T cell receptor complex. In one embodiment, the cytoplasmic signaling domain comprises a primary signaling domain (e.g., the primary signaling domain of CD3-zeta). In one embodiment, the cytoplasmic signaling domain further comprises one or more functional signaling domains derived from at least one costimulatory molecule, as defined below. In one embodiment, the costimulatory molecule is selected from 4-1BB (i.e., CD137), CD27, ICOS, and / or CD28. In one embodiment, the CAR comprises a chimeric fusion protein comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a functional signaling domain derived from a stimulatory molecule. In one embodiment, the CAR comprises a chimeric fusion protein comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a functional signaling domain derived from a costimulatory molecule and a functional signaling domain derived from a stimulatory molecule. In one embodiment, the CAR comprises a chimeric fusion protein comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a functional signaling domain derived from one or more costimulatory molecules and two functional signaling domains derived from a stimulatory molecule. In one embodiment, the CAR comprises a chimeric fusion protein comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain comprising at least two functional signaling domains derived from one or more costimulatory molecules and a functional signaling domain derived from a stimulatory molecule. In one embodiment, the CAR comprises an optional leader sequence at the amino-terminus (N-ter) of the CAR fusion protein. In one embodiment, the CAR further comprises a leader sequence at the N-terminus of the extracellular antigen-binding domain, which is optionally cleaved from the antigen recognition domain (e.g., scFv) during cellular processing and cell membrane localization of the CAR.
[0150] The term "signaling domain" refers to a functional portion of a protein that functions by transmitting information within a cell to regulate cellular activity through a defined signaling pathway by generating a second messenger or functioning as an effector in response to such a messenger. In some embodiments, the signaling domain of a CAR described herein is derived from a stimulatory molecule or costimulatory molecule described herein, or is a synthetic or engineered signaling domain.
[0151] As used herein, the term "CD19" refers to the cluster of differentiation 19 protein, an antigenic determinant detectable on leukemia progenitor cells. Human and mouse amino acid and nucleic acid sequences can be found in public databases such as GenBank, UniProt, and Swiss-Prot. For example, the amino acid sequence of human CD19 can be found under UniProt / Swiss-Prot accession number P15391, and the nucleotide sequence encoding human CD19 can be found under accession number NM_001178098. As used herein, "CD19" includes proteins containing mutations of full-length wild-type CD19, such as point mutations, fragments, insertions, deletions, and splice variants. CD19 is expressed in most B-cell lineage cancers, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma. Other cells that express CD19 are provided below in the definition of "diseases associated with CD19 expression." It is also an early marker of B-cell progenitor cells. See, e.g., Nicholson et al. Mol. Immun. 34(16-17):1157-1165 (1997). In one embodiment, the antigen-binding portion of the CART recognizes and binds to an antigen within the extracellular domain of the CD19 protein. In one embodiment, the CD19 protein is expressed on cancer cells.
[0152] The term "antibody" or "antibody molecule," as used herein, refers to a protein or polypeptide sequence derived from an immunoglobulin molecule that specifically binds to an antigen. Antibodies can be polyclonal or monoclonal, multi-chain or single-chain, or intact immunoglobulins, and can be derived from natural or recombinant sources. An antibody can be a tetramer of immunoglobulin molecules. In one embodiment, an antibody or antibody molecule comprises, e.g., consists of, an antibody fragment.
[0153] The term "antibody fragment" refers to at least a portion of an intact antibody or a recombinant variant thereof, and refers to the antigen-binding domain of an intact antibody, e.g., the antigen-determining variable region, sufficient to result in recognition and specific binding of the antibody fragment to a target such as an antigen. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab'), and Fv fragments, scFv antibody fragments, linear antibodies, single domain antibodies (either VL or VH) such as sdAbs, camelid VHH domains, and multispecific antibodies formed from antibody fragments such as bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region, and isolated CDRs or other epitope-binding fragments of antibodies. Antigen-binding fragments can also be incorporated into single domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs, and bis-scFvs (see, e.g., Hollinger and Hudson, Nature Biotechnology 23:1126-1136, 2005). Antigen-binding fragments can also be grafted onto polypeptide-based scaffolds, such as fibronectin type III (Fn3) (see U.S. Pat. No. 6,703,199, which describes fibronectin polypeptide minibodies).
[0154] The term "scFv" refers to a fusion protein comprising at least one antibody fragment comprising a light chain variable region and at least one antibody fragment comprising a heavy chain variable region, wherein the light and heavy chain variable regions are closely linked by a short flexible polypeptide linker, capable of being expressed as a single-chain polypeptide, and wherein the scFv retains the specificity of the intact antibody from which it is derived. Unless specified, as used herein, an scFv can have the VL and VH variable regions in either order, e.g., relative to the N- and C-terminal ends of the polypeptide, and can comprise a VL-linker-VH or a VH-linker-VL.
[0155] The term "complementarity-determining region" or "CDR," as used herein, refers to a sequence of amino acids within an antibody variable region that confers antigen specificity and binding affinity. For example, there are typically three CDRs in each heavy chain variable region (e.g., HCDR1, HCDR2, and HCDR3) and three CDRs in each light chain variable region (LCDR1, LCDR2, and LCDR3). The precise amino acid sequence boundaries of a given CDR can be determined using any of several well-known schemes, including Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD ("Kabat" numbering scheme), Al-Lazikani et al., (1997) JMB 273, 927-948 ("Chothia" numbering scheme), or a combination thereof. Based on the Kabat numbering scheme, in some embodiments, the CDR amino acid residues of the heavy chain variable domain (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3), and the CDR amino acid residues of the light chain variable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3). Based on the Chothia numbering scheme, in some embodiments, the CDR amino acid residues of the VH are numbered 26-32 (HCDR1), 52-56 (HCDR2), and 95-102 (HCDR3), and the CDR amino acid residues of the VL are numbered 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3). In a combination of the Kabat and Chothia numbering schemes, in some embodiments, the CDRs correspond to amino acid residues that are part of a Kabat CDR, a Chothia CDR, or both.For example, in some embodiments, the CDRs correspond to amino acid residues 26-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3) of a VH, e.g., a mammalian VH, e.g., a human VH, and amino acid residues 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3) of a VL, e.g., a mammalian VL, e.g., a human VL.
[0156] The portion of the CAR of the present invention comprising an antibody or antibody fragment thereof can exist in various forms, where the antigen-binding domain is expressed as part of a continuous polypeptide chain, including, for example, scFv antibody fragments, linear antibodies, single-domain antibodies (either VL or VH) such as sdAbs, camelid VHH domains, humanized antibodies, bispecific antibodies, and antibody conjugates (Harlow et al., 1999, In: Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, In: Antibodies: A Laboratory Manual, Cold Spring Harbor, New York; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426). In one embodiment, the antigen-binding domain of the CAR of the present invention comprises an antibody fragment. In a further embodiment, the CAR comprises an antibody fragment comprising an scFv.
[0157] As used herein, the term "antibody molecule" refers to a protein, e.g., an immunoglobulin chain or fragment thereof, that comprises at least one immunoglobulin variable domain sequence. The term antibody molecule encompasses antibodies and antibody fragments. In one embodiment, an antibody molecule comprises a "binding domain" (also referred to herein as an "anti-target (e.g., CD19) binding domain" or a "target (e.g., CD19) binding domain"). In certain embodiments, an antibody molecule is a multispecific antibody molecule, e.g., it comprises a plurality of immunoglobulin variable domain sequences, wherein a first immunoglobulin variable domain sequence of the plurality has binding specificity for a first epitope and a second immunoglobulin variable domain sequence of the plurality has binding specificity for a second epitope. In certain embodiments, a multispecific antibody molecule is a bispecific antibody molecule. A bispecific antibody has specificity for no more than two antigens. Bispecific antibody molecules are characterized by a first immunoglobulin variable domain sequence that has binding specificity for a first epitope and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope.
[0158] The term "antibody heavy chain" refers to the larger of the two polypeptide chains present in antibody molecules in their naturally occurring conformation, and which usually determines the class to which the antibody belongs.
[0159] The term "antibody light chain" refers to the smaller of the two polypeptide chains present in antibody molecules in their naturally occurring conformation. Kappa (κ) and lambda (λ) light chains refer to the two major antibody light chain isotypes.
[0160] The term "recombinant antibody" refers to an antibody made using recombinant DNA techniques, such as, for example, an antibody expressed in a bacteriophage or yeast expression system. The term should also be construed to mean an antibody made by synthesis of a DNA molecule encoding the antibody and which expresses the antibody protein, or an amino acid sequence specifying that antibody, where the DNA or amino acid sequence was obtained using well-known recombinant DNA or amino acid sequence techniques available in the art.
[0161] The term "antigen" or "Ag" refers to a molecule that elicits an immune response. This immune response may include either or both antibody production or activation of specific immunologically competent cells. Those skilled in the art will understand that any macromolecule can be an antigen, including virtually any protein or peptide. Furthermore, antigens can be derived from recombinant or genomic DNA. Those skilled in the art will therefore understand that any DNA containing a nucleotide sequence or partial nucleotide sequence encoding a protein that elicits an immune response encodes an "antigen" as that term is used herein. Furthermore, those skilled in the art will understand that an antigen need not be encoded solely by the full-length nucleotide sequence of a gene. It is readily apparent that the present invention includes, but is not limited to, the use of partial nucleotide sequences of two or more genes, and that these nucleotide sequences are arranged in various combinations to encode a polypeptide that elicits a desired immune response. Furthermore, those skilled in the art will understand that an antigen need not be encoded by a "gene" at all. It is readily apparent that an antigen can be synthetically produced, obtained from a biological sample, or can be a macromolecule other than a polypeptide. Such biological samples may include, but are not limited to, tissue samples, tumor samples, cells or bodily fluids, along with other biological components.
[0162] The term "anti-cancer effect" refers to a biological effect that can be manifested by various means, including, but not limited to, a reduction in tumor volume, a reduction in the number of cancer cells, a reduction in the number of metastases, an increase in life expectancy, a reduction in cancer cell proliferation, a reduction in cancer cell survival, or an improvement in various physiological symptoms associated with a cancerous condition. An "anti-cancer effect" can also be manifested by the ability of peptides, polynucleotides, cells, and antibodies in preventing the development of cancer in the first place. The term "anti-tumor effect" refers to a biological effect that can be manifested by various means, including, but not limited to, a reduction in tumor volume, a reduction in tumor cell number, a reduction in tumor cell proliferation, or a reduction in tumor cell survival.
[0163] The term "autologous" refers to any material originating from the same individual that is later reintroduced into that individual.
[0164] The term "allogeneic" refers to any material derived from a different animal of the same species as the individual into which the material is introduced. Two or more individuals are said to be allogeneic to each other when the genes at one or more loci are not identical. In some embodiments, allogeneic materials from individuals of the same species may be genetically different enough to interact antigenically.
[0165] The term "xenogeneic" refers to a graft derived from an animal of a different species.
[0166] The term "cancer" refers to a disease characterized by the uncontrolled growth of abnormal cells. Cancer cells can spread locally or through the bloodstream and lymphatic system to other parts of the body. Various examples of cancer are described herein and include, but are not limited to, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, kidney cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer, etc. The terms "tumor" and "cancer" are used interchangeably herein; for example, both terms encompass solid and liquid tumors, e.g., diffuse or circulating tumors. As used herein, the term "cancer" or "tumor" includes precancerous as well as malignant cancers and tumors.
[0167] The terms "cancer-associated antigen," or "tumor antigen," or "proliferative disorder antigen," or "antigen associated with a proliferative disorder" refer synonymously to a molecule (typically a protein, carbohydrate, or lipid) that is preferentially expressed on the surface of cancer cells, either intact or as fragments (e.g., MHC / peptides), compared to normal cells, and that is useful for preferential targeting of pharmacological agents to cancer cells. In some embodiments, the tumor antigen is a marker expressed by both normal and cancer cells, such as a lineage marker, e.g., CD19 on B cells. In particular aspects, the tumor antigens of the present invention are derived from cancers, including, but not limited to, primary or metastatic melanoma, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukemia, uterine cancer, cervical cancer, bladder cancer, renal cancer, and adenocarcinomas, such as breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, etc. In some embodiments, the tumor antigen is an antigen common to a particular proliferative disorder. In some embodiments, the cancer-associated antigen is a cell surface molecule that is overexpressed on cancer cells compared to normal cells, e.g., by 1-fold, 2-fold, 3-fold, or more. In some embodiments, the cancer-associated antigen is a cell surface molecule that is inappropriately synthesized on cancer cells, e.g., a molecule that contains a deletion, addition, or mutation compared to a molecule expressed on normal cells. In some embodiments, the cancer-associated antigen is expressed entirely or as a fragment (e.g., MHC / peptide) only on the cell surface of cancer cells, and is not synthesized or expressed on the surface of normal cells. In some embodiments, the CAR of the present invention includes a CAR that contains an antigen-binding domain (e.g., an antibody or antibody fragment) that binds to an MHC-presented peptide. Typically, peptides derived from endogenous proteins fit into the pocket of major histocompatibility complex (MHC) class I molecules and are recognized by T cell receptors (TCRs) on CD8+ T lymphocytes. MHC class I complexes are constitutively expressed by all nucleated cells. In cancer, virus-specific and / or tumor-specific peptide / MHC complexes represent a unique class of cell surface targets for immunotherapy.TCR-like antibodies that target peptides derived from viral or tumor antigens in the context of human leukocyte antigen (HLA)-A1 or HLA-A2 have been described (see, e.g., Sastry et al., J Virol. 2011 85(5):1935-1942; Sergeeva et al., Bood, 2011 117(16):4262-4272; Verma et al., J Immunol 2010 184(4):2156-2165; Willemsen et al., Gene Ther 2001 8(21):1601-1608; Dao et al., Sci Transl Med 2013 5(176):176ra33; Tassev et al., Cancer Gene Ther 2012 19(2):84-100). For example, TCR-like antibodies can be identified from screening libraries such as human scFv phage display libraries.
[0168] The phrase "disease associated with CD19 expression" includes diseases associated with expression of CD19 (e.g., wild-type or mutant CD19), or conditions associated with cells that express or have at any time expressed CD19 (e.g., wild-type or mutant CD19), or non-cancer-related indications associated with cells that express CD19, including, but not limited to, proliferative diseases such as cancer or malignant tumors, or precancerous conditions such as myelodysplasia, myelodysplastic syndrome, or preleukemia. For the avoidance of doubt, diseases associated with CD19 expression may include conditions associated with cells that once expressed CD19 but no longer express CD19, e.g., due to downregulation of CD19 expression, e.g., by treatment with a molecule that targets CD19, e.g., a CD19 CAR. In one embodiment, the cancer associated with CD19 expression is a hematological cancer. In one embodiment, the hematological cancer is leukemia or lymphoma. In one aspect, cancers associated with expression of CD19 include cancers and malignancies including, but not limited to, one or more acute leukemias, for example, but not limited to, B-cell acute lymphoblastic leukemia (BALL), T-cell acute lymphoblastic leukemia (TALL), acute lymphoblastic leukemia (ALL), one or more chronic leukemias, for example, but not limited to, chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL). Additional cancers or hematological conditions associated with expression of CD19 include, but are not limited to, B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma, multiple myeloma, myelodysplastic and myelodysplastic syndromes, non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom's macroglobulinemia, and "preleukemias," a group of diverse hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells. Additionally, diseases associated with the expression of CD19 expression include, but are not limited to, atypical and / or non-classical cancers, malignancies, precancerous conditions or proliferative disorders associated with the expression of CD19.Non-cancer-related indications associated with CD19 expression include, but are not limited to, autoimmune diseases (e.g., lupus), inflammatory disorders (allergies and asthma), and transplantation. In some embodiments, CD19-expressing cells express, or have expressed at some point, CD19 mRNA. In certain embodiments, CD19-expressing cells produce CD19 protein (e.g., wild-type or mutant), which may be present at normal or reduced levels. In certain embodiments, CD19-expressing cells transiently produce detectable levels of CD19 protein, but subsequently cease to produce substantially detectable CD19 protein.
[0169] As used herein, the term "programmed death 1" or "PD-1" includes isoforms, mammalian, e.g., human, PD-1, species homologs of human PD-1, and analogs that share at least one common epitope with PD-1. The amino acid sequence of PD-1, e.g., human PD-1, is known in the art. See, e.g., Shinohara T et al. (1994) Genomics 23(3):704-6; Finger LR, et al. Gene (1997) 197(1-2):177-87.
[0170] The term "conservative sequence modifications" refers to amino acid modifications that do not significantly affect or alter the binding characteristics of an antibody or antibody fragment containing that amino acid sequence. Such conservative modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into an antibody or antibody fragment of the present invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are those in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues within a CAR of the invention can be replaced with another amino acid residue from the same side chain family, and the altered CAR can be tested, for example, for its ability to bind to CD19 using the functional assays described herein.
[0171] The term "stimulation" refers to a primary response induced by the binding of a stimulatory molecule (e.g., a TCR / CD3 complex or a CAR) to its cognate ligand (or tumor antigen in the case of a CAR), thereby mediating a signal transduction event, such as, but not limited to, signaling through the TCR / CD3 complex or signaling through the signaling domain of an appropriate NK receptor or CAR. Stimulation can mediate changes in the expression of specific molecules, such as downregulation of TGF-β and / or remodeling of cytoskeletal structure.
[0172] The term "stimulatory molecule" refers to a molecule expressed by an immune effector cell (e.g., T cell, NK cell, B cell) that provides one or more cytoplasmic signaling sequences that regulate immune effector cell activation in a stimulatory manner with respect to at least some aspect of an immune effector cell signaling pathway, e.g., a T cell signaling pathway. In one embodiment, the signal is initiated, for example, by binding of the TCR / CD3 complex to a peptide-loaded MHC molecule, and is the primary signal that leads to mediation of a T cell response, including, but not limited to, proliferation, activation, differentiation, etc. The primary cytoplasmic signaling sequence (also referred to as a "primary signaling domain") that functions in a stimulatory manner can contain a signaling motif known as an immunoreceptor tyrosine-based activation motif, or ITAM. Examples of ITAM-containing primary cytoplasmic signaling sequences that are particularly useful in the present invention include, but are not limited to, those derived from CD3ζ, common FcRγ (FCER1G), FcγRIIa, FcRβ (FcεR1b), CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b, CD278 (also known as "ICOS"), FcεRI, DAP10, DAP12, and CD66d. In specific CARs of the invention, the intracellular signaling domain of any one or more CARs of the invention comprises an intracellular signaling sequence, e.g., the primary signaling sequence of CD3-ζ. In specific CARs of the invention, the primary signaling sequence of CD3-ζ is the amino acid sequence provided as SEQ ID NO: 9, or equivalent residues from a non-human species, such as mouse, rodent, monkey, ape, etc. In a specific CAR of the invention, the primary signaling sequence of CD3-zeta is the amino acid sequence as provided in SEQ ID NO: 10, or equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc.
[0173] The term "antigen-presenting cell" or "APC" refers to a cell of the immune system, such as an accessory cell (e.g., a B cell, a dendritic cell, etc.), that presents foreign antigens complexed with major histocompatibility complexes (MHC) on its surface. T cells can recognize such complexes using their T cell receptors (TCRs). APCs process antigens and present them to T cells.
[0174] As used herein, the term "intracellular signaling domain" refers to the intracellular portion of a molecule. The intracellular signaling domain generates a signal that promotes immune effector function of a CAR-expressing cell, such as a CART cell or a CAR-expressing NK cell. For example, examples of immune effector function in a CART cell or a CAR-expressing NK cell include helper activity, including cytolytic activity and cytokine secretion. While the entire intracellular signaling domain can be used, it is often not necessary to use the entire chain. To the extent that a truncated portion of the intracellular signaling domain is used, it can be used in place of the intact chain, so long as such truncated portion transmits an effector function signal. Thus, the term intracellular signaling domain is intended to include any truncated portion of the intracellular signaling domain sufficient to transmit an effector function signal.
[0175] In some embodiments, the intracellular signaling domain can comprise a primary intracellular signaling domain. Exemplary primary intracellular signaling domains include those derived from molecules involved in primary stimulation or antigen-dependent stimulation. In some embodiments, the intracellular signaling domain can comprise a costimulatory intracellular domain. Exemplary costimulatory intracellular signaling domains include those derived from molecules involved in costimulatory signals or antigen-independent stimulation. In some embodiments, the intracellular signaling domain is synthetic or engineered. For example, in the case of CAR-expressing immune effector cells, such as CART cells or CAR-expressing NK cells, the primary intracellular signaling domain can comprise a cytoplasmic sequence of a T cell receptor, the primary intracellular signaling domain can comprise a cytoplasmic sequence of a T cell receptor, and the costimulatory intracellular signaling domain can comprise a cytoplasmic sequence from a co-receptor or costimulatory molecule.
[0176] The primary intracellular signaling domain may contain a signaling motif known as an immunoreceptor tyrosine-based activation motif, or ITAM. Examples of ITAM-containing primary cytoplasmic signaling sequences include, but are not limited to, those derived from CD3ζ, common FcRγ (FCER1G), FcγRIIa, FcRβ, CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b, CD278 ("ICOS"), FcεRI CD66d, DAP10, and DAP12.
[0177] The term "ζ" or alternatively "ζ chain," "CD3-ζ," or "TCR-ζ" is defined as the protein provided under GenBank Accession No. BAG36664.1, or equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc., and "ζ stimulatory domain" or alternatively "CD3-ζ stimulatory domain" or "TCR-ζ stimulatory domain" is defined as the amino acid residues from the cytoplasmic domain of the ζ chain sufficient to functionally transmit an early signal necessary for T cell activation. In one embodiment, the cytoplasmic domain of ζ comprises residues 52-164 of GenBank Accession No. BAG36664.1, or equivalent residues from a non-human species that is a functional ortholog thereof, e.g., mouse, rodent, monkey, ape, etc. In one embodiment, the "ζ stimulatory domain" or "CD3-ζ stimulatory domain" is the sequence provided as SEQ ID NO: 10. In one embodiment, the "zeta stimulatory domain" or "CD3-zeta stimulatory domain" is the sequence provided as SEQ ID NO: 9. Also encompassed herein are CD3zeta domains that include one or more mutations relative to the amino acid sequences described herein, e.g., SEQ ID NO: 9.
[0178] The term "costimulatory molecule" refers to a cognate binding partner on a T cell that specifically binds to a costimulatory ligand, thereby mediating a costimulatory response by the T cell, such as, but not limited to, proliferation. Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands that are required for an efficient immune response. Costimulatory molecules include, but are not limited to, MHC class I molecules, TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocyte activation molecules (SLAM proteins), activating NK cell receptors, BTLA, Toll ligand receptors, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a / CD18), and 4-1BB. (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NK p44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL2Rβ, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA- 6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), CEA These include ligands that specifically bind to CAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, and CD83.
[0179] A costimulatory intracellular signaling domain can be the intracellular portion of a costimulatory molecule. The intracellular signaling domain can include the entire intracellular portion of the molecule from which it is derived, or the entire native intracellular signaling domain, or a functional fragment thereof.
[0180] The term "4-1BB" refers to a member of the TNFR superfamily having the amino acid sequence provided as GenBank Accession No. AAA62478.2, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc., and a "4-1BB costimulatory domain" is defined as amino acid residues 214-255 of GenBank Accession No. AAA62478.2, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc. In one embodiment, the "4-1BB costimulatory domain" is the sequence provided as SEQ ID NO: 7, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc.
[0181] "Immune effector cells," as the term is used herein, refer to cells that are involved in an immune response, e.g., promoting an immune effector response. Examples of immune effector cells include T cells, e.g., α / β T cells and γ / δ T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells, and bone marrow-derived phagocytes.
[0182] "Immune effector function or immune effector response," as the term is used herein, refers to a function or response, e.g., of an immune effector cell, that enhances or promotes an immune attack of a target cell. For example, an immune effector function or response refers to a property of a T cell or NK cell that promotes the killing or growth or proliferation inhibition of a target cell. In the case of T cells, primary stimulation and costimulation are examples of immune effector functions or responses.
[0183] The term "effector function" refers to a specialized function of a cell. For example, the effector function of a T cell can be cytolytic activity or helper activity, including secretion of cytokines.
[0184] The term "encoding" refers to the inherent property of a specific nucleotide sequence within a polynucleotide, such as a gene, cDNA, or mRNA, to serve as a template for the synthesis of other polymers and macromolecules in biological processes that have either a defined nucleotide sequence (i.e., rRNA, tRNA, and mRNA) or a defined amino acid sequence. Thus, a gene, cDNA, or RNA encodes a protein when the protein is produced in a cell or other biological system by transcription and translation of the mRNA corresponding to that gene. Both the coding strand, whose nucleotide sequence is identical to the mRNA sequence and is usually provided in a sequence listing, and the non-coding strand, which is used as a transcription template for a gene or cDNA, can be said to encode the protein or other product of that gene's cDNA.
[0185] Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. The phrase nucleotide sequence encoding a protein or RNA can also include introns, to the extent that the nucleotide sequence encoding the protein may, in some versions, contain one or more introns.
[0186] The terms "effective amount" or "therapeutically effective amount" are used interchangeably herein and refer to an amount of a compound, formulation, material, or composition as described herein that is effective to achieve a particular biological result.
[0187] The term "endogenous" refers to any material that is derived from or produced within an organism, cell, tissue, or system.
[0188] The term "exogenous" refers to any material introduced from or produced outside an organism, cell, tissue or system.
[0189] The term "expression" refers to the transcription and / or translation of a particular nucleotide sequence driven by its promoter.
[0190] The term "transfer vector" refers to a composition containing an isolated nucleic acid that can be used to deliver the isolated nucleic acid into a cell. Many vectors are known in the art, including, but not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term "transfer vector" includes self-replicating plasmids or viruses. This term should be construed to further include non-plasmid and non-viral compounds that facilitate the transfer of nucleic acids into cells, such as polylysine compounds and liposomes. Examples of viral transfer vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, retroviral vectors, lentiviral vectors, and the like.
[0191] The term "expression vector" refers to a vector containing a recombinant polynucleotide comprising expression control sequences operably linked to a nucleotide sequence to be expressed. An expression vector contains sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system. Expression vectors include all those known in the art, including cosmids, plasmids (e.g., naked or contained in liposomes), and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate the recombinant polynucleotide.
[0192] The term "lentivirus" refers to a genus of the Retroviridae family. Lentiviruses are unique among retroviruses in that they can infect non-dividing cells, and they can deliver large amounts of genetic information into the DNA of host cells, making them one of the most efficient gene delivery vectors. HIV, SIV, and FIV are all examples of lentiviruses.
[0193] The term "lentiviral vector" refers to a vector derived from at least a portion of a lentiviral genome, including, inter alia, self-inactivating lentiviral vectors as provided in Milone et al., Mol. Ther. 17(8):1453-1464 (2009). Other examples of lentiviral vectors that may be used clinically include, but are not limited to, the LENTIVECTOR® gene delivery technology from Oxford BioMedica and the LENTIMAX™ vector system from Lentigen. Non-clinical types of lentiviral vectors are also available and will be known to those skilled in the art.
[0194] The term "homologous" or "identity" refers to the subunit sequence identity between two polymer molecules, e.g., between two nucleic acid molecules, such as two DNA molecules or two RNA molecules, or between two polypeptide molecules. When a subunit position in both of the two molecules is occupied by the same monomer subunit, e.g., if each position in two DNA molecules is occupied by adenine, they are homologous or identical at that position. The homology between two sequences is a direct function of the number of matching or homologous positions. For example, if half of the positions in two sequences are homologous (e.g., 5 positions in a polymer 10 subunits long), the two sequences are 50% homologous. If 90% of the positions (e.g., 9 out of 10) are matched or homologous, the two sequences are 90% homologous.
[0195] The term "humanized" refers to forms of non-human (e.g., murine) antibodies that are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab', F(ab')2, or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin. In most cases, humanized antibodies and antibody fragments thereof are those in which residues from a recipient complementarity-determining region (CDR) of a human immunoglobulin (recipient antibody or antibody fragment) are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies / antibody fragments can comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications can further refine and optimize antibody or antibody fragment performance. Generally, a humanized antibody or antibody fragment thereof will comprise a large portion of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody or antibody fragment can also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature, 321:522-525, 1986; Reichmann et al., Nature, 332:323-329, 1988; Presta, Curr. Op. Struct. Biol., 2:593-596, 1992.
[0196] The term "fully human" refers to an immunoglobulin, such as an antibody or antibody fragment, whose entire molecule is of human origin or consists of an amino acid sequence identical to a human form of an antibody or immunoglobulin.
[0197] The term "isolated" means altered or removed from the natural state. For example, a nucleic acid or peptide that is naturally present in a living animal is not "isolated," but the same nucleic acid or peptide that has been partially or completely separated from the coexisting materials of its natural state is "isolated." An isolated nucleic acid or protein can exist in a substantially purified form, or can exist in a non-native environment, such as, for example, a host cell.
[0198] In the context of the present invention, the following abbreviations are used for commonly occurring nucleobases: "A" refers to adenosine, "C" refers to cytosine, "G" refers to guanosine, "T" refers to thymidine, and "U" refers to uridine.
[0199] The term "operably linked" or "transcriptional control" refers to a functional linkage between a regulatory sequence and a heterologous nucleic acid sequence that results in expression of the latter. For example, a first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence if it affects the transcription or expression of the coding sequence. Operably linked DNA sequences can be contiguous with each other and, where necessary to join two protein-coding regions, in the same reading frame.
[0200] The term "parenteral" administration of an immunogenic composition includes, for example, subcutaneous (sc), intravenous (iv), intramuscular (im), or intrasternal injection, intratumoral, or infusion techniques.
[0201] The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof in either single- or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions can be achieved by creating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).
[0202] The terms "peptide," "polypeptide," and "protein" are used interchangeably and refer to compounds composed of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, with no limit on the maximum number of amino acids that can comprise a protein or peptide sequence. A polypeptide includes any peptide or protein containing two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, commonly referred to in the art as peptides, oligopeptides, and oligomers, and to the numerous types of longer chains generally referred to in the art as proteins. "Polypeptide" specifically includes, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, and fusion proteins. A polypeptide includes natural peptides, recombinant peptides, recombinant peptides, or combinations thereof.
[0203] The term "promoter" refers to a DNA sequence recognized by the synthetic machinery of a cell or introduced synthetic machinery necessary to initiate the specific transcription of a polynucleotide sequence.
[0204] The term "promoter / regulatory sequence" refers to a nucleic acid sequence required for expression of a gene product operably linked to that promoter / regulatory sequence. In some instances, this sequence may be a core promoter sequence, and in other instances, this sequence may also include an enhancer sequence and other regulatory elements required for expression of the gene product. The promoter / regulatory sequence may, for example, be one that confers tissue-specific expression of the gene product.
[0205] The term "constitutive" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide that encodes or specifies a gene product, causes the production of the gene product in a cell under most or all physiological conditions of the cell.
[0206] The term "inducible" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes production of the gene product in a cell substantially only when an inducer corresponding to the promoter is present in the cell.
[0207] The term "tissue-specific" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide encoding or specified by a gene, causes the production of a gene product in a cell substantially only if the cell is a cell of the tissue type corresponding to the promoter.
[0208] The term "flexible polypeptide linker" or "linker," when used in the context of an scFv, refers to a peptide linker composed of amino acids such as glycine and / or serine residues used alone or in combination to link the variable heavy and variable light chain regions together. In one embodiment, the flexible polypeptide linker is a Gly / Ser linker and comprises the amino acid sequence (Gly-Gly-Gly-Ser)n, where n is a positive integer equal to or greater than 1 (SEQ ID NO:40), e.g., n=1, n=2, n=3, n=4, n=5, and n=6, n=7, n=8, n=9, and n=10 (SEQ ID NO:41). In one embodiment, flexible polypeptide linkers include, but are not limited to, (Gly4Ser)4 (SEQ ID NO:27) or (Gly4Ser)3 (SEQ ID NO:28). In another embodiment, the linker comprises multiple repeats of (Gly2Ser), (GlySer), or (Gly3Ser) (SEQ ID NO:29). Also included within the scope of the present invention are the linkers described in WO 2012 / 138475, which is incorporated herein by reference.
[0209] As used herein, a 5' cap (RNA cap, RNA 7-methylguanosine cap or RNA m 7 A 5' cap (also called a G-cap) is a modified guanine nucleotide added to the "pre" or 5' end of eukaryotic messenger RNA immediately after transcription initiation. The 5' cap consists of a terminal group attached to the first transcribed nucleotide. Its presence is important for ribosome recognition and protection from RNases. Capping is coupled to transcription and occurs cotranscriptionally, with each cap affecting the other. Shortly after transcription initiation, a cap-synthesizing complex associated with RNA polymerase binds to the 5' end of the mRNA being synthesized. This enzyme complex catalyzes the chemical reactions required for mRNA capping. Synthesis proceeds as a multistep biochemical reaction. The capping moiety can be modified to adjust mRNA functions such as its stability or translation efficiency.
[0210] As used herein, "in vitro transcribed RNA" refers to in vitro synthesized RNA, preferably mRNA. Generally, in vitro transcribed RNA is generated from an in vitro transcription vector. The in vitro transcription vector contains a template used to generate the in vitro transcribed RNA.
[0211] As used herein, "poly(A)" refers to a series of adenosines added to mRNA by polyadenylation. In a preferred embodiment of a construct for transient expression, the poly(A) is 50 to 5,000 (SEQ ID NO: 30), preferably greater than 64, more preferably greater than 100, and most preferably greater than 300 or 400. The poly(A) sequence can be modified chemically or enzymatically to adjust mRNA function, such as localization, stability, or translation efficiency.
[0212] As used herein, "polyadenylation" refers to the covalent attachment of a polyadenylyl moiety, or modified variants thereof, to a messenger RNA molecule. In eukaryotes, most messenger RNA (mRNA) molecules are polyadenylated at the 3' end. The 3' poly(A) tail is a long sequence (often several hundred) of adenine nucleotides added to pre-mRNA by the action of the enzyme polyadenylate polymerase. In higher eukaryotes, the poly(A) tail is added to transcripts containing a specific sequence, the polyadenylation signal. The poly(A) tail and its associated proteins help protect the mRNA from exonuclease degradation. Polyadenylation is also important for transcription termination, mRNA nuclear export, and translation. Polyadenylation occurs in the nucleus immediately after DNA-to-RNA transcription, but can also occur later in the cytoplasm. After transcription is terminated, the mRNA strand is cleaved by the action of an endonuclease complex associated with RNA polymerase. The cleavage site is usually characterized by the presence of the base sequence AAUAAA near the cleavage site. After the mRNA is cleaved, an adenosine residue is added to the free 3' end of the cleavage site.
[0213] As used herein, "transient" refers to expression of a non-integrated transgene for a period of hours, days, or weeks, which is shorter than the period of expression of the gene when integrated into the genome or contained in a stable plasmid replicon in the host cell.
[0214] As used herein, the terms "treat," "treatment," and "treating" refer to a reduction or amelioration of the progression, severity, and / or duration of a proliferative disorder, or an amelioration of one or more symptoms (preferably one or more discernible symptoms) of a proliferative disorder, brought about by the administration of one or more therapies (e.g., one or more therapeutic agents, such as a CAR of the invention). In specific embodiments, the terms "treat," "treatment," and "treating" refer to an improvement in at least one measurable physical parameter of a proliferative disorder, such as tumor growth, which may not necessarily be discernible to the patient. In other embodiments, the terms "treat," "treatment," and "treating" refer to either or both of a physical inhibition of the progression of a proliferative disorder, e.g., by stabilization of a discernible symptom, or a physiological inhibition, e.g., by stabilization of a physical parameter. In other embodiments, the terms "treat," "treatment," and "treating" refer to a reduction or stabilization of tumor size or cancerous cell number.
[0215] A dosage regimen, e.g., a therapeutic dosage regimen, can include one or more treatment intervals. A dosage regimen can produce at least one beneficial or desired clinical result, whether detectable or undetectable, including, but not limited to, alleviation of symptoms, reduction in the extent of the disease, stabilization of (i.e., not worsening of) the disease state, delay or slowing of disease progression, or improvement or palliation of the disease state.
[0216] As used herein, "treatment interval" refers to a treatment cycle, e.g., a course of administration of a therapeutic agent, which may be repeated, for example, on a regular schedule. In embodiments, a dosage regimen may have one or more periods during which no therapeutic agent is administered over the treatment interval. For example, a treatment interval may include a dose of a CAR molecule administered in combination with (before, concurrently with, or after) the administration of a second therapeutic agent, e.g., an inhibitor (e.g., a kinase inhibitor as described herein).
[0217] The term "signal transduction pathway" refers to the biochemical relationships between various signaling molecules that play a role in transmitting a signal from one part of a cell to another part of the cell. The phrase "cell surface receptor" includes molecules and molecular complexes that have the ability to receive a signal and transmit the signal across the membrane of a cell.
[0218] The term "subject" is intended to include living organisms (e.g., mammals, humans) capable of generating an immune response. In certain embodiments, the subject is a mammal. In certain embodiments, the subject is a human. In certain embodiments, the subject is a patient. In one embodiment, the subject is a pediatric subject. In other embodiments, the subject is an adult.
[0219] The term "substantially purified" cells refers to cells that are essentially free of other cell types. Substantially purified cells also refer to cells that have been separated from other cell types with which they are normally associated in their naturally occurring state. In some instances, a substantially purified cell population refers to a homogenous cell population. In other instances, the term simply refers to cells that have been separated from the cells with which they are naturally associated in their natural state. In some embodiments, the cells are cultured in vitro. In other embodiments, the cells are not cultured in vitro.
[0220] The term "therapeutic" as used herein means treatment. A therapeutic effect is achieved by the reduction, suppression, amelioration, or eradication of a disease state.
[0221] The term "prophylaxis" as used herein means the prevention or prophylactic treatment of a disease or disease state.
[0222] The terms "transfected" or "transformed" or "transduced" refer to the process of transferring or introducing exogenous nucleic acid into a host cell. A "transfected" or "transformed" or "transduced" cell is one that has been transfected, transformed or transduced with exogenous nucleic acid. The cell includes the primary subject cell and its progeny.
[0223] The term "specifically binds" refers to an antibody or ligand that recognizes and binds to a binding partner (e.g., a tumor antigen) protein present in a sample, but does not substantially recognize or bind to other molecules in the sample.
[0224] As used herein, a "regulatable chimeric antigen receptor (RCAR)" refers to a set of polypeptides, typically two polypeptides in the simplest embodiment, that, when present in an immune effector cell, confers specificity for a target cell, typically a cancer cell, and regulatable intracellular signal generation to the cell. In some embodiments, an RCAR comprises at least an extracellular antigen-binding domain, a transmembrane domain, and a cytoplasmic signaling domain (also referred to herein as an "intracellular signaling domain") that comprises a functional signaling domain derived from a stimulatory molecule and / or a costimulatory molecule as defined herein in the context of the CAR molecule. In some embodiments, the set of polypeptides of an RCAR are not contiguous with each other, e.g., on different polypeptide chains. In some embodiments, an RCAR comprises a dimerization switch that can couple the polypeptides to each other upon the presence of a dimerization molecule, e.g., can couple an antigen-binding domain to an intracellular signaling domain. In some embodiments, an RCAR is expressed in a cell (e.g., an immune effector cell) as described herein, e.g., an RCAR-expressing cell (also referred to herein as an "RCARX cell"). In some embodiments, the RCARX cells are T cells and are referred to as RCAR cells. In some embodiments, the RCARX cells are NK cells and are referred to as RCARN cells. The RCAR can confer specificity to the RCAR-expressing cells for target cells, typically cancer cells, and regulatable intracellular signal generation or proliferation, which can optimize the immune effector properties of the RCAR-expressing cells. In embodiments, the RCAR cells rely, at least in part, on the antigen-binding domain to confer specificity for target cells that contain the antigen bound by the antigen-binding domain.
[0225] "Membrane anchor" or "membrane tethering domain," as that term is used herein, refers to a polypeptide or moiety, e.g., a myristoyl group, sufficient to anchor an extracellular or intracellular domain to a cell membrane.
[0226] A "switch domain," as the term is used herein, e.g., in reference to an RCAR, refers to an entity, typically a polypeptide-based entity, that associates with another switch domain in the presence of a dimerization molecule. This association results in functional coupling between a first entity linked to, e.g., fused to, a first switch domain and a second entity linked to, e.g., fused to, a second switch domain. The first and second switch domains are collectively referred to as a dimerization switch. In embodiments, the first and second switch domains are identical to one another, e.g., they are polypeptides having the same primary amino acid sequence, and are collectively referred to as a homodimerization switch. In embodiments, the first and second switch domains are different from one another, e.g., they are polypeptides having different primary amino acid sequences, and are collectively referred to as a heterodimerization switch. In embodiments, the switch is intracellular. In embodiments, the switch is extracellular. In embodiments, the switch domain is a polypeptide-based entity, e.g., FKBP- or FRB-based, and the dimerization molecule is a small molecule, e.g., a rapalog. In embodiments, the switch domain is a polypeptide-based entity, e.g., an scFv that binds a myc peptide, and the dimerization molecule is a polypeptide, fragment thereof, or multimer of a polypeptide, e.g., a myc ligand or multimer of a myc ligand that binds one or more myc scFvs. In embodiments, the switch domain is a polypeptide-based entity, e.g., a myc receptor, and the dimerization molecule is an antibody or fragment thereof, e.g., a myc antibody.
[0227] "Dimerization molecule," as the term is used herein, e.g., in reference to an RCAR, refers to a molecule that promotes association of a first switch domain with a second switch domain. In embodiments, the dimerization molecule is not naturally present in a subject or is not present at concentrations that would result in significant dimerization. In embodiments, the dimerization molecule is a small molecule, e.g., rapamycin or a rapalog, e.g., RAD001.
[0228] The term "bioequivalent" refers to an amount of an agent other than a reference compound (e.g., RAD001) required to produce an effect equivalent to that produced by a reference dose or amount of a reference compound (e.g., RAD001). In some embodiments, the effect is the level of mTOR inhibition, e.g., as measured by P70 S6 kinase inhibition, e.g., as assessed in an in vivo or in vitro assay, e.g., an assay described herein, e.g., a Boulay assay, or by measuring phosphorylated S6 levels by Western blot. In some embodiments, the effect is a change in the ratio of PD-1-positive / PD-1-negative T cells, as measured by cell sorting. In some embodiments, a bioequivalent amount or dose of an mTOR inhibitor is an amount or dose that achieves the same level of P70 S6 kinase inhibition as the reference dose or reference amount of the reference compound. In some embodiments, a bioequivalent amount or dose of an mTOR inhibitor is an amount or dose that achieves the same level of change in the ratio of PD-1-positive / PD-1-negative T cells as the reference dose or reference amount of the reference compound.
[0229] The term "low immune enhancing dose," when used in conjunction with an mTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g., RAD001 or rapamycin, or a catalytic mTOR inhibitor, refers to a dose of the mTOR inhibitor that partially, but not completely, inhibits mTOR activity, e.g., as measured by inhibition of P70 S6 kinase activity. Methods for assessing mTOR activity, e.g., by inhibition of P70 S6 kinase, are discussed herein. The dose is insufficient to result in complete immune suppression, but sufficient to enhance the immune response. In some embodiments, a low immune enhancing dose of an mTOR inhibitor results in a decrease in the number of PD-1-positive T cells and / or an increase in the number of PD-1-negative T cells, or an increase in the ratio of PD-1-negative T cells / PD-1-positive T cells. In some embodiments, a low immune enhancing dose of an mTOR inhibitor results in an increase in the number of naive T cells. In some embodiments, a low immune enhancing dose of an mTOR inhibitor results in one or more of the following: For example, the following markers on memory T cells, e.g., on memory T cell precursors: CD62L high, CD127 high , CD27 + and increased expression of one or more of BCL2; For example, a decrease in the expression of KLRG1 on memory T cells, e.g., on memory T cell precursors, and Memory T cell precursors, e.g., those with the following characteristics: CD62L high Increased CD127 high Increased CD27 + an increase in the number of cells with any one or combination of increased KLRG1, decreased KLRG1, and increased BCL2. wherein any of the above-described changes occur, eg, at least transiently, eg, when compared to an untreated subject.
[0230] "Progressive," as used herein, refers to a disease, e.g., cancer, that is progressing or getting worse. In solid tumors, e.g., lung cancer, progressive disease typically indicates at least a 20% growth in tumor size or tumor spread since treatment began.
[0231] "Refractory," as used herein, refers to a disease, e.g., cancer, that does not respond to treatment. In embodiments, a refractory cancer may be resistant to treatment before or at the time of initiation of treatment. In other embodiments, a refractory cancer may become resistant during treatment. A refractory cancer is also referred to as a resistant cancer.
[0232] "Relapsed" or "recurring," as used herein, refers to the return or reappearance of a disease (e.g., cancer) or signs and symptoms of a disease, such as cancer, after a period of improvement or response, e.g., after prior treatment with a therapy, e.g., a cancer therapy. The initial period of response may involve levels of cancer cells below a certain threshold, e.g., below 20%, 1%, 10%, 5%, 4%, 3%, 2%, or 1%. Reappearance may include levels of cancer cells above a certain threshold, e.g., above 20%, 1%, 10%, 5%, 4%, 3%, 2%, or 1%. For example, in the context of B-ALL, reappearance may include the reappearance of blasts in the blood, bone marrow (>5%), or any extramedullary site, e.g., after a complete response. In this context, a complete response may include <5% BM blasts. More generally, in certain embodiments, a response (e.g., complete response or partial response) may include the absence of detectable MRD (minimal residual disease). In certain embodiments, the initial response period lasts for at least 1, 2, 3, 4, 5, or 6 days, at least 1, 2, 3, or 4 weeks, at least 1, 2, 3, 4, 6, 8, 10, or 12 months, or at least 1, 2, 3, 4, or 5 years.
[0233] "Complete response" or "CR" refers to the absence of detectable evidence of disease, e.g., cancer, in response to treatment, e.g., complete remission. A complete response can be identified, for example, using the NCCN Guidelines®, as described herein, or Cheson et al., J Clin Oncol 17:1244 (1999) and Cheson et al., "Revised Response Criteria for Malignant Lymphoma", J Clin Oncol 25:579-586 (2007), both of which are incorporated herein by reference in their entireties. For example, in the context of B-ALL, a complete response can be associated with <5% BM blasts.
[0234] A "complete responder," as used herein, refers to a subject with a disease, eg, cancer, who exhibits a complete response, eg, complete remission, to treatment.
[0235] A "partial response" or "PR" refers to a reduction in disease, eg, cancer, although, for example, detectable disease is still present.
[0236] "Partial responder," as used herein, refers to a subject with a disease, e.g., cancer, who experiences a partial response, e.g., partial remission, to a treatment. A partial response can be identified, for example, using the NCCN Guidelines® or the Cheson criteria, as described herein.
[0237] "Non-responder," as used herein, refers to a subject having a disease, e.g., cancer, who does not respond to treatment, e.g., the patient has stable disease or progressive disease after administration of a treatment, e.g., a treatment described herein. Non-responders can be identified, for example, using the NCCN Guidelines® or the Cheson criteria as described herein.
[0238] Whether a patient responds to treatment can be determined using several methods, including, for example, the criteria provided by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). For example, in the context of B-ALL, a complete response or complete responder may be associated with one or more of: <5% BM blasts, >1000 neutrophils / ANC ( / μL), >100,000 platelets ( / μL) without circulating blasts or extramedullary disease (no lymphadenopathy, splenomegaly, skin / gingival involvement / testicular mass / CNS lesions), trilineage hematopoiesis, and 4 weeks without relapse. A partial responder may be associated with one or more of: a ≥50% reduction in BM blasts, >1000 neutrophils / ANC ( / μL), >100,000 platelets ( / μL). A non-responder may exhibit disease progression, e.g., >25% BM blasts.
[0239] Ranges: Throughout this disclosure, various aspects of the invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be construed to include all the possible subranges specifically disclosed as well as individual numerical values within that range. For example, the description of a range such as 1 to 6 should be construed to include specifically disclosed subranges such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., as well as individual numerical values within that range, e.g., 1, 2, 2.7, 3, 4, 5, 5.3, and 6. As another example, a range such as 95-99% identity includes those with 95%, 96%, 97%, 98%, or 99% identity, and includes subranges such as 96-99%, 96-98%, 96-97%, 97-99%, 97-98%, and 98-99% identity. This applies regardless of the width of the range.
[0240] explanation Provided herein are compositions and methods for treating diseases such as cancer by administering cells comprising a chimeric antigen receptor, e.g., a CD19 CAR, that targets an antigen, e.g., an antigen described herein, e.g., CD19, in combination with a PD-1 inhibitor. Exemplary components for generating CAR molecules, e.g., CD19 CARs, and CAR-expressing cells (e.g., CD19 CAR-expressing cells), are disclosed herein. Exemplary PD-1 inhibitors are also described herein.
[0241] In embodiments, combination therapy of a CAR-expressing cell described herein (e.g., a CD19 CAR-expressing cell) with a PD-1 inhibitor described herein results in one or more of the following: improved or increased anti-tumor activity of the CAR-expressing cell, increased proliferation or persistence of the CAR-expressing cell, improved or increased infiltration of the CAR-expressing cell, improved inhibition of tumor progression, delayed tumor progression, inhibition or reduction of cancer cell proliferation, and / or a reduction in tumor burden, e.g., tumor volume, or size. In certain embodiments, combination therapy of a CD19 CAR-expressing cell, e.g., a plurality of CD19 CAR-expressing cells, with a PD-1 inhibitor described herein results in increased or improved persistence of the CD19 CAR-expressing cell, e.g., increased or improved persistence of a plurality of CD19 CAR-expressing cells.
[0242] In some embodiments, administration of a PD-1 inhibitor before or after administration of a CAR-expressing cell (e.g., a CD19 CAR-expressing cell) results in increased therapeutic efficacy, e.g., increased inhibition of tumor progression and / or tumor growth, in some cancers, e.g., when compared to administration of the PD-1 inhibitor or the CAR-expressing cell alone.
[0243] PD-1 is known to downregulate immune responses, e.g., anti-tumor immune responses. PD-1 and / or PD-L1 can also be expressed by cancer cells or cancer-associated cells, e.g., tumor-infiltrating lymphocytes (TILs). Without wishing to be bound by theory, in some embodiments, a subject administered a combination therapy described herein, e.g., a CAR-expressing cell (e.g., a CD19 CAR-expressing cell) and a PD-1 inhibitor, is likely to have increased anti-tumor activity compared to a subject not administered the combination therapy or a subject administered the CAR-expressing cell or the PD-1 inhibitor alone, if the subject has one or more of the following: a cancer that expresses, e.g., highly expresses, PD-1 and / or PD-L1, a cancer infiltrated by anti-tumor immune cells, e.g., tumor-infiltrating lymphocytes (TILs), and / or cancer-associated cells that express, e.g., highly express, PD-1 and / or PD-L1. For example, without wishing to be bound by theory, treatment with a PD-1 inhibitor prevents or reduces the downregulation of anti-tumor immune responses, e.g., the depletion of anti-tumor immune cells, e.g., TILs, thereby increasing the anti-tumor efficacy of CAR-expressing cells. Without wishing to be bound by theory, combination therapy, e.g., administration of CAR-expressing cells, e.g., CD19 CAR-expressing cells, with an immune checkpoint inhibitor, e.g., a PD-1 inhibitor, can reduce T cell depletion, leading to improved, e.g., prolonged, persistence of CAR-expressing cells. In certain embodiments, administration of a CD19 CAR-expressing cell in combination with a PD-1 inhibitor can result in improved, e.g., prolonged, persistence of CD19 CAR-expressing cells.
[0244] Chimeric antigen receptor (CAR) The present disclosure encompasses immune effector cells (e.g., T cells or NK cells) comprising a CAR molecule (CAR, e.g., a CD19 CAR) that targets, e.g., specifically binds to, an antigen, e.g., an antigen described herein, e.g., CD19. In one embodiment, the immune effector cell is engineered to express a CAR, e.g., a CD19 CAR. In one embodiment, the immune effector cell comprises a recombinant nucleic acid construct comprising a nucleic acid sequence encoding a CAR, e.g., a CD19 CAR.
[0245] In an embodiment, a CAR, e.g., a CD19 CAR, comprises an antigen-binding domain, e.g., an antigen-binding domain (e.g., a CD19-binding domain), that specifically binds to an antigen, e.g., CD19, a transmembrane domain, and an intracellular signaling domain. In one embodiment, the sequence of the antigen-binding domain is contiguous with and in the same reading frame as the nucleic acid sequence encoding the intracellular signaling domain. The intracellular signaling domain can comprise a costimulatory signaling domain and / or a primary signaling domain, e.g., a zeta chain. A costimulatory signaling domain refers to a portion of a CAR that comprises at least a portion of the intracellular domain of a costimulatory molecule.
[0246] Non-limiting example sequences of various components that can be part of the CAR molecules described herein (e.g., CD19 CAR molecules) are listed in Table 1, where "aa" represents an amino acid and "na" represents a nucleic acid that encodes the corresponding peptide.
[0247] In any of the methods or compositions described herein, in embodiments, the CAR molecule comprises a CD123 CAR described herein, such as the CD123 CAR described in U.S. Patent Application Publication No. 2014 / 0322212A1 or U.S. Patent Application Publication No. 2016 / 0068601A1 (both of which are incorporated herein by reference). In embodiments, the CD123 CAR comprises the amino acid or has the nucleotide sequence set forth in U.S. Patent Application Publication No. 2014 / 0322212A1 or U.S. Patent Application Publication No. 2016 / 0068601A1 (both of which are incorporated herein by reference). In other embodiments, the CAR molecule comprises a CD19 CAR molecule described herein, such as the CD19 CAR molecule described in U.S. Patent Application Publication No. 2015-0283178-A1, such as CTL019. In embodiments, the CD19 CAR comprises the amino acid or has the nucleotide sequence set forth in U.S. Patent Application Publication No. 2015-0283178-A1 (incorporated herein by reference). In one embodiment, the CAR molecule comprises a BCMA CAR molecule described herein, for example, the BCMA CAR described in U.S. Patent Application Publication No. 2016-0046724-A1. In embodiments, the BCMA CAR comprises the amino acid or has the nucleotide sequence set forth in U.S. Patent Application Publication No. 2016-0046724-A1 (incorporated herein by reference). In an embodiment, the CAR molecule comprises a CLL1 CAR described herein, for example, the CLL1 CAR described in U.S. Patent Application Publication No. 2016 / 0051651A1 (incorporated herein by reference). In embodiments, the CLL1 CAR comprises the amino acid or has the nucleotide sequence set forth in U.S. Patent Application Publication No. 2016 / 0051651A1, which is incorporated herein by reference. In some embodiments, the CAR molecule comprises a CD33 CAR described herein, such as the CD33 CAR described in U.S. Patent Application Publication No. 2016 / 0096892A1, which is incorporated herein by reference.In embodiments, the CD33 CAR comprises the amino acid sequence or has the nucleotide sequence set forth in U.S. Patent Application Publication No. 2016 / 0096892A1 (incorporated herein by reference). In some embodiments, the CAR molecule comprises an EGFRvIII CAR molecule described herein, such as the EGFRvIII CAR described in U.S. Patent Application Publication No. 2014 / 0322275A1 (incorporated herein by reference). In some embodiments, the EGFRvIII CAR comprises the amino acid sequence or has the nucleotide sequence set forth in U.S. Patent Application Publication No. 2014 / 0322275A1 (incorporated herein by reference). In some embodiments, the CAR molecule comprises a mesothelin CAR described herein, such as the mesothelin CAR described in WO 2015 / 090230 (incorporated herein by reference). In embodiments, the mesothelin CAR comprises the amino acid or has the nucleotide sequence set forth in WO 2015 / 090230, which is incorporated herein by reference.
[0248] [Table 1]
[0249] [Table 2]
[0250] [Table 3]
[0251] [Table 4]
[0252] [Table 5]
[0253] [Table 6]
[0254] In one embodiment, an exemplary CAR construct comprises an optional leader sequence (e.g., a leader sequence described herein), an extracellular antigen binding domain (e.g., an antigen binding domain described herein), a hinge (e.g., a hinge region described herein), a transmembrane domain (e.g., a transmembrane domain described herein), and an intracellular stimulatory domain (e.g., an intracellular stimulatory domain described herein). In one embodiment, an exemplary CAR construct comprises an optional leader sequence (e.g., a leader sequence described herein), an extracellular antigen binding domain (e.g., an antigen binding domain described herein), a hinge (e.g., a hinge region described herein), a transmembrane domain (e.g., a transmembrane domain described herein), an intracellular costimulatory signaling domain (e.g., a costimulatory signaling domain described herein), and / or an intracellular primary signaling domain (e.g., a primary signaling domain described herein).
[0255] In one embodiment, a CAR of the invention (e.g., a CD19 CAR) comprises at least one intracellular signaling domain selected from the group consisting of a CD137 (4-1BB) signaling domain, a CD28 signaling domain, a CD27 signaling domain, an ICOS signaling domain, a CD3ζ signal domain, and any combination thereof. In one embodiment, a CAR of the invention comprises at least one intracellular signaling domain from one or more costimulatory molecules selected from CD137 (4-1BB), CD28, CD27, or ICOS.
[0256] Exemplary CD19 CARs include those described herein, e.g., CD19 CARs in one or more tables described herein, or those described in Xu et al. Blood 123.24(2014):3750-9; Kochenderfer et al. Blood 122.25(2013):4129-39, Cruz et al. Blood 122.17(2013):2965-73, NCT00586391, NCT01087294, NCT02456350, NCT00840853, NCT02659943, NCT02650999, NCT02640209, NCT01747486, NCT02 546739, NCT02656147, NCT02772198, NCT00709033, NCT02081937, NCT00924326, NCT02735083, NCT02794246, NCT02746952, NCT01593696, NCT0 2134262, NCT01853631, NCT02443831, NCT02277522, NCT02348216, NCT02614066, NCT02030834, NCT02624258, NCT02625480, NCT02030847, NC T02644655, NCT02349698, NCT02813837, NCT02050347, NCT01683279, NCT02529813, NCT02537977, NCT02799550, NCT02672501, NCT02819583, N CT02028455, NCT01840566, NCT01318317, NCT01864889, NCT02706405, NCT01475058, NCT01430390, NCT02146924, NCT02051257, NCT02431988 , NCT01815749, NCT02153580, NCT01865617, NCT02208362, NCT02685670, NCT02535364, NCT02631044, NCT02728882, NCT02735291, NCT0186093 7, NCT02822326, NCT02737085, NCT02465983, NCT02132624, NCT02782351, NCT01493453, NCT02652910, NCT02247609, NCT01029366, NCT01626495, NCT02721407, NCT01044069, NCT00422383, NCT01680991, NCT02794961, or NCT02456207 (each of which is incorporated by reference herein in its entirety).
[0257] antigen-binding domain In one aspect, the CAR of the present disclosure comprises a target-specific binding element, otherwise referred to as an antigen-binding domain. In one embodiment, the portion of the CAR that comprises an antigen-binding domain comprises an antigen-binding domain that targets, e.g., specifically binds to, an antigen, such as an antigen described herein, e.g., CD19. In one embodiment, the antigen-binding domain targets, e.g., specifically binds to, human CD19.
[0258] The antigen-binding domain can be any domain that binds to an antigen, including, but not limited to, monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies, and functional fragments thereof, such as, but not limited to, single-domain antibodies, such as heavy chain variable domains (VH), light chain variable domains (VL), and variable domains of camelid-derived nanobodies (VHH), and alternative scaffolds known in the art to function as antigen-binding domains, such as recombinant fibronectin domains. In some cases, it is beneficial for the antigen-binding domain to be derived from the same species in which the CAR will ultimately be used. For example, for human use, it may be beneficial for the antigen-binding domain of the CAR to comprise human or humanized residues in the antigen-binding domain of an antibody or antibody fragment. Thus, in one embodiment, the antigen-binding domain comprises a human antibody or antibody fragment.
[0259] In one embodiment, the antigen-binding domain comprises one, two, three (e.g., all three) heavy chain CDRs, HC CDR1, HC CDR2, HC CDR3, HC CDR4, HC CDR5, HC CDR6, HC CDR7, HC CDR8, HC CDR9, HC CDR10, HC CDR11, HC CDR12, HC CDR13, HC CDR14, HC CDR15, HC CDR16, HC CDR17, HC CDR18, HC CDR19 ... and / or one, two, three (e.g., all three) light chain CDRs, LC CDR2 and HC CDR3, from an antibody described herein (e.g., an antibody described in WO 2015 / 142675, U.S. Patent Application Publication No. 2015-0283178-A1, U.S. Patent Application Publication No. 2016-0046724-A1, U.S. Patent Application Publication No. 2014 / 0322212A1, U.S. Patent Application Publication No. 2016 / 0068601A1, U.S. Patent Application Publication No. 2016 / 0051651A1, U.S. Patent Application Publication No. 2016 / 0096892A1, U.S. Patent Application Publication No. 2014 / 0322275A1, or WO 2015 / 090230, which are incorporated by reference herein). In one embodiment, the antigen-binding domain comprises a heavy chain variable region and / or a variable light chain region of an antibody listed above.
[0260] In embodiments, the antigen binding domain is an antigen binding domain described in WO 2015 / 142675, US 2015-0283178-A1, US 2016-0046724-A1, US 2014 / 0322212A1, US 2016 / 0068601A1, US 2016 / 0051651A1, US 2016 / 0096892A1, US 2014 / 0322275A1, or WO 2015 / 090230 (incorporated herein by reference).
[0261] In embodiments, the antigen binding domain targets BCMA and is described in U.S. Patent Application Publication No. 2016-0046724-A1.
[0262] In embodiments, the antigen binding domain targets CD19 and is described in US Patent Application Publication No. 2015-0283178-A1.
[0263] In embodiments, the antigen binding domain targets CD123 and is described in US Patent Application Publication No. 2014 / 0322212A1, US Patent Application Publication No. 2016 / 0068601A1.
[0264] In embodiments, the antigen binding domain targets CLL and is described in US Patent Application Publication No. 2016 / 0051651A1.
[0265] In embodiments, the antigen binding domain targets CD33 and is described in US Patent Application Publication No. 2016 / 0096892A1.
[0266] Exemplary target antigens that can be targeted using CAR-expressing cells include, but are not limited to, CD19, CD123, EGFRvIII, CD33, mesothelin, BCMA, and GFR ALPHA-4, among others, as described, for example, in WO 2014 / 153270, WO 2014 / 130635, WO 2016 / 028896, WO 2014 / 130657, WO 2016 / 014576, WO 2015 / 090230, WO 2016 / 014565, WO 2016 / 014535, and WO 2016 / 025880 (each of which is incorporated herein by reference in its entirety).
[0267] In other embodiments, the CAR-expressing cells can specifically bind humanized CD19 and may comprise, for example, a CAR molecule or antigen-binding domain (e.g., a humanized antigen-binding domain) according to Table 3 of WO 2014 / 153270 (incorporated herein by reference). Amino acid and nucleotide sequences encoding CD19 CAR molecules and antigen-binding domains (e.g., comprising one, two, or three VH CDRs and one, two, or three VL CDRs according to Kabat or Chothia) are specified in WO 2014 / 153270.
[0268] In other embodiments, the CAR-expressing cells can specifically bind to CD123 and can comprise, for example, a CAR molecule (e.g., any of CAR1-CAR8) or antigen-binding domain according to Tables 1-2 of WO 2014 / 130635 (incorporated herein by reference). Amino acid and nucleotide sequences encoding CD123 CAR molecules and antigen-binding domains (e.g., comprising one, two, or three VH CDRs and one, two, or three VL CDRs according to Kabat or Chothia) are specified in WO 2014 / 130635.
[0269] In other embodiments, the CAR-expressing cells can specifically bind CD123 and can comprise, for example, a CAR molecule (e.g., any of CAR123-1 through CAR123-4 and hzCAR123-1 through hzCAR123-32) or antigen-binding domain according to Tables 2, 6, and 9 of WO 2016 / 028896 (incorporated herein by reference). Amino acid and nucleotide sequences encoding CD123 CAR molecules and antigen-binding domains (e.g., comprising one, two, or three VH CDRs and one, two, or three VL CDRs according to Kabat or Chothia) are specified in WO 2016 / 028896.
[0270] In other embodiments, the CAR-expressing cells can specifically bind EGFRvIII and may comprise, for example, a CAR molecule or antigen-binding domain according to Table 2 or SEQ ID NO: 11 of WO 2014 / 130657 (incorporated herein by reference). Amino acid and nucleotide sequences encoding EGFRvIII CAR molecules and antigen-binding domains (e.g., comprising one, two, or three VH CDRs and one, two, or three VL CDRs according to Kabat or Chothia) are specified in WO 2014 / 130657.
[0271] In other embodiments, the CAR-expressing cells can specifically bind CD33 and can comprise, for example, a CAR molecule (e.g., any of CAR33-1 through CAR-33-9) or antigen-binding domain according to Table 2 or Table 9 of WO 2016 / 014576 (incorporated herein by reference). Amino acid and nucleotide sequences encoding CD33 CAR molecules and antigen-binding domains (e.g., comprising one, two, or three VH CDRs and one, two, or three VL CDRs according to Kabat or Chothia) are specified in WO 2016 / 014576.
[0272] In other embodiments, the CAR-expressing cells can specifically bind mesothelin and can comprise, for example, a CAR molecule or antigen-binding domain according to Tables 2-3 of WO 2015 / 090230 (incorporated herein by reference). Amino acid and nucleotide sequences encoding mesothelin CAR molecules and antigen-binding domains (e.g., comprising one, two, or three VH CDRs and one, two, or three VL CDRs according to Kabat or Chothia) are specified in WO 2015 / 090230.
[0273] In other embodiments, the CAR-expressing cells can specifically bind BCMA and may comprise, for example, a CAR molecule or antigen-binding domain according to Table 1 or Table 16, SEQ ID NO: 271 or SEQ ID NO: 273 of WO 2016 / 014565 (incorporated herein by reference). Amino acid and nucleotide sequences encoding BCMA CAR molecules and antigen-binding domains (e.g., comprising one, two, or three VH CDRs and one, two, or three VL CDRs according to Kabat or Chothia) are specified in WO 2016 / 014565.
[0274] In other embodiments, the CAR-expressing cells can specifically bind to CLL-1 and may comprise, for example, a CAR molecule or antigen-binding domain according to Table 2 of WO 2016 / 014535 (incorporated herein by reference). Amino acid and nucleotide sequences encoding CLL-1 CAR molecules and antigen-binding domains (e.g., comprising one, two, or three VH CDRs and one, two, or three VL CDRs according to Kabat or Chothia) are specified in WO 2016 / 014535.
[0275] In other embodiments, the CAR-expressing cells can specifically bind GFR ALPHA-4 and may comprise, for example, a CAR molecule or antigen binding domain according to Table 2 of WO 2016 / 025880 (incorporated herein by reference). Amino acid and nucleotide sequences encoding GFR ALPHA-4 CAR molecules and antigen binding domains (e.g., comprising one, two, or three VH CDRs and one, two, or three VL CDRs according to Kabat or Chothia) are specified in WO 2016 / 025880.
[0276] In one embodiment, the antigen binding domain of any of the CAR molecules described herein (e.g., any of CD19, CD123, EGFRvIII, CD33, mesothelin, BCMA, and GFR ALPHA-4) comprises one, two, three (e.g., all three) heavy chain CDRs, HC CDR1, HC CDR2, and HC CDR3, from an antibody listed above, and / or one, two, three (e.g., all three) light chain CDRs, LC CDR1, LC CDR2, and LC CDR3, from an antigen binding domain listed above. In one embodiment, the antigen binding domain comprises the heavy chain variable region and / or the variable light chain region of an antibody listed or described above.
[0277] In one embodiment, the CD19-binding domain comprises one or more (e.g., all three) light chain complementarity determining region 1 (LC CDR1), light chain complementarity determining region 2 (LC CDR2), and light chain complementarity determining region 3 (LC CDR3) of a CD19-binding domain selected from SEQ ID NO: 45 to 56, 69 to 80, 106, 109, 110, 112, or 115, and one or more (e.g., all three) heavy chain complementarity determining region 1 (HC CDR1), heavy chain complementarity determining region 2 (HC CDR2), and heavy chain complementarity determining region 3 (HC CDR3) of a CD19-binding domain selected from SEQ ID NO: 45 to 56, 69 to 80, 106, 109, 110, 112, or 115. In one embodiment, the CD19 binding domain comprises a light chain variable region described herein (e.g., in Table 2 or Table 3) and / or a heavy chain variable region described herein (e.g., in Table 2 or Table 3). In one embodiment, the CD19 binding domain is an scFv comprising a light chain variable region and a heavy chain variable region of the amino acid sequences of Table 2 or Table 3. In one embodiment, the CD19-binding domain (e.g., scFV) comprises a light chain variable region comprising an amino acid sequence having at least one, two, or three alterations (e.g., substitutions) but not more than 30, 20, or 10 alterations (e.g., substitutions) of the amino acid sequence of a light chain variable region provided in Table 2 or Table 3, or a sequence having 95 to 99% identity to an amino acid sequence of Table 2 or Table 3, and / or a heavy chain variable region comprising an amino acid sequence having at least one, two, or three alterations (e.g., substitutions) but not more than 30, 20, or 10 alterations (e.g., substitutions) of the amino acid sequence of a heavy chain variable region provided in Table 2 or Table 3, or a sequence having 95 to 99% identity to an amino acid sequence of Table 2 or Table 3.
[0278] In one embodiment, the CD19 binding domain comprises a light chain variable region comprising an amino acid sequence described herein, e.g., in Table 2 or Table 3, attached to a heavy chain variable region comprising an amino acid sequence described herein, e.g., in Table 2 or Table 3, via a linker, e.g., a linker described herein. In one embodiment, the humanized anti-CD19 binding domain comprises a (Gly4-Ser)n linker (SEQ ID NO: 26), where n is 1, 2, 3, 4, 5, or 6, preferably 3 or 4. The light chain variable region and heavy chain variable region of the scFv can be in, for example, any of the following orientations: light chain variable region-linker-heavy chain variable region or heavy chain variable region-linker-light chain variable region.
[0279] In another embodiment, the CD19 binding domain comprises any antibody or antibody fragment thereof known in the art that binds to CD19.
[0280] In one embodiment, the antibodies of the present invention may exist in a variety of other forms, including, for example, Fab, Fab', F(ab'), Fv fragments, scFv antibody fragments, disulfide-linked Fvs (sdFvs), Fd fragments consisting of the VH and CH1 domains, linear antibodies, single-domain antibodies (either VL or VH) such as sdAbs, camelid VHH domains, multispecific antibodies formed from antibody fragments such as bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region, and isolated CDRs or other epitope-binding fragments of antibodies. In one embodiment, the antibody fragments provided herein are scFvs. In some examples, human scFvs may also be derived from yeast display libraries.
[0281] Humanized antibodies can be prepared by a variety of techniques, including CDR-grafting (see, e.g., EP 239,400; WO 91 / 09967; and U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089, each of which is incorporated by reference in its entirety), veneering, or resurfacing (see, e.g., EP 592,106 and 519,596, each of which is incorporated by reference in its entirety; Padlan, 1991, Molecular Immunology, 28(4 / 5):489-498; Studnicka et al., 1994, Protein Engineering, 7(6):805-814; and Roguska et al., 1994, Protein Engineering, 7(6):805-814). al., 1994, PNAS, 91:969-973), chain shuffling (see, e.g., U.S. Pat. No. 5,565,332, which is incorporated herein by reference in its entirety), as well as methods such as those described in U.S. Patent Application Publication Nos. 2005 / 0042664, 2005 / 0048617, U.S. Pat. No. 6,407,213, U.S. Pat. No. 5,766,886, WO 9317105, Tan et al., J. Immunol., 169:1119-25 (2002), Caldas et al., Protein Eng., 13(5):353-60 (2000), Morea et al., Methods, 20(3):267-79 (2000), Baca et al. al.,J.Biol.Chem.,272(16):10678-84(1997),Roguska et al.,Protein Eng.,9(10):895-904(1996),Couto et al.,Cancer Res.,55(23 Supp):5973s-5977s(1995),Couto et al.,Cancer Res., 55(8):1717-22(1995), Sandhu JS, Gene, 150(2):409-10(1994) and Pedersen et al., J.Mol.Biol., 235(3):959-73 (1994). Further information regarding framework regions and humanized antibodies is provided on pages 169-170 of International Publication No. WO 2016 / 164731, filed April 8, 2016, which is incorporated by reference in its entirety.
[0282] The selection of human variable domains, both light and heavy, used to produce humanized antibodies is intended to reduce antigenicity. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable domain sequences. The human sequence that most closely resembles the rodent is then accepted as the human framework (FR) for the humanized antibody (see Sims et al., J. Immunol., 151:2296 (1993); Chothia et al., J. Mol. Biol., 196:901 (1987), the entire contents of which are incorporated herein by reference). Another method uses a specific framework derived from the consensus sequence of all light or heavy chain antibodies of a particular subgroup. The same framework can be used for several different humanized antibodies (see, e.g., Nicholson et al. Mol. Immun. 34(16-17):1157-1165 (1997); Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); Presta et al., J. Immunol., 151:2623 (1993), the contents of which are incorporated herein by reference in their entirety). In one embodiment, the framework regions of the heavy chain variable region, e.g., all four framework regions, are derived from the VH4_4-59 germline sequence. In one embodiment, the framework regions can include, for example, one, two, three, four, or five modifications, e.g., substitutions, from the amino acids of the corresponding murine sequence (e.g., of SEQ ID NO: 109). In one embodiment, the framework regions of the light chain variable region, e.g., all four framework regions, are derived from the VK3_1.25 germline sequence. In one embodiment, the framework regions can include, for example, one, two, three, four, or five modifications, e.g., substitutions, from the amino acids of the corresponding murine sequence (e.g., of SEQ ID NO: 109). The design of humanized antibodies or antibody fragments based on three-dimensional conformational structures is described in detail on page 171 of WO 2016 / 164731, filed April 8, 2016, which is incorporated by reference in its entirety.
[0283] A humanized antibody or antibody fragment may retain the same antigen specificity as the original antibody, e.g., in the present disclosure, human CD19 binding ability. In some embodiments, a humanized antibody or antibody fragment may have improved affinity and / or specificity of binding to human CD19.
[0284] In one embodiment, the binding domain (e.g., an antigen-binding domain that binds to CD19) is a fragment, such as a single-chain variable fragment (scFv). In one embodiment, the binding domain is an Fv, Fab, (Fab')2, or a bifunctional (e.g., bispecific) hybrid antibody (e.g., Lanzavecchia et al., Eur. J. Immunol. 17, 105 (1987)). In one embodiment, the antibodies and fragments thereof of the present invention bind to the CD19 protein with wild-type or enhanced affinity.
[0285] In some instances, scFvs can be produced by methods known in the art (see, e.g., Bird et al., (1988) Science 242:423-426 and Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). ScFv molecules can be produced by linking the VH and VL domains together using a flexible polypeptide linker. The scFv molecule contains a linker (e.g., a Ser-Gly linker) of optimal length and / or amino acid composition. Linker length can significantly affect how the variable regions of an scFv fold and interact. Indeed, when short polypeptide linkers are used (e.g., 5-10 amino acids), intrachain folding is prevented. Intrachain folding is also required for the two variable regions to unite and form a functional epitope-binding site. For examples of linker orientations and sizes, see, e.g., Hollinger et al. 1993 Proc Natl Acad. Sci. USA 90:6444-6448, U.S. Patent Application Publication Nos. 2005 / 0100543, 2005 / 0175606, 2007 / 0014794, and WO 2006 / 020258 and WO 2007 / 024715, which are incorporated herein by reference.
[0286] An scFv can include a linker of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, or more amino acid residues between its VL and VH regions. The linker sequence can include any naturally occurring amino acid. In one embodiment, the linker sequence includes the amino acids glycine and serine. In another embodiment, the linker sequence includes a series of glycine and serine repeats, such as (Gly4Ser)n, where n is a positive integer equal to or greater than 1 (SEQ ID NO: 25). In one embodiment, the linker can be (Gly4Ser)4 (SEQ ID NO: 27) or (Gly4Ser)3 (SEQ ID NO: 28). Varying the linker length can maintain or enhance activity, resulting in superior efficacy in activity tests.
[0287] In some embodiments, the amino acid sequence of the antigen-binding domain (e.g., the antigen-binding domain that binds CD19) or other portions, or the entire CAR, can be modified; for example, the amino acid sequences described herein can be modified, e.g., by conservative substitutions. Families of amino acid residues having similar side chains have been defined in the art, and include basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
[0288] Percent identity, in the context of two or more nucleic acid or polypeptide sequences, refers to two or more sequences that are the same. Two sequences are "substantially identical" if, when compared and aligned for maximum correspondence over a comparison window, or indicated region, the two sequences have a specified percentage of amino acid residues or nucleotides that are the same (e.g., 60% identity over a specified region, or, if not specified, over the entire sequence; optionally, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity) as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Optionally, identity exists over a region that is at least about 50 nucleotides in length (or 10 amino acids in length), or over a region that is 100 to 500 or 1000 or more nucleotides in length (or 20, 50, 200 or more amino acids in length).
[0289] In sequence comparison, typically, one sequence serves as a reference sequence, with which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated as needed, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. Then, the sequence comparison algorithm calculates the percent sequence identity of the test sequence compared to the reference sequence based on the program parameters. Methods for aligning sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be achieved, for example, by the local homology algorithm of Smith and Waterman, (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch, (1970) J. Mol. Biol. 48:443, by the similarity search method of Pearson and Lipman, (1988) Proc. Nat'l. Acad. Sci. USA 85:2444, by computer implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Brent et al., (2003) Current Protocols in Molecular Biology).
[0290] Two examples of suitable algorithms for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., (1977) Nuc. Acids Res. 25:3389-3402 and Altschul et al., (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
[0291] The percent identity between two amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller, (1988) Comput. Appl. Biosci. 4:11-17) as incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:444-453) as incorporated into the GAP program of the GCG software package (available at www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and gap weights of 16, 14, 12, 10, 8, 6, or 4 and length weights of 1, 2, 3, 4, 5, or 6.
[0292] In one aspect, the present disclosure contemplates modifications of the amino acid sequence of a starting antibody or fragment (e.g., scFv) that result in a functionally equivalent molecule. For example, the binding domain (e.g., the antigen binding domain that binds to CD19) comprised in a CAR, e.g., the VH or VL of an scFv, can be modified to retain at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity of the starting VH or VL framework region of the anti-CD19 binding domain, e.g., scFv. The present invention contemplates modification of the entire CAR construct, such as modification of one or more amino acid sequences of various domains of the CAR construct, to generate functionally equivalent molecules. The CAR construct can be modified to retain at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to the starting CAR construct.
[0293] In some examples, scFvs can be prepared by methods known in the art (see, for example, Bird et al., (1988) Science 242:423-426 and Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). ScFv molecules can be generated by linking VH and VL domains together, for example, using a flexible polypeptide linker. scFv molecules can include linkers of optimized length and / or amino acid composition (e.g., Ser-Gly linkers). Linker length can have a significant impact on how the variable regions of an scFv fold and interact. In fact, when short polypeptide linkers (e.g., 5-10 amino acids) are utilized, intrachain folding is prevented. Interchain folding is also required for the two variable regions to unite and form a functional epitope-binding site. For examples of linker orientations and sizes, see, e.g., Hollinger et al. 1993 Proc Natl Acad. Sci. USA 90:6444-6448, U.S. Patent Application Publication Nos. 2005 / 0100543, 2005 / 0175606, 2007 / 0014794, and WO 2006 / 020258 and 2007 / 024715, which are incorporated herein by reference.
[0294] Exemplary CD19 Antigen Binding Domain and CAR Constructs Exemplary CD19 CAR constructs disclosed herein comprise an scFv (e.g., a human scFv) as disclosed in Table 2 or Table 3 herein, optionally preceded by an optional leader sequence (e.g., SEQ ID NO: 1 and SEQ ID NO: 12 for exemplary leader amino acid and nucleotide sequences, respectively). The sequences of the scFv fragments (amino acid sequences of SEQ ID NOs: 45-56, 69-80, 106, 109, 110, 112, or 115) are provided in Table 2 or Table 3 herein. The CD19 CAR construct further comprises an optional hinge domain, e.g., a CD8 hinge domain (e.g., comprising the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO: 2 or SEQ ID NO: 13); a transmembrane domain, e.g., a CD8 transmembrane domain (e.g., comprising the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 6 or SEQ ID NO: 17); an intracellular domain, e.g., a 4-1BB intracellular domain (e.g., comprising the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 7 or SEQ ID NO: 18), and a functional signaling domain, e.g., a CD3ζ domain (e.g., comprising the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 9 or 10 or SEQ ID NO: 20 or 21). In one embodiment, the domains are adjacent or in the same reading frame to form a single fusion protein. In other embodiments, the domains are in separate polypeptides, such as, for example, in an RCAR molecule as described herein.
[0295] In one embodiment, the full-length CD19 CAR molecule comprises the amino acid sequence of, or is encoded by the nucleotide sequence of, CAR1-CAR12, CTL019, mCAR1-mCAR3, or SSJ25-C1 provided in Table 2 or 3, or a sequence substantially identical (e.g., 95-99% identical, or up to 20, 15, 10, 8, 6, 5, 4, 3, 2, or 1 amino acid change) to any of these sequences.
[0296] In one embodiment, the CD19 CAR molecule or CD19 antigen binding domain comprises the scFv amino acid sequence of, or is encoded by the nucleotide sequence of, CAR1-CAR12, CTL019, mCAR1-mCAR3, or SSJ25-C1 provided in Table 2 or 3, or a sequence substantially identical (e.g., 95-99% identical, or up to 20, 15, 10, 8, 6, 5, 4, 3, 2, or 1 amino acid change) to any of these sequences.
[0297] In one embodiment, the CD19 CAR molecule or CD19 antigen binding domain comprises a heavy chain variable region and / or a light chain variable region of CAR1-CAR12, CTL019, mCAR1-mCAR3, or SSJ25-C1 provided in Table 2 or 3, or a sequence substantially identical (e.g., 95-99% identical, or up to 20, 15, 10, 8, 6, 5, 4, 3, 2, or 1 amino acid change) to any of these sequences.
[0298] In one embodiment, the CD19 CAR molecule or CD19 antigen binding domain comprises one, two, or three CDRs (e.g., HCDR1, HCDR2, and / or HCDR3) from the heavy chain variable region of CAR1-CAR12, CTL019, mCAR1-mCAR3, or SSJ25-C1 provided in Table 2 or 3, and / or one, two, or three CDRs (e.g., LCDR1, LCDR2, and / or LCDR3) of the light chain variable region of CAR1-CAR12, CTL019, mCAR1-mCAR3, or SSJ25-C1 provided in Table 2 or 3, or a sequence substantially identical (e.g., 95-99% identical, or up to 5, 4, 3, 2, or 1 amino acid changes) to any of the foregoing sequences.
[0299] The sequences of the CDR sequences of the scFv domains are shown in Table 4 for the heavy chain variable domain and Table 5 for the light chain variable domain.
[0300] The amino acid and nucleic acid sequences of the CD19 scFv domain and the CD19 CAR molecule are provided in Tables 2 and 3. In one embodiment, the CD19 CAR molecule comprises a leader sequence as described herein, for example, underlined in the sequences provided in Tables 2 and 3. In one embodiment, the CD19 CAR molecule does not comprise a leader sequence.
[0301] In one embodiment, the CAR molecule comprises an antigen-binding domain that specifically binds to CD19 (CD19 CAR). In one embodiment, the antigen-binding domain targets human CD19. In one embodiment, the antigen-binding domain of the CAR has the same or similar binding specificity as the FMC63 scFv fragment described in Nicholson et al. Mol. Immun. 34(16-17):1157-1165 (1997). In one embodiment, the antigen-binding domain of the CAR comprises the scFv fragment described in Nicholson et al. Mol. Immun. 34(16-17):1157-1165 (1997). The CD19 antibody molecule can be, for example, an antibody molecule (e.g., a humanized anti-CD19 antibody molecule) described in WO 2014 / 153270, the entire contents of which are incorporated herein by reference. WO 2014 / 153270 also describes methods for assaying the binding and efficacy of various CAR constructs.
[0302] In one aspect, the parent murine scFv sequence is the CAR19 construct provided in WO 2012 / 079000 (incorporated herein by reference) and provided herein as SEQ ID NO: 108. In one embodiment, the anti-CD19 binding domain is the scFv described in WO 2012 / 079000 and provided herein as SEQ ID NO: 109.
[0303] In one embodiment, the CAR molecule comprises the polypeptide sequence provided as SEQ ID NO: 12 in WO 2012 / 079000 and provided herein as SEQ ID NO: 108, wherein the scFv domain is replaced by one or more sequences selected from SEQ ID NOs: 93-104. In one embodiment, the scFv domain of SEQ ID NOs: 93-104 is a humanized variant of the scFv domain of SEQ ID NO: 109, a mouse-derived scFv fragment that specifically binds to human CD19. Humanization of this mouse scFv may be desirable for clinical conditions where mouse-specific residues can induce a human anti-mouse antigen (HAMA) response in patients undergoing CART19 treatment, e.g., treatment with T cells transduced with a CAR19 construct.
[0304] In one embodiment, the CD19 CAR comprises the amino acid sequence provided in WO 2012 / 079000 as SEQ ID NO: 12. In an embodiment, the amino acid sequence is [ka] or a sequence substantially homologous thereto.
[0305] In one embodiment, the amino acid sequence is [ka] or a sequence substantially homologous thereto.
[0306] In one embodiment, the CD19 CAR has the USAN name TISAGENLECLEUCEL-T. In embodiments, CTL019 is generated by genetic modification of T cells, mediated by stable insertion by transduction with a self-inactivating, replication-deficient lentiviral (LV) vector containing the CTL019 transgene under the control of the EF-1α promoter. CTL019 can be a mixture of transgene-positive and transgene-negative T cells delivered to a subject based on percent transgene-positive T cells.
[0307] In other embodiments, the CD19 CAR comprises an antigen-binding domain (e.g., a humanized antigen-binding domain) described in Table 3 of WO 2014 / 153270, which is incorporated herein by reference.
[0308] In embodiments, the CAR molecule is a CD19 CAR molecule described herein, such as a humanized CAR molecule described herein, such as a humanized CD19 CAR molecule of Table 2, or has CDRs as described in Tables 4 and 5.
[0309] In embodiments, the CAR molecule is a CD19 CAR molecule described herein, such as a murine CAR molecule described herein, such as a murine CD19 CAR molecule in Table 3, or has CDRs as described in Tables 4 and 5.
[0310] In some embodiments, the CAR molecule comprises one, two, and / or three CDRs from the heavy chain variable region and / or one, two, and / or three CDRs from the light chain variable region of a murine or humanized CD19 CAR of Tables 4 and 5.
[0311] In one embodiment, the antigen-binding domain comprises one, two, three (e.g., all three) heavy chain CDRs, HC CDR1, HC CDR2, and HC CDR3, from an antibody enumerated herein, and / or one, two, three (e.g., all three) light chain CDRs, LC CDR1, LC CDR2, and LC CDR3, from an antibody enumerated herein. In one embodiment, the antigen-binding domain comprises the heavy chain variable region and / or the light chain variable region of an antibody enumerated herein.
[0312] Humanization of a murine anti-CD19 antibody Humanization of murine CD19 antibodies is desirable for clinical conditions where murine-specific residues can induce a human anti-mouse antigen (HAMA) response in patients undergoing CART19 treatment, i.e., treatment with T cells transduced with a CAR19 construct. The production, characterization, and efficacy of humanized CD19 CAR sequences are described in WO 2014 / 153270, which is incorporated by reference in its entirety, including Examples 1-5 (pages 115-159), e.g., Tables 3, 4, and 5 (pages 125-147).
[0313] CAR constructs, e.g., CD19 CAR constructs The specific sequences of the CD19 CAR constructs described in WO 2014 / 153270 are reproduced herein.
[0314] The sequences of the humanized scFv fragments (SEQ ID NOs: 45-56) are provided below in Table 2. Full CAR constructs were made using SEQ ID NOs: 45-56 together with the additional sequences shown below, for example from Table 1, to make the full CAR constructs of SEQ ID NOs: 93-104.
[0315] All of these clones contained Q / K residue changes in the signaling domain of the costimulatory domain derived from 4-1BB.
[0316] [Table 7]
[0317] [Table 8]
[0318] [Table 9]
[0319] [Table 10]
[0320]
Table 11
[0321]
Table 12
[0322]
Table 13
[0323]
Table 14
[0324]
Table 15
[0325] Table 16
[0326]
Table 17
[0327]
Table 18
[0328]
Table 19
[0329] Table 20
[0330] Table 21
[0331] Table 22
[0332] Table 23
[0333] Table 24
[0334] Table 25
[0335] Table 26
[0336] Table 27
[0337] Table 28
[0338] Table 29
[0339]
Table 30
[0340] Table 31
[0341] [Table 32]
[0342] [Table 33]
[0343] [Table 34]
[0344] [Table 35]
[0345] [Table 36]
[0346] In some embodiments, the antigen binding domain comprises an HC CDR1, an HC CDR2, and an HC CDR3 of any of the heavy chain binding domain amino acid sequences listed in Table 2 or 3. In embodiments, the antigen binding domain further comprises an LC CDR1, an LC CDR2, and an LC CDR3. In embodiments, the antigen binding domain comprises an LC CDR1, an LC CDR2, and an LC CDR3 of any of the light chain binding domain amino acid sequences listed in Table 2 or 3.
[0347] In some embodiments, the antigen binding domain comprises one, two, or all of the LC CDR1, LC CDR2, and LC CDR3 of any of the light chain binding domain amino acid sequences listed in Table 2 or 3, and one, two, or all of the HC CDR1, HC CDR2, and HC CDR3 of any of the heavy chain binding domain amino acid sequences listed in Table 2 or 3.
[0348] In some embodiments, the CDRs are defined according to the Kabat numbering scheme, the Chothia numbering scheme, or a combination thereof.
[0349] The sequences of the humanized CDR sequences of the scFv domains are shown in Table 4 for the heavy chain variable domain and in Table 5 for the light chain variable domain. "ID" refers to the respective SEQ ID NO of each CDR.
[0350] [Table 37]
[0351] [Table 38]
[0352] The CAR scFv fragment was then cloned into a lentiviral vector to generate a full-length CAR construct in a single coding frame, using the EF1α promoter (SEQ ID NO: 11) for expression.
[0353] In some embodiments, the CD19 CAR comprises an antigen-binding domain derived from (e.g., comprising the amino acid sequence of) an anti-CD19 antibody (e.g., an anti-CD19 monospecific or bispecific antibody), or a fragment or conjugate thereof. In one embodiment, the anti-CD19 antibody is a humanized antigen-binding domain as described in WO 2014 / 153270 (e.g., Table 3 of WO 2014 / 153270), which is incorporated herein by reference, or a conjugate thereof. Other exemplary anti-CD19 antibodies or fragments or conjugates thereof include, but are not limited to, bispecific T cell engagers targeting CD19 (e.g., blinatumomab), SAR3419 (Sanofi), MEDI-551 (MedImmune LLC), Combotox, DT2219ARL (Masonic Cancer Center), MOR-208 (also referred to as XmAb-5574; MorphoSys), XmAb-5871 (Xencor), MDX-1342 (Bristol-Myers Squibb), SGN-CD19A (Seattle Genetics), and AFM11 (Affimed Therapeutics). See, e.g., Hammer.MAbs.4.5(2012):571-77. Blinatumomab is a bispecific antibody composed of two scFvs, one that binds to CD19 and one that binds to CD3. Blinatumomab directs T cells to attack cancer cells. See, e.g., Hammer et al.; Clinical Trial Identification Numbers NCT00274742 and NCT01209286. MEDI-551 is a humanized anti-CD19 antibody engineered with Fc-enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). See, e.g., Hammer et al.; Clinical Trial Identification Number NCT01957579. Combotox is a mixture of immunotoxins that bind to CD19 and CD22. The immunotoxin is composed of an scFv antibody fragment fused to a deglycosylated ricin A chain.See, e.g., Hammer et al.; and Herrera et al. J. Pediatr. Hematol. Oncol. 31.12(2009):936-41; Schindler et al. Br. J. Haematol. 154.4(2011):471-6. DT2219ARL is a bispecific immunotoxin targeting CD19 and CD22, comprising two scFvs and a truncated diphtheria toxin. See, e.g., Hammer et al.; and clinical trial identification number NCT00889408. SGN-CD19A is an antibody-drug conjugate (ADC) comprising an anti-CD19 humanized monoclonal antibody linked to the synthetic cytotoxic cell-killing agent monomethyl auristatin F (MMAF). See, e.g., Hammer et al.; and clinical trial identification numbers NCT01786096 and NCT01786135. SAR3419 is an anti-CD19 antibody-drug conjugate (ADC) comprising an anti-CD19 humanized monoclonal antibody conjugated to a maytansine derivative via a cleavable linker. See, e.g., Younes et al. J. Clin. Oncol. 30.2(2012):2776-82; Hammer et al.; Clinical Trial Identification Number NCT00549185; and Blanc et al. Clin Cancer Res. 2011;17:6448-58. XmAb-5871 is an Fc-engineered humanized anti-CD19 antibody. See, e.g., Hammer et al. MDX-1342 is a human Fc-engineered anti-CD19 antibody with enhanced ADCC. See, e.g., Hammer et al. In embodiments, the antibody molecule is a bispecific anti-CD19 and anti-CD3 molecule. For example, AFM11 is a bispecific antibody targeting CD19 and CD3. See, e.g., Hammer et al.; and clinical trial identification number NCT02106091.In some embodiments, the anti-CD19 antibodies described herein are conjugated or otherwise linked to a therapeutic agent, such as a chemotherapeutic agent, a peptide vaccine (such as those described in Izumoto et al. 2008 J Neurosurg 108:963-971), an immunosuppressant, or an immunoablative agent, such as cyclosporine, azathioprine, methotrexate, mycophenolate, FK506, CAMPATH, an anti-CD3 antibody, cytoxin, fludarabine, rapamycin, mycophenolic acid, a steroid, FR901228, or a cytokine.
[0354] In one embodiment, an antigen binding domain against CD19 is an antigen binding portion, e.g., a CDR, of an antigen binding domain described in the Tables herein. In one embodiment, the CD19 antigen binding domain can be from any CD19 CAR, such as LG-740; U.S. Pat. No. 8,399,645; U.S. Pat. No. 7,446,190; Xu et al., Leuk Lymphoma. 2013 54(2):255-260 (2012); Cruz et al., Blood 122(17):2965-2973 (2013); Brentjens et al., Blood, 118(18):4817-4828 (2011); Kochenderfer et al., Blood 116(20):4099-102 (2010); Kochenderfer et al., Blood 122(25):4129-39 (2013); and 16th Annu Meet Am Soc Gen Cell Ther (ASGCT) (May 15-18, Salt Lake City) 2013, Abst 10 (each of which is incorporated herein by reference in its entirety).
[0355] Exemplary BCMA Antigen Binding Domain and CAR Constructs In embodiments, a BCMA CAR comprises an anti-BCMA binding domain (e.g., a human or humanized anti-BCMA binding domain), a transmembrane domain, and an intracellular signaling domain, wherein said anti-BCMA binding domain comprises heavy chain complementarity determining region 1 (HC CDR1), heavy chain complementarity determining region 2 (HC CDR2), and heavy chain complementarity determining region 3 (HC CDR3) of any anti-BMCA heavy chain binding domain amino acid sequence listed in Table 7 or Table 8.
[0356] In one embodiment, the anti-BCMA binding domain comprises a light chain variable region described herein (e.g., in Table 7 or Table 8) and / or a heavy chain variable region described herein (e.g., in Table 7 or Table 8).
[0357] In one embodiment, the encoded anti-BCMA binding domain is an scFv comprising a light chain and a heavy chain of the amino acid sequences of Table 7 or Table 8.
[0358] In one embodiment, the human or humanized anti-BCMA binding domain (e.g., scFv) comprises a light chain variable region comprising an amino acid sequence having at least one, two, or three alterations (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20, or 10 alterations (e.g., substitutions, e.g., conservative substitutions) of, or a sequence with at least 95% (e.g., 95-99%) identity to, the amino acid sequence of a light chain variable region provided in Table 7 or Table 8, and / or a heavy chain variable region comprising an amino acid sequence having at least one, two, or three alterations (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20, or 10 alterations (e.g., substitutions, e.g., conservative substitutions) of, or a sequence with at least 95% (e.g., 95-99%) identity to, the amino acid sequence of a heavy chain variable region provided in Table 7 or Table 8.
[0359] [Table 39]
[0360] [Table 40]
[0361] Table 41
[0362] Table 42
[0363] Table 43
[0364] Table 44
[0365] Table 45
[0366] Table 46
[0367] Table 47
[0368] Table 48
[0369] Table 49
[0370] Table 50
[0371] Table 51
[0372] Table 52
[0373] Table 53
[0374] Table 54
[0375] Table 55
[0376] Table 56
[0377] Table 57
[0378] Table 58
[0379] Table 59
[0380] Table 60
[0381] Table 61
[0382] Table 62
[0383] Table 63
[0384] Table 64
[0385] Table 65
[0386] Table 66
[0387] Table 67
[0388] Table 68
[0389] Table 69
[0390] Table 70
[0391] Table 71
[0392] Table 72
[0393] Table 73
[0394] Table 74
[0395] Table 75
[0396] Table 76
[0397] Table 77
[0398] Table 78
[0399] Table 79
[0400] Table 80
[0401] Table 81
[0402] Table 82
[0403] Table 83
[0404] Table 84
[0405] Table 85
[0406] Table 86
[0407] Table 87
[0408] Table 88
[0409] Table 89
[0410] Table 90
[0411]
Table 91
[0412] Table 92
[0413] Table 93
[0414] Table 94
[0415] Table 95
[0416] Table 96
[0417] Table 97
[0418] Table 98
[0419]
Table 99
[0420]
Table 100
[0421] Table 101
[0422] Table 102
[0423] Table 103
[0424] Table 104
[0425] Table 105
[0426] Table 106
[0427] Table 107
[0428] Table 108
[0429] Table 109
[0430] Table 110
[0431] Table 111
[0432] Table 112
[0433] Table 113
[0434] [Table 114]
[0435] Bispecific CAR In one embodiment, a multispecific antibody molecule is a bispecific antibody molecule. Bispecific antibodies have specificity for no more than two antigens. Bispecific antibody molecules are characterized by a first immunoglobulin variable domain sequence that has binding specificity for a first epitope and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope. In one embodiment, the first and second epitopes are the same antigen, e.g., the same protein (or subunit of a multimeric protein). In one embodiment, the first and second epitopes overlap. In one embodiment, the first and second epitopes do not overlap. In one embodiment, the first and second epitopes are on different antigens, e.g., different proteins (or different subunits of a multimeric protein). In one embodiment, a bispecific antibody molecule comprises heavy and light chain variable domain sequences that have binding specificity for a first epitope and heavy and light chain variable domain sequences that have binding specificity for a second epitope. In one embodiment, a bispecific antibody molecule comprises a half antibody having binding specificity for a first epitope and a half antibody having binding specificity for a second epitope. In one embodiment, a bispecific antibody molecule comprises a half antibody or fragment thereof having binding specificity for a first epitope and a half antibody or fragment thereof having binding specificity for a second epitope. In one embodiment, a bispecific antibody molecule comprises an scFv or fragment thereof having binding specificity for a first epitope and an scFv or fragment thereof having binding specificity for a second epitope.
[0436] In one embodiment, the antibody molecule is a multispecific (e.g., bispecific or trispecific) antibody molecule. Protocols for producing bispecific or heterodimeric antibody molecules are known in the art and include, for example, the "knobs-in-a-hole" approach described in U.S. Pat. No. 5,731,168; electrostatic steering Fc pairing, as described in, for example, WO 09 / 089004, WO 06 / 106905, and WO 2010 / 129304; strand exchange engineering domain (SEED) heterodimerization, as described in, for example, WO 07 / 110205; Fab arm exchange, as described, for example, in WO 08 / 119353, WO 2011 / 131746, and WO 2013 / 060867; double antibody conjugates by antibody cross-linking, for example, using heterobifunctional reagents with amine-reactive groups and sulfhydryl-reactive groups to produce bispecific structures, as described, for example, in U.S. Pat. No. 4,433,059; disulfide bond cleavage between the two chains, as described, for example, in U.S. Pat. No. 4,444,878; Bispecific antibody determinants produced by recombinantly combining half antibodies (heavy-light chain pairs or Fab) from different antibodies that undergo cycles of reduction and oxidation; trifunctional antibodies, 3Fab' fragments cross-linked by sulfhydryl-reactive groups, as described, for example, in U.S. Pat. No. 5,273,743; biosynthetic binding proteins, such as pairs of scFvs cross-linked by C-terminal tails, preferably by disulfide or amine-reactive chemical cross-linking bonds, as described, for example, in U.S. Pat. No. 5,534,254; bifunctional antibodies, such as Fab fragments with different binding properties that have substituted constant domains and are dimerized by a leucine zipper (e.g., c-fos and c-jun), as described, for example, in U.S. Pat. No. 5,582,996; bispecific and oligospecific monovalent and oligovalent receptors, such as the VH-CH1 regions of two antibodies (two Fab fragments) linked via a polypeptide spacer between the CH1 region of one antibody and the VH region of another antibody, typically accompanied by a light chain, as described, for example, in U.S. Pat. No. 5,591,828;Bispecific DNA-antibody conjugates, e.g., cross-linking of antibodies or Fab fragments via double-stranded DNA segments, as described in U.S. Pat. No. 5,635,602; bispecific fusion proteins, e.g., expression constructs comprising two scFvs with a hydrophilic helical peptide linker between them and containing complete constant regions, as described in U.S. Pat. No. 5,637,481; multivalent and multispecific binding proteins, e.g., dimers of polypeptides having a first domain with a binding region of an Ig heavy chain variable region and a second domain with a binding region of an Ig light chain variable region, commonly referred to as bispecific antibodies (including higher order structures to create bispecific, trispecific, and tetraspecific molecules), as described in U.S. Pat. No. 5,837,242; mimetics having linked VL and VH chains further joined by a peptide spacer to the antibody hinge and CH3 regions, which can dimerize to form bispecific / multivalent molecules, as described in U.S. Pat. No. 5,837,821. Examples of suitable bispecific antibodies include, but are not limited to, nibody constructs; VH and VL domains linked in either orientation by a short peptide linker (e.g., 5 or 10 amino acids) or no linker, which can dimerize to form bispecific antibodies; trimers and tetramers, as described, for example, in U.S. Pat. No. 5,844,094; a series of VH domains (or VL domains in family members) linked by a peptide bond to a crosslinkable group at the C-terminus, which is further combined with a VL domain to form a series of FVs (or scFvs), as described, for example, in U.S. Pat. No. 5,864,019; and single-chain binding polypeptides having both VH and VL domains linked by a peptide linker, which are combined into multivalent structures by non-covalent or chemical crosslinking to form, for example, homobivalent, heterobivalent, trivalent, and tetravalent structures, using both scFV or bispecific antibody formats, as described, for example, in U.S. Pat. No. 5,869,620. Further examples of multispecific and bispecific molecules and methods for producing them are described, for example, in U.S. Pat. Nos. 5,910,573, 5,932,448, 5,959,083, 5,989,830, 6,005,079, 6,239,259,U.S. Patent No. 6,294,353, U.S. Patent No. 6,333,396, U.S. Patent No. 6,476,198, U.S. Patent No. 6,511,663, U.S. Patent No. 6,670,453, U.S. Patent No. 6,743,896, U.S. Patent No. 6,809,185, U.S. Patent No. 6,833,441, U.S. Patent No. 7,129,330, U.S. Patent No. 7,183,076, U.S. Patent No. 7,521,056, U.S. Patent No. 7,527,787, U.S. Patent No. 7,534,866, U.S. Patent No. 7,612,181, U.S. Patent Application Publication No. US Patent Application Publication No. 002004587A1, US Patent Application Publication No. 2002076406A1, US Patent Application Publication No. 2002103345A1, US Patent Application Publication No. 2003207346A1, US Patent Application Publication No. 2003211078A1, US Patent Application Publication No. 2004219643A1, US Patent Application Publication No. 2004220388A1, US Patent Application Publication No. 2004242847A1, US Patent Application Publication No. 2005003403A1, US Patent Application Publication No. 2005004352A1 Publication No. 2005069552A1, Publication No. 2005079170A1, Publication No. 2005100543A1, Publication No. 2005136049A1, Publication No. 2005136051A1, Publication No. 2005163782A1, Publication No. 2005266425A1, Publication No. 2006083747A1, Publication No. 2006120960A1, Publication No. 200 6204493A1, U.S. Patent Application Publication No. 2006263367A1, U.S. Patent Application Publication No. 2007004909A1, U.S. Patent Application Publication No. 2007087381A1, U.S. Patent Application Publication No. 2007128150A1, U.S. Patent Application Publication No. 2007141049A1, U.S. Patent Application Publication No. 2007154901A1, U.S. Patent Application Publication No. 2007274985A1, U.S. Patent Application Publication No. 2008050370A1, U.S. Patent Application Publication No. 2008069820A1,U.S. Patent Application Publication No. 2008152645A1, U.S. Patent Application Publication No. 2008171855A1, U.S. Patent Application Publication No. 2008241884A1, U.S. Patent Application Publication No. 2008254512A1, U.S. Patent Application Publication No. 2008260738A1, U.S. Patent Application Publication No. 2009130106A1, U.S. Patent Application Publication No. 2009148905A1, U.S. Patent Application Publication No. 2009155275A1, U.S. US Patent Application Publication No. 2009162359A1, US Patent Application Publication No. 2009162360A1, US Patent Application Publication No. 2009175851A1, US Patent Application Publication No. 2009175867A1, US Patent Application Publication No. 2009232811A1, US Patent Application Publication No. 2009234105A1, US Patent Application Publication No. 2009263392A1, US Patent Application Publication No. 2009274649A1, European Patent Patent No. 346087A2 specification, International Publication No. 0006605A2 pamphlet, International Publication No. 02072635A2 pamphlet, International Publication No. 04081051A1 pamphlet, International Publication No. 06020258A2 pamphlet, International Publication No. 2007044887A2 pamphlet, International Publication No. 2007095338A2 pamphlet, International Publication No. 2007137760A2 pamphlet, International Publication No. 2008119353A1 pamphlet, International Publication These and other related applications can be found in WO 2009021754A2, WO 2009068630A1, WO 9103493A1, WO 9323537A1, WO 9409131A1, WO 9412625A2, WO 9509917A1, WO 9637621A2, and WO 9964460A1. The contents of the above-cited applications are incorporated herein by reference in their entireties.
[0437] Within each antibody or antibody fragment (e.g., scFv) of a bispecific antibody molecule, the VH can be upstream or downstream of the VL. In one embodiment, the upstream antibody or antibody fragment (e.g., scFv) is arranged with its VH (VH1) upstream of its VL (VL1), and the downstream antibody or antibody fragment (e.g., scFv) is arranged with its VH (VH2) upstream of its VL (VL2), such that the overall bispecific antibody molecule has the configuration VH1-VL1-VL2-VH2. In another embodiment, the upstream antibody or antibody fragment (e.g., scFv) is arranged with its VL (VL1) upstream of its VH (VH1), and the downstream antibody or antibody fragment (e.g., scFv) is arranged with its VL (VL2) upstream of its VH (VH2), such that the overall bispecific antibody molecule has the configuration VL1-VH1-VH2-VL2. Optionally, a linker is placed between two antibodies or antibody fragments (e.g., scFvs), for example, between VL1 and VL2 when the construct is arranged as VH1-VL1-VL2-VH2, or between VH1 and VH2 when the construct is arranged as VL1-VH1-VH2-VL2. The linker can be a linker described herein, for example, a (Gly4-Ser)n linker (SEQ ID NO: 26) (where n is 1, 2, 3, 4, 5, or 6, preferably 4). Generally, the linker between two scFvs should be long enough to avoid mispairing between the domains of the two scFvs. Optionally, the linker is placed between the VL and VH of the first scFv. Optionally, the linker is placed between the VL and VH of the second scFv. In constructs with multiple linkers, any two or more of the linkers can be the same or different. Thus, in one embodiment, the bispecific CAR comprises a VL, a VH and optionally one or more linkers in an arrangement as described herein.
[0438] In certain embodiments, the antibody molecule is a bispecific antibody molecule having a first binding specificity for a first B cell epitope and a second binding specificity for another B cell antigen. For example, in some embodiments, the bispecific antibody molecule has a first binding specificity for CD19 and a second binding specificity for one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. In some embodiments, the bispecific antibody molecule has a first binding specificity for CD19 and a second binding specificity for CD22.
[0439] Chimeric TCR In one embodiment, the CD19 antigens and antigen fragments of the present invention (e.g., those disclosed in Tables 2 or 3) can be grafted into one or more constant domains of a T cell receptor ("TCR") chain, e.g., a TCR α or TCR β chain, to create a chimeric TCR that specifically binds to CD19. Without being bound by theory, it is believed that the chimeric TCR signals through the TCR complex upon antigen binding. For example, a CD19 scFv as described herein can be grafted into the constant domains of a TCR chain, e.g., the TCR α chain and / or the TCR β chain, e.g., at least a portion of the extracellular constant domain, transmembrane domain, and cytoplasmic domain. As another example, a CD19 antibody fragment, e.g., a VL domain as described herein, can be grafted into the constant domain of a TCR α chain, and a CD19 antibody fragment, e.g., a VH domain as described herein, can be grafted into the constant domain of a TCR β chain (or alternatively, the VL domain can be grafted into the constant domain of a TCR β chain, and the VH domain can be grafted into the TCR α chain). As another example, the CDRs of a CD19 antibody or antibody fragment, such as those listed in Tables 4 or 5, can be grafted onto the TCR alpha and / or beta chains to generate a chimeric TCR that specifically binds to CD19. For example, an LCDR described herein can be grafted into the variable domain of a TCR alpha chain, and an HCDR described herein can be grafted into the variable domain of a TCR beta chain, or vice versa. Such chimeric TCRs can be produced by methods known in the art (e.g., Willemsen RA et al., Gene Therapy 2000;7:1369-1377; Zhang T et al., Cancer Gene Ther 2004;11:487-496; Aggen et al., Gene Ther. 2012 Apr;19(4):365-74).
[0440] Transmembrane domain With regard to the transmembrane domain, in various embodiments, a CAR can be designed to include a transmembrane domain that connects to the extracellular domain of the CAR. The transmembrane domain can include one or more additional amino acids adjacent to the transmembrane region, such as one or more amino acids associated with the extracellular region of the protein from which the transmembrane is derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the extracellular region) and / or one or more additional amino acids associated with the intracellular region of the protein from which the transmembrane protein is derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the intracellular region). In one aspect, a transmembrane domain is used that is associated with one of the other domains of the CAR; for example, in one embodiment, the transmembrane domain can be from the same protein from which the signaling domain, costimulatory domain, or hinge domain is derived. In another aspect, the transmembrane domain is not derived from the same protein from which any other domain of the CAR is derived. In some instances, the transmembrane domain can be selected or modified by amino acid substitution to avoid binding of such domains to transmembrane domains of the same or different surface membrane proteins, e.g., to minimize interactions with other members of the receptor complex. In one embodiment, the transmembrane domain can homodimerize with another CAR on the cell surface of a CAR-expressing cell. In a different embodiment, the amino acid sequence of the transmembrane domain can be modified or substituted to minimize interactions with the binding domain of a natural binding partner present on the same CAR-expressing cell.
[0441] The transmembrane domain can be derived from natural or recombinant sources. When the source is natural, the domain can be derived from any membrane-bound or transmembrane protein. In one embodiment, the transmembrane domain can transmit a signal to the intracellular domain whenever the CAR binds to the target. Transmembrane domains particularly useful in the present invention can include at least the transmembrane domains of, for example, the α, β, or ζ chain of the T cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8 (e.g., CD8α, CD8β), CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154. In one embodiment, the transmembrane domain is selected from the group consisting of, for example, KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, IL2Rβ, IL2Rγ, IL7Rα, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM , CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG / Cbp, NKG2D, and at least the transmembrane domains of NKG2C.
[0442] In certain instances, the transmembrane domain can be attached to the extracellular region of the CAR, e.g., the antigen-binding domain of the CAR, via a hinge, e.g., a hinge from a human protein. For example, in one embodiment, the hinge can be a human Ig (immunoglobulin) hinge (e.g., an IgG4 hinge, an IgD hinge), a GS linker (e.g., a GS linker described herein), a KIR2DS2 hinge, or a CD8a hinge. In one embodiment, the hinge or spacer comprises (e.g., consists of) the amino acid sequence of SEQ ID NO: 2. In one aspect, the transmembrane domain comprises (e.g., consists of) the transmembrane domain of SEQ ID NO: 6.
[0443] In one aspect, the hinge or spacer comprises an IgG4 hinge. For example, in one embodiment, the hinge or spacer comprises the hinge of the amino acid sequence SEQ ID NO:3.
[0444] In some embodiments, the hinge or spacer comprises a hinge encoded by the nucleotide sequence SEQ ID NO:14.
[0445] In one aspect, the hinge or spacer comprises an IgD hinge. For example, in one embodiment, the hinge or spacer comprises the hinge of the amino acid sequence SEQ ID NO:4.
[0446] In some embodiments, the hinge or spacer comprises a hinge encoded by the nucleotide sequence of SEQ ID NO:15.
[0447] In one embodiment, the transmembrane domain may be recombinant, in which case it contains predominantly hydrophobic residues such as leucine and valine, hi one embodiment, triplets of phenylalanine, tryptophan and valine can be found at each end of the recombinant transmembrane domain.
[0448] Optionally, a short oligo- or polypeptide linker, 2-10 amino acids in length, can form the bond between the transmembrane domain and the cytoplasmic signaling region of the CAR. A glycine-serine doublet provides a particularly suitable linker. For example, in one aspect, the linker comprises the amino acid sequence GGGGSGGGGS (SEQ ID NO: 5). In one embodiment, the linker is encoded by the nucleotide sequence GGTGGCGGAGGTTCTGGAGGTGGAGGTTCC (SEQ ID NO: 16).
[0449] In one embodiment, the hinge or spacer comprises a KIR2DS2 hinge and portions thereof.
[0450] Cytoplasmic domain The cytoplasmic domain or region of the CAR comprises an intracellular signaling domain. The intracellular signaling domain is generally involved in activating at least one of the normal effector functions of the immune cell into which the CAR is introduced. The term "effector function" refers to a specialized function of a cell. For example, the effector function of a T cell can be cytolytic activity or helper activity, including cytokine secretion. Thus, the term "intracellular signaling domain" refers to a portion of a protein that transmits an effector function signal and directs the cell to perform a specialized function. Typically, the entire intracellular signaling domain can be utilized, but in many cases, it is not necessary to use the entire chain. To the extent that a truncated portion of the intracellular signaling domain is used, such a truncated portion can be used instead of the intact chain, as long as it transmits the effector function signal. Thus, the term intracellular signaling domain is meant to include any truncated portion of the intracellular signaling domain sufficient to transmit the effector function signal.
[0451] Examples of intracellular signaling domains for use in the CARs of the invention include the cytoplasmic sequences of T cell receptors (TCRs) and co-receptors that function in concert to initiate signal transduction following antigen receptor binding, as well as any derivatives or variants thereof and any recombinant sequences with the same functional capabilities.
[0452] It is known that signals generated by the TCR alone are insufficient for full activation of T cells; secondary and / or costimulatory signals are also required. Therefore, T cell activation can be said to be mediated by two distinct classes of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation via the TCR (primary intracellular signaling domain) and those that act in an antigen-independent manner to provide secondary or costimulatory signals (secondary cytoplasmic domains, e.g., costimulatory domains).
[0453] The primary cytoplasmic signaling domain controls the primary activation of the TCR complex in either a stimulatory or inhibitory manner. Primary intracellular signaling domains that act in a stimulatory manner may contain signaling motifs known as immunoreceptor tyrosine-based activation motifs, or ITAMs.
[0454] Examples of ITAM-containing primary intracellular signaling domains that are particularly useful in the present invention include those of CD3ζ, consensus FcRγ (FCER1G), FcγRIIa, FcRβ (FcεR1b), CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b, CD278 (also known as "ICOS"), FcεRI, CD66d, DAP10, and DAP12. In one embodiment, a CAR of the invention comprises an intracellular signaling domain, e.g., a primary signaling domain, of CD3-ζ, e.g., a CD3-ζ sequence described herein.
[0455] In one embodiment, the primary signaling domain comprises a modified ITAM domain, e.g., a mutated ITAM domain, that has altered (e.g., increased or decreased) activity compared to a native ITAM domain. In one embodiment, the primary signaling domain comprises a modified ITAM-containing primary intracellular signaling domain, e.g., an optimized and / or truncated ITAM-containing primary intracellular signaling domain. In one embodiment, the primary signaling domain comprises one, two, three, four, or more ITAM motifs.
[0456] Further examples of molecules containing primary intracellular signaling domains that are particularly useful in the present invention include those of DAP10, DAP12 and CD32.
[0457] The intracellular domain of a CAR can comprise a CD3ζ signaling domain by itself or in combination with any other desired intracellular signaling domain useful in the context of the CAR of the present invention. For example, the intracellular signaling domain of a CAR can comprise a CD3ζ chain portion and a costimulatory signaling domain. A costimulatory signaling domain refers to the portion of a CAR that contains the intracellular domain of a costimulatory molecule. A costimulatory molecule is a cell surface molecule other than an antigen receptor or its ligand that is required for an efficient lymphocyte response to an antigen. Examples of such molecules include CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1 (also known as PD1), ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and ligands that specifically bind to CD83. For example, CD27 costimulation has been demonstrated to enhance the expansion, effector function, and survival of human CART cells in vitro, and increases human T cell persistence and anti-tumor activity in vivo (Song et al. Blood. 2012;119(3):696-706).Further examples of such costimulatory molecules include MHC class I molecules, TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocyte activation molecules (SLAM proteins), activating NK cell receptors, BTLA, Toll ligand receptors, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a / CD18), 4-1B B (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), N Kp44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL2Rβ, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA- 6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), CEA These include ligands that specifically bind to CAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, and CD83. For example, CD27 costimulation has been shown to enhance the proliferation, effector function, and survival of human CART cells in vitro and enhance human T cell persistence and antitumor activity in vivo (Song et al. Blood. 2012;119(3):696-706).
[0458] The intracellular signaling domains within the cytoplasmic portion of the CAR of the present invention can be linked to each other randomly or in a specific order. Optionally, a short oligo- or polypeptide linker, e.g., 2-10 amino acids (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids) in length, can form the linkage between the intracellular signaling domains. In one embodiment, a glycine-serine doublet can be used as a suitable linker. In one embodiment, a single amino acid, e.g., alanine, glycine, can be used as a suitable linker.
[0459] In one aspect, the intracellular signaling domain is designed to comprise two or more, e.g., two, three, four, five, or more, costimulatory signaling domains. In one embodiment, the two or more, e.g., two, three, four, five, or more, costimulatory signaling domains are separated by a linker molecule, e.g., a linker molecule described herein. In one embodiment, the intracellular signaling domain comprises two costimulatory signaling domains. In one embodiment, the linker molecule is a glycine residue. In one embodiment, the linker molecule is an alanine residue.
[0460] In one embodiment, the intracellular signaling domain is designed to comprise the signaling domain of CD3ζ and the signaling domain of CD28. In one embodiment, the intracellular signaling domain is designed to comprise the signaling domain of CD3ζ and the signaling domain of 4-1BB. In one embodiment, the signaling domain of 4-1BB is the signaling domain of SEQ ID NO: 7. In one embodiment, the signaling domain of CD3ζ is the signaling domain of SEQ ID NO: 9 (mutant CD3ζ) or SEQ ID NO: 10 (wild-type human CD3ζ).
[0461] In one embodiment, the intracellular vector is designed to contain the signaling domain of CD3-zeta and the signaling domain of 4-1BB. In one embodiment, the signaling domain of 4-1BB comprises the amino acid sequence of SEQ ID NO: 7. In one embodiment, the signaling domain of 4-1BB is encoded by the nucleic acid sequence of SEQ ID NO: 18.
[0462] In one embodiment, the intracellular signaling domain is designed to comprise the signaling domain of CD3ζ and the signaling domain of CD27. In one embodiment, the signaling domain of CD27 comprises the amino acid sequence of SEQ ID NO: 8. In one embodiment, the signaling domain of CD27 is encoded by the nucleic acid sequence of SEQ ID NO: 44.
[0463] In one embodiment, the intracellular signaling domain is designed to comprise the signaling domain of CD3ζ and the signaling domain of CD28. In one embodiment, the signaling domain of CD28 comprises the amino acid sequence of SEQ ID NO: 36. In one embodiment, the signaling domain of CD28 is encoded by the nucleic acid sequence of SEQ ID NO: 37.
[0464] In one embodiment, the intracellular signaling domain is designed to comprise the signaling domain of CD3ζ and the signaling domain of ICOS. In one embodiment, the signaling domain of ICOS comprises the amino acid sequence of SEQ ID NO: 38 or 43. In one embodiment, the signaling domain of ICOS is encoded by the nucleic acid sequence of SEQ ID NO: 44.
[0465] Natural killer cell receptor (NKR) CAR In some embodiments, the CAR molecules described herein comprise one or more components of natural killer cell receptors (NKRs), thereby forming NKR-CARs. The NKR components include the following natural killer cell receptors: killer cell immunoglobulin-like receptors (KIRs), such as KIR2DL1, KIR2DL2 / L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, DIR2DS5, KIR3DL1 / S1, KIR3DL2, KIR3DL3, KIR2DP1, and KIR3DP1; natural cytotoxicity receptors (NCRs), For example, the transmembrane domain, hinge domain, or cytoplasmic domain from any of NKp30, NKp44, NKp46; the signaling lymphocyte activation molecule (SLAM) family of immune cell receptors, such as CD48, CD229, 2B4, CD84, NTB-A, CRACC, BLAME, and CD2F-10; Fc receptors (FcRs), such as CD16 and CD64; and Ly49 receptors, such as LY49A and LY49C. The NKR-CAR molecules described herein may interact with an adaptor molecule or intracellular signaling domain, such as DAP12. Exemplary configurations and sequences of CAR molecules containing NKR components are described in International Publication No. WO 2014 / 145252, the contents of which are incorporated herein by reference.
[0466] Split CAR In some embodiments, the CAR-expressing cells described herein use split CARs. The split CAR approach is described in further detail in International Publication Nos. 2014 / 055442 and 2014 / 055657 (incorporated herein by reference). Briefly, the split CAR system comprises a cell expressing a first CAR having a first antigen-binding domain and a costimulatory domain (e.g., 4-1BB), and the cell also expresses a second CAR having a second antigen-binding domain and an intracellular signaling domain (e.g., CD3ζ). When the cell encounters the first antigen, the costimulatory domain is activated, causing the cell to proliferate. When the cell encounters the second antigen, the intracellular signaling domain is activated, initiating cell-killing activity. Thus, the CAR-expressing cell is only fully activated in the presence of both antigens. In embodiments, the first antigen binding domain recognizes a tumor antigen or a B cell antigen described herein, e.g., comprises an antigen binding domain described herein, and the second antigen binding domain recognizes a second antigen, e.g., a second tumor antigen or a second B cell antigen described herein.
[0467] Co-expression of CAR with other molecules or drugs Co-expression of a second CAR In one aspect, a CAR-expressing cell described herein can further comprise a second CAR, e.g., a second CAR comprising a different antigen binding domain, e.g., directed against the same target (CD19) or a different target (e.g., a target other than CD19, e.g., a B cell antigen other than CD19, e.g., CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a). In one embodiment, the CAR-expressing cell comprises a first CAR that targets a first antigen and comprises an intracellular signaling domain with a costimulatory signaling domain but without a primary signaling domain, and a second CAR that targets a second, different antigen and comprises an intracellular signaling domain with a primary signaling domain but without a costimulatory signaling domain. Placement of a costimulatory signaling domain, e.g., 4-1BB, CD28, CD27, OX-40, or ICOS, on the first CAR and a primary signaling domain, e.g., CD3ζ, on the second CAR restricts CAR activity to cells in which both targets are expressed. In one embodiment, the CAR-expressing cell comprises a first CD19 CAR comprising a CD19 binding domain, a transmembrane domain, and a costimulatory domain, and a second CAR that targets an antigen other than CD19 (e.g., a target other than CD19, e.g., a B cell antigen other than CD19, e.g., CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a), where the second CAR comprises an antigen binding domain, a transmembrane domain, and a primary signaling domain. In another embodiment, the CAR-expressing cell comprises a first CD19 CAR comprising a CD19 binding domain, a transmembrane domain, and a primary signaling domain, and a second CAR that targets an antigen other than CD19 (e.g., a target other than CD19, e.g., a B cell antigen other than CD19, e.g., CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a), wherein the second CAR comprises an antigen binding domain for that antigen, a transmembrane domain, and a costimulatory signaling domain.
[0468] In one embodiment, the CAR-expressing cells include the CD19 CAR and inhibitory CAR described herein. In one embodiment, the inhibitory CAR comprises an antigen-binding domain that binds to an antigen found on normal cells, e.g., normal cells that express CD19, but not on cancer cells. In one embodiment, the inhibitory CAR comprises an antigen-binding domain, a transmembrane domain, and an intracellular domain of an inhibitory molecule. For example, the intracellular domain of the inhibitory CAR can be the intracellular domain of PD1, PD-L1, CTLA4, TIM3, CEACAM, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, or TGFβ.
[0469] In one embodiment, when a CAR-expressing cell comprises two or more different CARs, the antigen-binding domains of the various CARs are such that the antigen-binding domains do not interact with each other. For example, a cell expressing a first and a second CAR can have the antigen-binding domain of the first CAR, e.g., as a fragment, e.g., an scFv, that does not form a bond with the antigen-binding domain of the second CAR, e.g., a VHH.
[0470] In one embodiment, the antigen-binding domain comprises a single-domain antigen-binding (SDAB) molecule, including molecules in which the complementary determining regions are part of a single-domain polypeptide. Examples include, but are not limited to, binding molecules that naturally lack a heavy chain variable domain, a light chain, single domains derived from conventional four-chain antibodies, engineered domains, and single-domain scaffolds other than those derived from antibodies. SDAB molecules can be any current or future single-domain molecule in the art. SDAB molecules can be derived from any species, including, but not limited to, mouse, human, camel, llama, lamprey, fish, shark, goat, rabbit, and cow. The term also includes naturally occurring single-domain antibody molecules from species other than Camelidae and sharks.
[0471] In one embodiment, SDAB molecules can be derived from the variable regions of immunoglobulins found in fish, such as from the immunoglobulin isotype known as the novel antigen receptor (NAR) found in shark serum. Methods for producing single domain molecules derived from the variable regions of NARs ("IgNARs") are described in WO 03 / 014161 and Streltsov (2005) Protein Sci. 14:2901-2909.
[0472] In another embodiment, the SDAB molecule is a naturally occurring single-domain antigen-binding molecule known as a heavy chain devoid of light chains. Such single-domain molecules are described, for example, in WO 9404678 and Hamers-Casterman, C. et al. (1993) Nature 363:446-448. For clarity, this variable domain from a heavy chain molecule naturally devoid of light chains is known herein as a VHH or nanobody to distinguish it from the conventional VH of four-chain immunoglobulins. Such VHH molecules can be derived from Camelidae species, such as camel, llama, dromedary, alpaca, and guanaco. Other species outside of Camelidae can produce heavy chain molecules naturally devoid of light chains, and such VHHs are within the scope of the present invention.
[0473] SDAB molecules may be recombinant, CDR-grafted, humanized, camelized, deimmunized and / or produced in vitro (eg, selected by phage display).
[0474] It has also been found that cells having multiple chimeric membrane-embedded receptors comprising antigen-binding domains that interact with each other may be undesirable, for example, because they prevent one or more of the antigen-binding domains from binding to their cognate antigen. Accordingly, disclosed herein are cells having first and second non-naturally occurring chimeric membrane-embedded receptors comprising antigen-binding domains that minimize such interactions. Also disclosed herein are nucleic acids encoding first and second non-naturally occurring chimeric membrane-embedded receptors comprising antigen-binding domains that minimize such interactions, as well as methods for making and using such cells and nucleic acids. In one embodiment, one of the antigen-binding domains of the first and second non-naturally occurring chimeric membrane-embedded receptors comprises an scFv, and the other comprises a single VH domain, e.g., a camelid, shark, or lamprey single VH domain, or a single VH domain derived from a human or mouse sequence.
[0475] In one embodiment, the invention comprises a first and a second CAR, wherein the antigen-binding domain of one of the first and second CARs does not comprise a variable light domain and a variable heavy domain. In one embodiment, the antigen-binding domain of one of the first and second CARs is an scFv, and the other is not an scFv. In one embodiment, the antigen-binding domain of one of the first and second CARs comprises a single VH domain, such as a camelid, shark, or lamprey single VH domain, or a single VH domain derived from a human or mouse sequence. In one embodiment, the antigen-binding domain of one of the first and second CARs comprises a nanobody. In one embodiment, the antigen-binding domain of one of the first and second CARs comprises a camelid VHH domain.
[0476] In one embodiment, the antigen-binding domain of one of the first and second CARs comprises an scFv, and the other comprises a single VH domain, such as a camelid, shark, or lamprey single VH domain, or a single VH domain derived from a human or mouse sequence. In one embodiment, the antigen-binding domain of one of the first and second CARs comprises an scFv, and the other comprises a nanobody. In one embodiment, the antigen-binding domain of one of the first and second CARs comprises an scFv, and the other comprises a camelid VHH domain.
[0477] In one embodiment, when present on the surface of a cell, binding of the antigen-binding domain of the first CAR to its cognate antigen is not substantially reduced by the presence of the second CAR, hi one embodiment, binding of the antigen-binding domain of the first CAR to its cognate antigen in the presence of the second CAR is 85%, 90%, 95%, 96%, 97%, 98% or 99% of the binding of the antigen-binding domain of the first CAR to its cognate antigen in the absence of the second CAR.
[0478] In one embodiment, when present on the surface of a cell, the antigen binding domains of the first and second CARs bind to each other less than when both are scFv antigen binding domains, hi one embodiment, the antigen binding domains of the first and second CARs bind to each other 85%, 90%, 95%, 96%, 97%, 98% or 99% less than when both are scFv antigen binding domains.
[0479] Co-expression of drugs that enhance CAR activity In another embodiment, the CAR-expressing cells described herein can further express another agent, for example, an agent that enhances the activity or compatibility of the CAR-expressing cell.
[0480] For example, in one embodiment, the agent can be an agent that inhibits a molecule that modulates or regulates, e.g., inhibits, T cell function. In some embodiments, the molecule that modulates or regulates T cell function is an inhibitory molecule. Inhibitory molecules, such as PD-1, can, in some embodiments, reduce the ability of CAR-expressing cells to mount an immune effector response. Examples of inhibitory molecules include PD-1, PD-L1, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, or TGFβ.
[0481] In embodiments, an agent, e.g., an inhibitory nucleic acid, e.g., a dsRNA, e.g., an siRNA or shRNA, or, e.g., an inhibitory protein or system, e.g., as described herein, e.g., clustered regularly interspaced short palindromic repeats (CRISPR), transcription activator-like effector nuclease (TALEN), or zinc finger endonuclease (ZFN), can be used to inhibit the expression of a molecule that modulates or regulates, e.g., inhibits, T cell function in a CAR-expressing cell. In some embodiments, the agent is an shRNA, e.g., an shRNA described herein. In some embodiments, an agent that modulates or regulates, e.g., inhibits, T cell function is inhibited in a CAR-expressing cell. For example, a dsRNA molecule that inhibits the expression of a molecule that modulates or regulates, e.g., inhibits, T cell function is linked to a nucleic acid encoding a component, e.g., all of the components, of the CAR.
[0482] In one embodiment, an agent that inhibits an inhibitory molecule comprises a first polypeptide, e.g., an inhibitory molecule, associated with a second polypeptide that provides a positive signal to a cell, e.g., an intracellular signaling domain described herein. In one embodiment, the agent comprises a first polypeptide of an inhibitory molecule, e.g., PD-1, PD-L1, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, or TGFβ, or a fragment of any of these (e.g., at least a portion of the extracellular domain of any of these), and an intracellular signaling domain described herein (e.g., a costimulatory domain (e.g., a co-stimulatory domain, e.g., 4-1BB, CD27, or CD28 as described herein). 8) and / or a second polypeptide that is a primary signaling domain (e.g., comprising a CD3ζ signaling domain described herein). In one embodiment, the agent comprises a first polypeptide of PD-1 or a fragment thereof (e.g., at least a portion of the extracellular domain of PD-1) and a second polypeptide of an intracellular signaling domain described herein (e.g., a CD28 signaling domain described herein and / or a CD3ζ signaling domain described herein). PD-1 is an inhibitory member of the CD28 family of receptors, which also includes CD28, CTLA-4, ICOS, and BTLA. PD-1 is expressed on activated B cells, T cells, and myeloid cells (Agata (Et al. 1996 Int. Immunol 8:765-75). Two ligands for PD-1, PD-L1 and PD-L2, have been shown to downregulate T cell activation by binding to PD-1 (Freeman et al. 2000 J Exp Med 192:1027-34; Latchman et al. 2001 Nat Immunol 2:261-8; Carter et al. 2002 Eur J Immunol 32:634-43).PD-L1 is abundant in human cancers (Dong et al. 2003 J Mol Med 81:281-7; Blank et al. 2005 Cancer Immunol. Immunother 54:307-314; Konishi et al. 2004 Clin Cancer Res 10:5094). Immune suppression can be reversed by blocking the local interaction between PD-1 and PD-L1.
[0483] In one embodiment, an agent comprising the extracellular domain (ECD) of an inhibitory molecule, such as programmed cell death 1 (PD-1), can be fused to a transmembrane domain and an intracellular signaling domain, such as 4-1BB and CD3ζ (referred to herein as a PD1 CAR). In one embodiment, the PD1 CAR improves T cell persistence when used in combination with a CD19 CAR described herein. In one embodiment, the CAR is a PD1 CAR comprising the extracellular domain of PD-1 as underlined in SEQ ID NO:24 and the signal sequence at amino acids 1-21 of SEQ ID NO:24. In one embodiment, the PD1 CAR comprises the amino acid sequence of SEQ ID NO:24.
[0484] In one embodiment, the PD1 CAR without the N-terminal signal sequence comprises the amino acid sequence provided in SEQ ID NO:22.
[0485] In one embodiment, the agent comprises a nucleic acid sequence encoding a PD1 CAR, such as a PD1 CAR described herein, that includes an N-terminal signal sequence. In one embodiment, the nucleic acid sequence of a PD1 CAR is shown in Table 1, with the PD1 ECD underlined in SEQ ID NO:23.
[0486] In another example, in one embodiment, the agent that enhances the activity of a CAR-expressing cell can be a costimulatory molecule or costimulatory molecule ligand. Examples of costimulatory molecules include MHC class I molecules, BTLA and Toll ligand receptors, as well as OX40, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), and 4-1BB (CD137). Further examples of such costimulatory molecules include, for example, CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, CD4, CD8α, CD8β, IL2Rβ, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, and CD18, as described herein. , LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, and ligands that specifically bind to CD83. Examples of costimulatory molecule ligands include CD80, CD86, CD40L, ICOSL, CD70, OX40L, 4-1BBL, GITRL, and LIGHT. In embodiments, the costimulatory molecule ligand is a ligand of a costimulatory molecule that is different from the costimulatory molecule domain of the CAR. In embodiments, the costimulatory molecule ligand is a ligand of the same costimulatory molecule as the costimulatory molecule domain of the CAR. In one embodiment, the costimulatory molecule ligand is 4-1BBL.In some embodiments, the costimulatory ligand is CD80 or CD86. In some embodiments, the costimulatory molecule ligand is CD70. In embodiments, the CAR-expressing immune effector cells described herein can be further engineered to express one or more additional costimulatory molecules or costimulatory molecule ligands.
[0487] Co-expression of CAR and chemokine receptors In embodiments, the CAR-expressing cells described herein, e.g., CD19 CAR-expressing cells, further comprise a chemokine receptor molecule. Transgenic expression of the chemokine receptors CCR2b or CXCR2 in T cells promotes their trafficking to CCL2- or CXCL1-secreting solid tumors, including melanoma and neuroblastoma (Craddock et al., J Immunother. 2010 Oct;33(8):780-8 and Kershaw et al., Hum Gene Ther. 2002 Nov 1;13(16):1971-80). Therefore, without wishing to be bound by theory, it is believed that a chemokine receptor expressed on a CAR-expressing cell that recognizes a chemokine secreted by a tumor, e.g., a solid tumor, improves homing of the CAR-expressing cell to the tumor, promotes tumor infiltration of the CAR-expressing cell, and enhances the anti-tumor effect of the CAR-expressing cell. The chemokine receptor molecule includes a naturally occurring or recombinant chemokine receptor or a chemokine-binding fragment thereof. Chemokine receptor molecules suitable for expression in a CAR-expressing cell (e.g., a CAR-Tx) described herein include a C-X-C chemokine receptor (e.g., CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, or CXCR7), a C-C chemokine receptor (e.g., CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, or CCR11), a C-C chemokine receptor (e.g., CX3CR1), an X-C chemokine receptor (e.g., XCR1), or a chemokine-binding fragment thereof. In one embodiment, the chemokine receptor molecule expressed with a CAR described herein is selected based on a chemokine expressed by the tumor. In one embodiment, a CAR-expressing cell described herein further comprises, e.g., expresses, a CCR2b receptor or a CXCR2 receptor. In one embodiment, the CAR and chemokine receptor molecule described herein are on the same vector or on two different vectors. In embodiments described herein in which the CAR and chemokine receptor molecules are on the same vector, the CAR and chemokine receptor molecules are each under the control of two different promoters or under the control of the same promoter.
[0488] Nucleic acid construct encoding CAR The present invention provides a CAR transgene comprising a nucleic acid sequence encoding one or more CAR constructs of the present invention. In one embodiment, the CAR transgene is provided as a messenger RNA transcript. In one embodiment, the CAR transgene is provided as a DNA construct.
[0489] Accordingly, in one aspect, the present invention relates to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an anti-CD19 binding domain (e.g., a murine anti-CD19 binding domain or a humanized anti-CD19 binding domain), a transmembrane domain, and an intracellular signaling domain comprising a stimulatory domain. In one embodiment, the anti-CD19 binding domain is an anti-CD19 binding domain described herein, e.g., an anti-CD19 binding domain comprising a sequence selected from the group consisting of SEQ ID NOs: 45-56, 69-80, 106, 109, 110, 112, or 115, or a sequence having 95-99% identity thereto. In one embodiment, the isolated nucleic acid molecule further comprises a sequence encoding a costimulatory domain. In one embodiment, the transmembrane domain is a transmembrane domain of a protein selected from the group consisting of the α, β, or ζ chain of the T cell receptor, CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154. In one embodiment, the transmembrane domain comprises the sequence of SEQ ID NO: 6, or a sequence having 95-99% identity thereto. In one embodiment, the anti-CD19 binding domain is connected to the transmembrane domain by a hinge region, e.g., a hinge described herein. In one embodiment, the hinge region comprises SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 16, or SEQ ID NO: 39, or a sequence having 95-99% identity thereto. In one embodiment, the isolated nucleic acid molecule further comprises a sequence encoding a costimulatory domain. In one embodiment, the costimulatory domain is a functional signaling domain of a protein selected from the group consisting of OX40, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), and 4-1BB (CD137).Further examples of such costimulatory molecules include CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, CD4, CD8α, CD8β, IL2Rβ, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, C D18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, and PAG / Cbp. In one embodiment, the costimulatory domain comprises the sequence of SEQ ID NO: 7 or a sequence having 95-99% identity thereto. In one embodiment, the intracellular signaling domain comprises a functional signaling domain of 4-1BB and a functional signaling domain of CD3ζ. In one embodiment, the intracellular signaling domain comprises the sequence of SEQ ID NO:7 or SEQ ID NO:8, or a sequence having 95-99% identity thereto, and the sequence of SEQ ID NO:9 or SEQ ID NO:10, or a sequence having 95-99% identity thereto, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.In another aspect, the present invention provides an scFv domain having a leader sequence of SEQ ID NO: 1, a sequence selected from the group consisting of SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 106, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 112, and SEQ ID NO: 115 (or a sequence having 95 to 99% identity thereto), a scFv domain having a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 106, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 112, and SEQ ID NO: 115 (or a sequence having 95 to 99% identity thereto), a scFv domain having a sequence selected from the group consisting of SEQ ID 5, SEQ ID NO: 16, or SEQ ID NO: 39 (or a sequence having 95-99% identity thereto), a transmembrane domain having the sequence of SEQ ID NO: 6 (or a sequence having 95-99% identity thereto), a 4-1BB costimulatory domain having the sequence of SEQ ID NO: 7 (or a sequence having 95-99% identity thereto) or a CD27 costimulatory domain having the sequence of SEQ ID NO: 8 (or a sequence having 95-99% identity thereto), and a CD3ζ stimulatory domain having the sequence of SEQ ID NO: 9 or SEQ ID NO: 10 (or a sequence having 95-99% identity thereto).
[0490] In another aspect, the present invention relates to an isolated polypeptide molecule encoded by a nucleic acid molecule. In one embodiment, the isolated polypeptide molecule comprises a sequence selected from the group consisting of SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:108, SEQ ID NO:111, SEQ ID NO:113, SEQ ID NO:114, and SEQ ID NO:116, or a sequence having 95 to 99% identity thereto.
[0491] In another aspect, the present invention relates to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR) molecule comprising an anti-CD19 binding domain, a transmembrane domain, and an intracellular signaling domain comprising a stimulatory domain, wherein the nucleic acid encoding the anti-CD19 binding domain comprises a sequence selected from the group consisting of SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, and SEQ ID NO:105, or a sequence having 95-99% identity thereof.
[0492] In one embodiment, the encoded CAR molecule further comprises a sequence encoding a costimulatory domain. In one embodiment, the costimulatory domain is a functional signaling domain of a protein selected from the group consisting of OX40, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a / CD18), and 4-1BB (CD137). In one embodiment, the costimulatory domain comprises the sequence of SEQ ID NO: 7. In one embodiment, the transmembrane domain is a transmembrane domain of a protein selected from the group consisting of the α, β, or ζ chain of the T cell receptor, CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154. In one embodiment, the transmembrane domain comprises the sequence of SEQ ID NO: 6. In one embodiment, the intracellular signaling domain comprises a functional signaling domain of 4-1BB and a functional signaling domain of ζ. In one embodiment, the intracellular signaling domain comprises the sequence of SEQ ID NO:7 and the sequence of SEQ ID NO:9, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame as a single polypeptide chain. In one embodiment, the anti-CD19 binding domain is connected to the transmembrane domain by a hinge region. In one embodiment, the hinge region comprises SEQ ID NO:2. In one embodiment, the hinge region comprises SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:16, or SEQ ID NO:39.
[0493] In another aspect, the invention relates to an isolated CAR molecule comprising a leader sequence of SEQ ID NO: 1, an scFv domain having a sequence selected from the group consisting of SEQ ID NOs: 45-46, 109, 110, 112, and 115, or a sequence with 95-99% identity thereto, SEQ ID NO: 2, or SEQ ID NO: 3, or SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 16, or SEQ ID NO: 39, a transmembrane domain having a sequence of SEQ ID NO: 6, a 4-1BB costimulatory domain having a sequence of SEQ ID NO: 7, or a CD27 costimulatory domain having a sequence of SEQ ID NO: 8, and a CD3ζ stimulatory domain having a sequence of SEQ ID NO: 9 or SEQ ID NO: 10. In one embodiment, the encoded CAR molecule comprises a sequence selected from the group consisting of SEQ ID NOs: 93-104, 108, 111, 114, 116, or a sequence with 95-99% identity thereto.
[0494] The present invention further provides a vector comprising a CAR transgene. In one embodiment, the CAR vector can be directly transduced into cells, such as T cells or NK cells. In one embodiment, t...
Claims
1. 1. A chimeric antigen receptor (CAR) therapy comprising a population of immune effector cells expressing a CAR for use in combination with a PD-1 inhibitor, wherein the CAR comprises an antigen (e.g., CD19) binding domain, a transmembrane domain, and an intracellular signaling domain, and wherein the dose of the PD-1 inhibitor, e.g., an anti-PD-1 antibody molecule, is about 200 mg to about 450 mg, e.g., about 300 mg to about 400 mg, administered, e.g., every 2 weeks, 3 weeks, 4 weeks, or 5 weeks.
2. 1. A method of treating a subject having cancer, comprising: (i) a chimeric antigen receptor (CAR) therapy comprising a population of immune effector cells expressing a CAR, the CAR comprising an antigen (e.g., CD19) binding domain, a transmembrane domain, and an intracellular signaling domain; and (ii) PD-1 inhibitor to the subject, wherein the dose of the PD-1 inhibitor, e.g., an anti-PD-1 antibody molecule, is about 200 mg to about 450 mg, e.g., about 300 mg to about 400 mg, administered, e.g., every 2, 3, 4, or 5 weeks.
3. 1. A chimeric antigen receptor (CAR) therapy comprising a population of immune effector cells expressing a CAR for use in combination with a PD-1 inhibitor, wherein the CAR comprises an antigen (e.g., CD19) binding domain, a transmembrane domain, and an intracellular signaling domain, and wherein administration of the PD-1 inhibitor is initiated within 20 days after administration of the CAR therapy.
4. 1. A method of treating a subject having cancer, comprising: (i) a chimeric antigen receptor (CAR) therapy comprising a population of immune effector cells expressing a CAR, the CAR comprising an antigen (e.g., CD19) binding domain, a transmembrane domain, and an intracellular signaling domain; and (ii) PD-1 inhibitor to the subject, wherein administration of the PD-1 inhibitor is initiated within 20 days after administration of the CAR therapy.
5. 5. The CAR therapy or method for use of claim 3 or 4, wherein administration of the PD-1 inhibitor is initiated within 16 days, within 15 days, within 14 days, within 13 days, within 12 days, within 11 days, within 10 days, within 9 days, within 8 days, within 7 days, within 6 days, within 5 days, within 4 days, within 3 days, or within 2 days after administration of the CAR therapy.
6. 1. A chimeric antigen receptor (CAR) therapy comprising a population of immune effector cells expressing a CAR for use in combination with a PD-1 inhibitor, the CAR comprising an antigen (e.g., CD19) binding domain, a transmembrane domain, and an intracellular signaling domain, and administration of the PD-1 inhibitor is administered to the subject when the subject: (a) a partial response or no detectable response to said CAR therapy; (b) recurrent cancer after said CAR therapy; (c) a cancer refractory to said CAR therapy; (d) the cancer has progressed following the CAR therapy; or (e) B cell recovery, e.g., less than 3 months, following the CAR therapy. CAR therapy is initiated after the patient has, or is identified as having, one or more of:
7. 1. A method of treating a subject having cancer, comprising: (i) a chimeric antigen receptor (CAR) therapy comprising a population of immune effector cells expressing a CAR, the CAR comprising an antigen (e.g., CD19) binding domain, a transmembrane domain, and an intracellular signaling domain; and (ii) PD-1 inhibitor to the subject, wherein administering the PD-1 inhibitor causes the subject to: (a) a partial response or no detectable response to said CAR therapy; (b) recurrent cancer after said CAR therapy; (c) a cancer refractory to the CAR therapy; or (d) the cancer has progressed following the CAR therapy; or (e) B cell recovery, e.g., less than 3 months, following the CAR therapy. The method is initiated after a subject has, or is identified as having, one or more of:
8. 1. A chimeric antigen receptor (CAR) therapy comprising a population of immune effector cells expressing a CAR for use in combination with a PD-1 inhibitor, wherein the CAR comprises an antigen (e.g., CD19) binding domain, a transmembrane domain, and an intracellular signaling domain, wherein administration of the PD-1 inhibitor is initiated after administration of the CAR therapy, and wherein the subject is (a) a partial response or no detectable response to said CAR therapy; (b) recurrent cancer after said CAR therapy; (c) a cancer refractory to said CAR therapy; (d) an advanced form of said cancer; or (e) B cell recovery, e.g., less than 3 months, following the CAR therapy. CAR therapy, not having or not identified as having one or more of:
9. 1. A method of treating a subject having cancer, comprising: (i) a chimeric antigen receptor (CAR) therapy comprising a population of immune effector cells expressing a CAR, the CAR comprising an antigen (e.g., CD19) binding domain, a transmembrane domain, and an intracellular signaling domain; and (ii) PD-1 inhibitor to the subject, wherein administration of the PD-1 inhibitor is initiated after administration of the CAR therapy, and the subject receives one of the following: (a) partial response or no detectable response to CAR therapy; (b) recurrent cancer after CAR therapy; (c) cancer refractory to CAR therapy; (d) an advanced form of said cancer; or (e) B cell recovery after CAR therapy, e.g., less than 3 months The method of claim 1, wherein the patient does not have or is not identified as having one or more of the following:
10. 10. The CAR therapy or method for use of any one of claims 1 to 9, further comprising administering one or more, such as 1, 2, 3, 4 or 5 or more subsequent doses of said PD-1 inhibitor.
11. 11. The CAR therapy or method for use of claim 10, wherein up to 6 doses of the PD-1 inhibitor are administered.
12. The CAR therapy or method for use according to any one of claims 1 to 11, wherein the method further comprises assessing the presence or absence of CRS in the subject.
13. 13. The CAR therapy or method for use according to any one of claims 1 to 12, wherein the subject does not have, or is identified as not having, CRS, such as severe CRS (e.g. CRS grade 3 or grade 4) following the CAR therapy.
14. 14. The CAR therapy or method for use of claim 12 or 13, wherein administration of the PD-1 inhibitor is initiated after the subject is identified as not having CRS, such as severe CRS (e.g., CRS grade 3 or grade 4), following the CAR therapy.
15. 15. The CAR therapy or method for use of any one of claims 12 to 14, wherein administration of the PD-1 inhibitor is initiated after treatment of CRS following the CAR therapy, such as after CRS resolution.
16. 16. The CAR therapy or method for use of any one of claims 1-15, wherein the CAR therapy and the PD-1 inhibitor are administered over a treatment interval, the treatment interval comprising a single dose of the PD-1 inhibitor and a single dose of the CAR-expressing cells.
17. 17. The CAR therapy or method for use of claim 16, wherein the treatment interval is initiated with administration of said dose of the CAR therapy and completed with administration of said dose of the PD-1 inhibitor.
18. 18. The CAR therapy or method for use of claim 16 or 17, wherein the treatment interval further comprises administering one or more, such as 1, 2, 3, 4 or 5 or more subsequent doses of the PD-1 inhibitor.
19. 20. The CAR therapy or method for use of claim 18, wherein up to 6 doses of the PD-1 inhibitor are administered during the treatment interval.
20. 20. The CAR therapy or method for use of any one of claims 1 or 2 or 6-19, wherein said dose of said CAR therapy is administered at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 days before said dose of PD-1 inhibitor is administered.
21. 21. The CAR therapy or method for use of claim 20, wherein said dose of said CAR therapy is administered 25-40 days (e.g., about 25-30, 30-35, or 35-40 days, e.g., about 35 days) before said dose of said PD-1 inhibitor is administered.
22. 16. The CAR therapy or method for use of any one of claims 1 or 2 or 12-15, wherein the CAR therapy and the PD-1 inhibitor are administered over a treatment interval, the treatment interval comprising first and second doses of the PD-1 inhibitor and a dose of the CAR therapy, wherein the dose of the CAR therapy is administered after administration of the first dose of the PD-1 inhibitor but before administration of the second dose of the PD-1 inhibitor.
23. 23. The CAR therapy or method for use of claim 22, wherein the treatment interval is initiated with administration of the first dose of the PD-1 inhibitor and completed with administration of the second dose of the PD-1 inhibitor.
24. 24. The CAR therapy or method for use of claim 22 or 23, wherein the second dose of the PD-1 inhibitor is administered at least 5 days, 7 days, 1 week, 2 weeks, or 3 weeks after administration of the first dose of the PD-1 inhibitor.
25. 25. The CAR therapy or method for use of any one of claims 22-24, wherein said dose of said CAR therapy is administered at least 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, or 2 weeks after administration of the first dose of the PD-1 inhibitor.
26. 26. The CAR therapy or method for use of any one of claims 22-25, wherein the second dose of the PD-1 inhibitor is administered at least 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, or 2 weeks after administration of the dose of the CAR therapy.
27. The CAR therapy or method for use according to any one of claims 16 to 26, wherein the treatment interval is repeated, for example one or more, such as 1, 2, 3, 4, or 5 further times.
28. 28. The CAR therapy or method for use according to any one of claims 16 to 27, wherein said treatment interval is followed by one or more, such as 1, 2, 3, 4, or 5, subsequent treatment intervals.
29. 30. The CAR therapy or method for use of claim 28, wherein the one or more subsequent treatment intervals are different from the initial or previous treatment interval.
30. 30. The CAR therapy or method for use of claim 28 or 29, wherein the one or more subsequent treatment intervals are administered at least one day, such as at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 2 weeks, at least 1 month, at least 3 months, at least 6 months, or at least 1 year after completion of the initial or previous treatment interval.
31. 31. The CAR therapy or method for use of any one of claims 16-30, wherein one or more subsequent doses, such as 1, 2, 3, 4 or 5 or more doses, of the PD-1 inhibitor are administered after completion of one or more treatment intervals.
32. 32. The CAR therapy or method for use of any one of claims 16-31, wherein a dose of the PD-1 inhibitor is administered every 5 days, 6 days, 7 days, 10 days, 2 weeks, 3 weeks, or 4 weeks following completion of one or more treatment intervals.
33. 33. The CAR therapy or method for use of any one of claims 16-32, wherein the treatment interval comprises a dose of CAR therapy administered 2-20 days, 5-17 days, 7-16 days, 8-16 days, 10-15 days, 14-21 days, or 2-3 weeks before the dose of the PD-1 inhibitor is administered, and the treatment interval is repeated 0-52 times, and the treatment interval is initiated at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 2 weeks, at least 1 month, at least 3 months, at least 6 months, or at least 1 year after completion of the previous treatment interval.
34. 34. The CAR therapy or method for use of claim 33, wherein one or more subsequent doses of the PD-1 inhibitor are administered every 5 days, 7 days, 2 weeks, 3 weeks, or 4 weeks after the second treatment interval.
35. 16. The CAR therapy or method for use of any one of claims 1 to 15, wherein the subject is administered a single dose of CAR-expressing cells and a single dose of a PD-1 inhibitor.
36. 36. The CAR therapy or method for use of claim 35, wherein said single dose of said CAR-expressing cells is administered at least 2 days, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days prior to administration of said single dose of the PD-1 inhibitor.
37. 37. The CAR therapy or method for use of claim 35 or 36, wherein the CAR therapy comprises an RNA CAR molecule, e.g., in vitro transcribed (IVT) RNA, and one or more, e.g., 1, 2, 3, 4, or 5 subsequent doses of CAR therapy are administered to the subject after an initial dose of the CAR therapy.
38. 38. The CAR therapy or method for use of claim 37, wherein the one or more subsequent doses of CAR-expressing cells are administered at least 2 days, such as 2, 3, 4, 5, 6, 7 days, 2 weeks, or 3 weeks after a previous dose of CAR-expressing cells.
39. 39. The CAR therapy or method for use of any one of claims 27-38, wherein after administration of said single dose of the PD-1 inhibitor one or more, such as 1, 2, 3, 4 or 5 or more, subsequent doses of a PD-1 inhibitor are administered.
40. 40. The CAR therapy or method for use of claim 39, wherein the one or more subsequent doses of the PD-1 inhibitor are administered at least 5 days, 7 days, 2 weeks, 3 weeks, or 4 weeks after the previous dose of the PD-1 inhibitor.
41. 41. The CAR therapy or method for use of claim 39 or 40, wherein the one or more subsequent doses of the PD-1 inhibitor are administered at least 1, 2, 3, 4, 5, 6, or 7 days, or 2 weeks or 3 weeks after a dose of the CAR therapy, e.g., the initial dose of the CAR therapy.
42. 42. The CAR therapy or method for use of any one of claims 27-41, wherein administration of the one or more doses of CAR-expressing cells and the one or more doses of a PD-1 inhibitor is repeated.
43. The CAR therapy is administered for about 10 4 ~about 10 9 cells / kg, e.g., about 10 4 ~about 10 5 cells / kg, approximately 10 5 ~about 10 6 cells / kg, approximately 10 6 ~about 10 7 cells / kg, approximately 10 7 ~about 10 8 cells / kg, approximately 10 8 ~about 10 9 cells / kg, or about 1-5 x 10 7 cells / kg ~ approx. 1-5 x 10 8 43. The CAR therapy or method for use according to any one of claims 1 to 42, comprising a dose of CAR-expressing cells comprising cells / kg.
44. The dose of CAR-expressing cells is about 1 to 5 x 10 7 44. The CAR therapy or method for use according to claim 43, wherein the cell volume is 100 μg / kg.
45. The dose of CAR-expressing cells is about 1 to 5 x 10 8 44. The CAR therapy or method for use according to claim 43, wherein the cell volume is 100 μg / kg.
46. 46. The CAR therapy or method for use of any one of claims 3 to 45, wherein the dose of the PD-1 inhibitor is 1 to 30 mg / kg, such as about 1 to 25 mg / kg, about 2 to 20 mg / kg, about 2 to 5 mg / kg, or about 2 mg / kg, about 3 mg / kg, about 4 mg / kg or about 5 mg / kg.
47. 47. The CAR therapy or method for use of claim 46, wherein the dose of the PD-1 inhibitor is about 1-20 mg / kg or about 2-5 mg / kg administered, e.g., every 2 weeks, 3 weeks, 4 weeks, or 5 weeks.
48. 46. The CAR therapy or method for use of any one of claims 1 to 45, wherein the dose of the PD-1 inhibitor, e.g., anti-PD-1 antibody molecule, is from about 200 mg to about 450 mg, e.g., from about 200 mg to about 400 mg, administered every 2 weeks, 3 weeks, 4 weeks, or 5 weeks.
49. 49. The CAR therapy or method for use of any one of claims 1 to 48, wherein the dose of the PD-1 inhibitor is about 200 mg or about 300 mg administered, e.g., by intravenous infusion, e.g. every 3 weeks.
50. 49. The CAR therapy or method for use of any one of claims 1 to 48, wherein the dose of the PD-1 inhibitor is about 400 mg administered, e.g., by intravenous infusion, e.g. every 4 weeks.
51. The PD-1 inhibitor is a PD-1 antibody molecule and is administered at a dose of about 300 mg every 2, 3, or 4 weeks, and the CAR therapy is administered at a dose of 1-5×10 8 The CAR therapy or method for use according to any one of claims 1 to 48, administered in doses of cells.
52. 52. The CAR therapy or method for use according to any one of claims 1 to 51, wherein the PD-1 inhibitor comprises an antibody molecule, a small molecule, a polypeptide, such as a fusion protein, or an inhibitory nucleic acid, such as an siRNA or shRNA.
53. The PD-1 inhibitor is as follows: a. Inhibiting or reducing PD-1 expression, e.g., the transcription or translation of PD-1; b. Inhibiting or reducing PD-1 activity, e.g., inhibiting or reducing binding of PD-1 to its cognate ligand, e.g., PD-L1 or PD-L2, or c. Binding to PD-1 or its ligands, such as PD-L1 or PD-L2 53. The CAR therapy or method for use according to any one of claims 1 to 52, characterized by one or more of:
54. The CAR therapy or method for use according to any one of claims 1 to 53, wherein the PD-1 inhibitor is an antibody molecule.
55. 55. The CAR therapy or method for use of any one of claims 1-54, wherein the PD-1 inhibitor is selected from the group consisting of nivolumab, pembrolizumab, PDR001, pidilizumab, AMP 514, AMP-224, and any anti-PD-1 antibody molecule provided in Table 6.
56. The PD-1 inhibitor is a. the heavy chain complementarity determining region 1 (HC CDR1), heavy chain complementarity determining region 2 (HC CDR2), and heavy chain complementarity determining region 3 (HC CDR3) of any PD-1 antibody molecule amino acid sequence listed in Table 6, and b. The light chain complementarity determining region 1 (LC CDR1), light chain complementarity determining region 2 (LC CDR2), and light chain complementarity determining region 3 (LC CDR3) of any PD-1 antibody molecule amino acid sequence listed in Table 6.
56. The CAR therapy or method for use of any one of claims 1 to 55, comprising an anti-PD-1 antibody molecule comprising:
57. The anti-PD-1 antibody molecule comprises: a) a HC CDR1 amino acid sequence selected from SEQ ID NO: 137 or 140, a HC CDR2 amino acid sequence of SEQ ID NO: 138 or 141, and a HC CDR3 amino acid sequence of SEQ ID NO: 139, and b) an LC CDR1 amino acid sequence of SEQ ID NO: 146 or 149, an LC CDR2 amino acid sequence of SEQ ID NO: 147 or 150, and an LC CDR3 amino acid sequence of SEQ ID NO: 148, 151, 166, or 167 (e.g., an LC CDR3 amino acid sequence of SEQ ID NO: 166 or 167).
57. The CAR therapy or method for use of claim 56, comprising:
58. The anti-PD-1 antibody molecule comprises: i) any heavy chain variable region amino acid sequence listed in Table 6, e.g., SEQ ID NOs: 142, 144, 154, 158, 172, 184, 216, or 220; ii) an amino acid sequence having at least one, two, or three modifications but no more than 30, 20, or 10 modifications relative to any of the heavy chain variable region amino acid sequences provided in Table 6, e.g., SEQ ID NOs: 142, 144, 154, 158, 172, 184, 216, or 220; or iii) an amino acid sequence having 95-99% identity to any of the heavy chain variable region amino acid sequences provided in Table 6, e.g., SEQ ID NOs: 142, 144, 154, 158, 172, 184, 216, or 220.
58. The CAR therapy or method for use of claim 56 or 57, comprising a heavy chain variable region comprising:
59. The anti-PD-1 antibody molecule comprises: i) any heavy chain amino acid sequence listed in Table 6, e.g., SEQ ID NOs: 156, 160, 174, 186, 218, 222, 225, or 236; ii) an amino acid sequence having at least one, two, or three modifications, but no more than 30, 20, or 10 modifications, relative to any heavy chain listed in Table 6, e.g., SEQ ID NOs: 156, 160, 174, 186, 218, 222, 225, or 236; or iii) an amino acid sequence having 95-99% identity to any heavy chain amino acid sequence listed in Table 6, e.g., SEQ ID NO: 156, 160, 174, 186, 218, 222, 225, or 236.
59. The CAR therapy or method for use according to any one of claims 56 to 58, comprising a heavy chain comprising:
60. The anti-PD-1 antibody molecule comprises: i) any light chain variable region amino acid sequence listed in Table 6, e.g., SEQ ID NOs: 152, 162, 168, 176, 180, 188, 192, 196, 200, 204, 208, or 212; ii) an amino acid sequence having at least one, two, or three modifications but no more than 30, 20, or 10 modifications relative to any of the light chain variable region amino acid sequences provided in Table 6, e.g., SEQ ID NOs: 152, 162, 168, 176, 180, 188, 192, 196, 200, 204, 208, or 212; or iii) an amino acid sequence having 95-99% identity to any of the light chain variable region amino acid sequences provided in Table 6, e.g., an amino acid sequence having 95-99% identity to SEQ ID NOs: 152, 162, 168, 176, 180, 188, 192, 196, 200, 204, 208, or 212. The CAR therapy or method for use of any one of claims 56 to 59, comprising a light chain variable region comprising:
61. The anti-PD-1 antibody molecule comprises: i) any light chain amino acid sequence listed in Table 6, e.g., SEQ ID NOs: 164, 170, 178, 182, 190, 194, 198, 202, 206, 210, or 214; ii) an amino acid sequence having at least one, two, or three modifications but no more than 30, 20, or 10 modifications relative to any light chain listed in Table 6, e.g., SEQ ID NOs: 164, 170, 178, 182, 190, 194, 198, 202, 206, 210, or 214; or iii) an amino acid sequence having 95-99% identity to any of the light chains listed in Table 6, e.g., an amino acid sequence having 95-99% identity to SEQ ID NOs: 164, 170, 178, 182, 190, 194, 198, 202, 206, 210, or 214.
61. The CAR therapy or method for use of any one of claims 56 to 60, comprising a light chain comprising:
62. The anti-PD-1 antibody molecule comprises: i) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 204; ii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 142 or 144 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 152; iii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 154 or 158 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 162; iv) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 154 or 158 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 168; v) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 176; vi) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 180; vii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 184 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 180; viii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 184 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 188; ix) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 188; x) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 192; xi) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 196; xii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 184 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 200; xiii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 200; xiv) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 184 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 204; xv) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 204; xvi) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 208; xvii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 212; xviii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 216 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 204; xix) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 216 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 200; xx) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 220 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 200; xxi) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 176; xxii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 188; xxiii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 200; or xxiv) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 184 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 204 62. The CAR therapy or method for use according to any one of claims 56 to 61, comprising:
63. The anti-PD-1 antibody molecule comprises: i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 225 and a light chain comprising the amino acid sequence of SEQ ID NO: 206; ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 144 and a light chain comprising the amino acid sequence of SEQ ID NO: 152; iii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 156 or 160 and a light chain comprising the amino acid sequence of SEQ ID NO: 164; iv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 156 or 160 and a light chain comprising the amino acid sequence of SEQ ID NO: 170; v) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 178; vi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 182; vii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 186 and a light chain comprising the amino acid sequence of SEQ ID NO: 182; viii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 186 and a light chain comprising the amino acid sequence of SEQ ID NO: 190; ix) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 190; x) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 194; xi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 198; xii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 186 and a light chain comprising the amino acid sequence of SEQ ID NO: 202; xiii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 202; xiv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 186 and a light chain comprising the amino acid sequence of SEQ ID NO: 206; xv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 206; xvi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 210; xvii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174 and a light chain comprising the amino acid sequence of SEQ ID NO: 214; xviii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 218 and a light chain comprising the amino acid sequence of SEQ ID NO: 206; xix) a heavy chain comprising the amino acid sequence of SEQ ID NO: 218 and a light chain comprising the amino acid sequence of SEQ ID NO: 202; xx) a heavy chain comprising the amino acid sequence of SEQ ID NO: 222 and a light chain comprising the amino acid sequence of SEQ ID NO: 202; xxi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 225 and a light chain comprising the amino acid sequence of SEQ ID NO: 178; xxii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 225 and a light chain comprising the amino acid sequence of SEQ ID NO: 190; xxiii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 225 and a light chain comprising the amino acid sequence of SEQ ID NO: 202; or xxiv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 236 and a light chain comprising the amino acid sequence of SEQ ID NO: 206 63. The CAR therapy or method for use according to any one of claims 56 to 62, comprising:
64. 64. The CAR therapy or method for use of any one of claims 56-63, wherein the PD-1 inhibitor comprises an anti-PD-1 antibody molecule comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:
204.
65. The anti-PD1 antibody molecule (i) a heavy chain variable (VH) region comprising a VHCDR1 amino acid sequence of SEQ ID NO:503, a VHCDR2 amino acid sequence of SEQ ID NO:504, and a VHCDR3 amino acid sequence of SEQ ID NO:505; and (ii) a light chain variable (VL) region comprising a VLCDR1 amino acid sequence of SEQ ID NO:500, a VLCDR2 amino acid sequence of SEQ ID NO:501, and a VLCDR3 amino acid sequence of SEQ ID NO:502; or Amino acid sequences that are at least 85%, 90%, 95% or more identical 65. The CAR therapy or method for use of claim 64, comprising:
66. 66. The CAR therapy or method for use according to any one of claims 1 to 65, wherein the CD19 binding domain comprises heavy chain complementarity determining region 1 (HC CDR1), heavy chain complementarity determining region 2 (HC CDR2), and heavy chain complementarity determining region 3 (HC CDR3) of any CD19 heavy chain binding domain amino acid sequence listed in Table 2 or Table 3, and light chain complementarity determining region 1 (LC CDR1), light chain complementarity determining region 2 (LC CDR2), and light chain complementarity determining region 3 (LC CDR3) of any CD19 light chain binding domain amino acid sequence listed in Table 2 or Table 3.
67. 67. The CAR therapy or method for use of claim 66, wherein the CD19 binding domain comprises a HC CDR1, a HC CDR2, and a HC CDR3 according to the HC CDR amino acid sequences of Table 4, and a LC CDR1, a LC CDR2, and a LC CDR3 according to the LC CDR amino acid sequences of Table 5.
68. The CD19 binding domain comprises: a. the amino acid sequence of any heavy chain variable region of a CD19 binding domain listed in Table 2 or Table 3; b. an amino acid sequence having at least 1, 2, or 3 modifications, but no more than 30, 20, or 10 modifications, relative to the amino acid sequence of any heavy chain variable region of a CD19 binding domain provided in Table 2 or Table 3; or c. An amino acid sequence that is at least 95% identical, e.g., has 95-99% identity, to the amino acid sequence of any heavy chain variable region of a CD19 binding domain provided in Table 2 or Table 3.
68. A CAR therapy or method for use according to any one of claims 1 to 67 comprising:
69. The CD19 binding domain comprises: a. the amino acid sequence of the heavy chain of any of the CD19 binding domains provided in Table 2 or Table 3; b. an amino acid sequence having at least 1, 2, or 3 modifications, but no more than 30, 20, or 10 modifications, relative to any heavy chain of a CD19 binding domain provided in Table 2 or Table 3; or c. An amino acid sequence that is at least 95% identical, e.g., has 95-99% identity, to the amino acid sequence for any heavy chain of the CD19 binding domain provided in Table 2 or Table 3.
69. The CAR therapy or method for use according to any one of claims 1 to 68, comprising:
70. The CD19 binding domain comprises: a. the amino acid sequence of any light chain variable region of the CD19 binding domain provided in Table 2 or Table 3; b. an amino acid sequence having at least 1, 2, or 3 modifications, but no more than 30, 20, or 10 modifications, relative to the amino acid sequence of any light chain variable region of a CD19 binding domain provided in Table 2 or Table 3; or c. An amino acid sequence that is at least 95% identical, e.g., has 95-99% identity, to the amino acid sequence of any light chain variable region of a CD19 binding domain provided in Table 2 or Table 3.
70. The CAR therapy or method for use according to any one of claims 1 to 69, comprising:
71. The CD19 binding domain comprises: a. the amino acid sequence of any light chain of the CD19 binding domain provided in Table 2 or Table 3; b. an amino acid sequence having at least 1, 2, or 3 modifications, but no more than 30, 20, or 10 modifications, relative to any light chain of the CD19 binding domain provided in Table 2 or Table 3; or c. An amino acid sequence that is at least 95% identical, e.g., has 95-99% identity, to the amino acid sequence for any light chain of the CD19 binding domain provided in Table 2 or Table 3.
71. The CAR therapy or method for use according to any one of claims 1 to 70, comprising:
72. 72. The CAR therapy or method for use of any one of claims 1 to 71, wherein the CD19 binding domain comprises any heavy chain variable region amino acid sequence listed in Table 2 or Table 3, and any light chain variable region amino acid sequence listed in Table 2 or Table 3.
73. The CD19 binding domain comprises: an amino acid sequence selected from the group consisting of SEQ ID NO:109, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:110, SEQ ID NO:112, or SEQ ID NO:115; b. an amino acid sequence having at least 1, 2, or 3 modifications but no more than 30, 20, or 10 modifications relative to any of SEQ ID NO:109, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:110, SEQ ID NO:112, or SEQ ID NO:115; or c. an amino acid sequence that is at least 95% identical, e.g., has 95-99% identity, to any of the amino acid sequences set forth in SEQ ID NO:109, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:110, SEQ ID NO:112, or SEQ ID NO:115 73. The CAR therapy or method for use according to any one of claims 1 to 72, comprising:
74. 74. The CAR therapy or method for use according to any one of claims 1 to 73, wherein said transmembrane domain comprises a transmembrane domain from a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154.
75. The transmembrane domain is (i) the amino acid sequence of SEQ ID NO:6; (ii) an amino acid sequence containing at least one, two, or three, but not more than 20, 10, or 5, modifications of the amino acid sequence of SEQ ID NO:6; or (iii) a sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:6, for example, a sequence that has 95-99% identity 75. The CAR therapy or method for use according to any one of claims 1 to 74, comprising:
76. 76. The CAR therapy or method for use of any one of claims 1 to 75, wherein the CD19 binding domain is attached to the transmembrane domain by a hinge region.
77. 77. The CAR therapy or method for use according to any one of claims 1 to 76, wherein the hinge region comprises SEQ ID NO:2 or a sequence having at least 95% identity thereto, such as 95-99% identity.
78. The intracellular signaling domain may be an MHC class I molecule, a TNF receptor protein, an immunoglobulin-like protein, a cytokine receptor, an integrin, a signaling lymphocyte activation molecule (SLAM protein), an activating NK cell receptor, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a / CD18), 4-1BB (CD137), B7-H3, CDS, ICA M-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8α, C D8β, IL2Rβ, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11 a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1 (CD2 26), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAM 78. The CAR therapy or method for use of any one of claims 1 to 77, comprising a costimulatory signaling domain comprising a functional signaling domain obtained from a protein selected from the group consisting of F6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, and a ligand that specifically binds CD83.
79. 60. The CAR therapy or method for use of claim 59, wherein the costimulatory domain comprises an amino acid sequence of SEQ ID NO:7, or an amino acid sequence having at least one, two, or three modifications but not more than 20, 10, or 5 modifications of the amino acid sequence of SEQ ID NO:7, or an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:
7.
80. The CAR therapy or method for use according to any one of claims 1 to 79, wherein said intracellular signalling domain comprises a functional signalling domain of 4-1BB and / or a functional signalling domain of CD3ζ.
81. 81. The CAR therapy or method for use according to any one of claims 1 to 80, wherein said intracellular signalling domain comprises the amino acid sequence of SEQ ID NO:7 and / or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, or an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of the amino acid sequence of SEQ ID NO:7 and / or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, or an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:7 and / or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:
10.
82. 82. The CAR therapy or method for use of any one of claims 1 to 81, wherein said intracellular signaling domain comprises the amino acid sequence of SEQ ID NO:7 and the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, and wherein the amino acid sequences comprising said intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.
83. 83. The CAR therapy or method for use according to any one of claims 1 to 82, wherein the CAR further comprises a leader sequence comprising the amino acid sequence of SEQ ID NO:
1.
84. The CAR is (i) any of the amino acid sequences of SEQ ID NO:108, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:111, SEQ ID NO:114, or SEQ ID NO:116; (ii) an amino acid sequence having at least one, two, or three modifications but no more than 30, 20, or 10 modifications relative to any of SEQ ID NO:108, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:111, SEQ ID NO:114, or SEQ ID NO:116; or (iii) an amino acid sequence having at least 95 identical sequences to any of SEQ ID NO:108, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:111, SEQ ID NO:114, or SEQ ID NO:
116.
84. The CAR therapy or method for use according to any one of claims 1 to 83, comprising:
85. 85. The CAR therapy or method for use according to any one of claims 1 to 84, wherein said cell comprising a CAR comprises a nucleic acid encoding said CAR.
86. 86. The CAR therapy or method for use of claim 85, wherein the nucleic acid encoding the CAR is a lentiviral vector.
87. 87. The CAR therapy or method for use of claim 85 or 86, wherein the nucleic acid encoding the CAR is introduced into the cell by lentiviral transduction.
88. 88. The CAR therapy or method for use according to any one of claims 85 to 87, wherein the nucleic acid encoding the CAR is RNA, such as an in vitro transcribed RNA.
89. 89. The CAR therapy or method for use of claim 88, wherein the nucleic acid encoding the CAR is introduced into the cell by electroporation.
90. The CAR therapy or method for use according to any one of claims 1 to 89, wherein the cell is a T cell or a NK cell.
91. 91. The CAR therapy or method for use of claim 90, wherein the T cells are autologous or allogeneic T cells.
92. 92. The CAR therapy or method for use of any one of claims 1 to 91, further comprising administering an additional anti-cancer agent.
93. 93. The CAR therapy or method for use according to any one of claims 1 to 92, wherein the cancer is a hematological cancer.
94. 94. The CAR therapy or method for use according to any one of claims 1 to 93, wherein the cancer is lymphoma or leukemia.
95. The cancers include B-cell acute lymphoblastic leukemia (BALL), T-cell acute lymphoblastic leukemia (TALL), small lymphocytic leukemia (SLL), acute lymphoblastic leukemia (ALL), chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and / or leukemia.
94. The CAR therapy or method for use of claim 93, wherein the cancer is selected from one or more of: myeloma, hairy cell leukemia, small or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplastic and myelodysplastic syndromes, non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, or Waldenstrom's macroglobulinemia.
96. 94. The CAR therapy or method for use according to claim 93, wherein the cancer is acute lymphocytic leukemia (ALL), e.g. childhood B-ALL, or B-cell lymphoma, e.g. childhood B-cell lymphoma.
97. 94. The CAR therapy or method for use of claim 93, wherein the cancer is diffuse large B-cell lymphoma (DLBCL), such as relapsed or refractory DLBCL.
98. The CAR therapy or method for use according to any one of claims 1 to 97, wherein the subject is a mammal, such as a human.
99. 99. The CAR therapy or method for use of any one of claims 1 to 98, wherein the subject expresses PD-1, PD-L1, and / or PD-L2.
100. 100. The CAR therapy or method for use of claim 99, wherein cancer cells or cells in proximity to cancer cells in the subject express PD-1, PD-L1, and / or PD-L2.
101. 101. The CAR therapy or method for use according to claim 99 or 100, wherein the cancer cells are from a DLBCL sample, such as from a relapsed or refractory DLBCL sample.
102. The CAR therapy or method for use according to any one of claims 1 to 101, wherein the cells expressing CAR express PD-1, PD-L1, and / or PD-L2.
103. The subject may have a greater number or a higher percentage of immune effector cells, e.g., CD4+, that express one, two, three, or all of PD-1, LAG-3, or TIM-3, as compared to a baseline, e.g., a complete responder to the CAR therapy. + and / or CD8 + 103. A CAR therapy or method for use according to any one of claims 1 to 102, comprising or identified as comprising T cells.
104. The subject has a high number of immune effector cells that express PD-1, e.g., CD4 + and / or CD8 + T cells, immune effector cells expressing PD-1 and LAG-3, e.g., CD4 + and / or CD8 + T cells, immune effector cells expressing PD-1 and TIM-3, e.g., CD4 + and / or CD8 + T cells, or immune effector cells that express PD-1, TIM-3, and LAG-3, such as CD4 + and / or CD8 + 104. The CAR therapy or method for use of claim 103, comprising or identified as comprising T cells.
105. The immune effector cells, e.g., CD4 + and / or CD8 + 105. The CAR therapy or method for use according to claim 103 or 104, wherein the T cells co-express a CAR, such as a CD19 CAR.
106. For use in treating cancer in a subject, a population of cells, e.g., immune effector cells, comprising a CAR, the CAR comprising an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain; and A PD-1 inhibitor selected from pembrolizumab, nivolumab, or any of the antibody molecules from Table 6, e.g., comprising the variable light and variable heavy chain amino acid sequences of SEQ ID NO:204 and SEQ ID NO:
172. Use in combination with.
107. a population of cells, e.g., immune effector cells, comprising a CAR, the CAR comprising an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain; and For example, a PD-1 inhibitor selected from Table 6, comprising the variable light and variable heavy chain amino acid sequences of SEQ ID NO:204 and SEQ ID NO:
172. A composition (e.g., one or more compositions or dosage forms) comprising:
108. 108. The method, combination or composition of any one of claims 1 to 107, wherein said CD19 binding domain is the amino acid sequence of SEQ ID NO: 109, or said CAR comprises the amino acid sequence of SEQ ID NO: 108.
